Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced.
Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.
Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.
Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.
Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.
Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.
Two or more vaccines in a single dosage form.
Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.
Vaccines or candidate vaccines designed to prevent SAIDS; (SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME); and containing inactivated SIMIAN IMMUNODEFICIENCY VIRUS or type D retroviruses or some of their component antigens.
Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV.
Antibodies reactive with HIV ANTIGENS.
A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans.
Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.
Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.
Semisynthetic vaccines consisting of polysaccharide antigens from microorganisms attached to protein carrier molecules. The carrier protein is recognized by macrophages and T-cells thus enhancing immunity. Conjugate vaccines induce antibody formation in people not responsive to polysaccharide alone, induce higher levels of antibody, and show a booster response on repeated injection.
Acquired defect of cellular immunity that occurs naturally in macaques infected with SRV serotypes, experimentally in monkeys inoculated with SRV or MASON-PFIZER MONKEY VIRUS; (MPMV), or in monkeys infected with SIMIAN IMMUNODEFICIENCY VIRUS.
The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte.
Any immunization following a primary immunization and involving exposure to the same or a closely related antigen.
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.
Vaccines made from antigens arising from any of the four strains of Plasmodium which cause malaria in humans, or from P. berghei which causes malaria in rodents.
The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50).
Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.
Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesized as protein precursors (POLYPROTEINS) and later cleaved into the final viral envelope glycoproteins by a viral protease.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Vaccines or candidate vaccines used to prevent PAPILLOMAVIRUS INFECTIONS. Human vaccines are intended to reduce the incidence of UTERINE CERVICAL NEOPLASMS, so they are sometimes considered a type of CANCER VACCINES. They are often composed of CAPSID PROTEINS, especially L1 protein, from various types of ALPHAPAPILLOMAVIRUS.
Immunoglobulins produced in response to VIRAL ANTIGENS.
Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.
External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV.
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.
A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed)
A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed)
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
Vaccines or candidate vaccines containing antigenic polysaccharides from Haemophilus influenzae and designed to prevent infection. The vaccine can contain the polysaccharides alone or more frequently polysaccharides conjugated to carrier molecules. It is also seen as a combined vaccine with diphtheria-tetanus-pertussis vaccine.
An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.
A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.
Vaccines or candidate vaccines used to prevent and treat RABIES. The inactivated virus vaccine is used for preexposure immunization to persons at high risk of exposure, and in conjunction with rabies immunoglobulin, for postexposure prophylaxis.
Vaccines or candidate vaccines used to prevent infection with ROTAVIRUS.
Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.
Vaccines or candidate vaccines used to prevent infection with VIBRIO CHOLERAE. The original cholera vaccine consisted of killed bacteria, but other kinds of vaccines now exist.
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Proteins encoded by the ENV GENE of the HUMAN IMMUNODEFICIENCY VIRUS.
Vaccines used to prevent TYPHOID FEVER and/or PARATYPHOID FEVER which are caused by various species of SALMONELLA. Attenuated, subunit, and inactivated forms of the vaccines exist.
A live VACCINIA VIRUS vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (Dorland, 28th ed)
Vaccines or candidate vaccines used to prevent or treat TUBERCULOSIS.
A live, attenuated varicella virus vaccine used for immunization against chickenpox. It is recommended for children between the ages of 12 months and 13 years.
A vaccine consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and whole-cell PERTUSSIS VACCINE. The vaccine protects against diphtheria, tetanus, and whooping cough.
An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41.
Proteins coded by the retroviral gag gene. The products are usually synthesized as protein precursors or POLYPROTEINS, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. gag is short for group-specific antigen.
A critical subpopulation of regulatory T-lymphocytes involved in MHC Class I-restricted interactions. They include both cytotoxic T-lymphocytes (T-LYMPHOCYTES, CYTOTOXIC) and CD8+ suppressor T-lymphocytes.
DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.
Vaccines used to prevent infection by MUMPS VIRUS. Best known is the live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had mumps or been immunized with live mumps vaccine. Children are usually immunized with measles-mumps-rubella combination vaccine.
The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression.
The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS.
Vaccines or candidate vaccines used to prevent infection with hepatitis A virus (HEPATOVIRUS).
Schedule giving optimum times usually for primary and/or secondary immunization.
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
A combined vaccine used to prevent MEASLES; MUMPS; and RUBELLA.
Vaccines or candidate vaccines used to prevent STREPTOCOCCAL INFECTIONS.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Vaccines or candidate vaccines used to prevent ANTHRAX.
Vaccines or candidate vaccines used to prevent infection with DENGUE VIRUS. These include live-attenuated, subunit, DNA, and inactivated vaccines.
A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes.
Vaccines using VIROSOMES as the antigen delivery system that stimulates the desired immune response.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
DNA sequences that form the coding region for the viral envelope (env) proteins in retroviruses. The env genes contain a cis-acting RNA target sequence for the rev protein (= GENE PRODUCTS, REV), termed the rev-responsive element (RRE).
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
Any vaccine raised against any virus or viral derivative that causes hepatitis.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
Vaccine used to prevent YELLOW FEVER. It consists of a live attenuated 17D strain of the YELLOW FEVER VIRUS.
Immunoglobulins produced in a response to BACTERIAL ANTIGENS.
A suspension of killed Yersinia pestis used for immunizing people in enzootic plague areas.
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Suspensions of attenuated or killed fungi administered for the prevention or treatment of infectious fungal disease.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunized and do not have serum antibodies to rubella. Children are usually immunized with measles-mumps-rubella combination vaccine. (Dorland, 28th ed)
Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.
The presence of viruses in the blood.
Antigenic determinants recognized and bound by the T-cell receptor. Epitopes recognized by the T-cell receptor are often located in the inner, unexposed side of the antigen, and become accessible to the T-cell receptors after proteolytic processing of the antigen.
Vaccines or candidate vaccines used to prevent infection with SALMONELLA. This includes vaccines used to prevent TYPHOID FEVER or PARATYPHOID FEVER; (TYPHOID-PARATYPHOID VACCINES), and vaccines used to prevent nontyphoid salmonellosis.
Inbred BALB/c mice are a strain of laboratory mice that have been selectively bred to be genetically identical to each other, making them useful for scientific research and experiments due to their consistent genetic background and predictable responses to various stimuli or treatments.
The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include pharmacokinetics, dosage analysis, or drug administration analysis.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Vaccines using supra-molecular structures composed of multiple copies of recombinantly expressed viral structural proteins. They are often antigentically indistinguishable from the virus from which they were derived.
Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.
An acute viral infection in humans involving the respiratory tract. It is marked by inflammation of the NASAL MUCOSA; the PHARYNX; and conjunctiva, and by headache and severe, often generalized, myalgia.
Products of the retroviral NEF GENE. They play a role as accessory proteins that influence the rate of viral infectivity and the destruction of the host immune system. nef gene products were originally found as factors that trans-suppress viral replication and function as negative regulators of transcription. nef stands for negative factor.
The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle.
Live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strains capable of inducing protective immunity.
Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.
Staphylococcal vaccines are prophylactic agents developed to prevent infections caused by Staphylococcus aureus, a pathogenic bacterium that frequently colonizes human skin and mucous membranes, often targeting surface proteins or toxins for immune response induction.
Combined vaccines consisting of DIPHTHERIA TOXOID; TETANUS TOXOID; and an acellular form of PERTUSSIS VACCINE. At least five different purified antigens of B. pertussis have been used in various combinations in these vaccines.
The interaction of persons or groups of persons representing various nations in the pursuit of a common goal or interest.
Vaccines or candidate vaccines used to prevent infection with CYTOMEGALOVIRUS.
Organized services to administer immunization procedures in the prevention of various diseases. The programs are made available over a wide range of sites: schools, hospitals, public health agencies, voluntary health agencies, etc. They are administered to an equally wide range of population groups or on various administrative levels: community, municipal, state, national, international.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
Vaccines used to prevent POLIOMYELITIS. They include inactivated (POLIOVIRUS VACCINE, INACTIVATED) and oral vaccines (POLIOVIRUS VACCINE, ORAL).
Delivery of medications through the nasal mucosa.
Vaccines or candidate vaccines used to prevent or treat both enterotoxigenic and enteropathogenic Escherichia coli infections.
Vaccines or candidate vaccines used to prevent infection with WEST NILE VIRUS.
Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination.
Vaccines or candidate vaccines used to prevent bacillary dysentery (DYSENTERY, BACILLARY) caused by species of SHIGELLA.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
Antibody-mediated immune response. Humoral immunity is brought about by ANTIBODY FORMATION, resulting from TH2 CELLS activating B-LYMPHOCYTES, followed by COMPLEMENT ACTIVATION.
Sorbitan mono-9-octadecanoate poly(oxy-1,2-ethanediyl) derivatives; complex mixtures of polyoxyethylene ethers used as emulsifiers or dispersing agents in pharmaceuticals.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.
Sites on an antigen that interact with specific antibodies.
Tetanus toxoid is a purified and chemically inactivated form of the tetanus toxin, used as a vaccine to induce active immunity against tetanus disease by stimulating the production of antibodies.
Vaccines or candidate vaccines used to prevent infection by any virus from the family HERPESVIRIDAE.
The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer.
Vaccines or candidate vaccines used to prevent infection with LEISHMANIA.
A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 1 and neuraminidase 1. The H1N1 subtype was responsible for the Spanish flu pandemic of 1918.
A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc.
Genotypic differences observed among individuals in a population.
Substances elaborated by bacteria that have antigenic activity.
Aluminum metal sulfate compounds used medically as astringents and for many industrial purposes. They are used in veterinary medicine for the treatment of ulcerative stomatitis, leukorrhea, conjunctivitis, pharyngitis, metritis, and minor wounds.
Vaccines or candidate vaccines used to prevent infection with viruses from the genus SIMPLEXVIRUS. This includes vaccines for HSV-1 and HSV-2.
The formaldehyde-inactivated toxin of Corynebacterium diphtheriae. It is generally used in mixtures with TETANUS TOXOID and PERTUSSIS VACCINE; (DTP); or with tetanus toxoid alone (DT for pediatric use and Td, which contains 5- to 10-fold less diphtheria toxoid, for other use). Diphtheria toxoid is used for the prevention of diphtheria; DIPHTHERIA ANTITOXIN is for treatment.
'Squalene' is a biologically occurring triterpene compound, naturally produced in humans, animals, and plants, that forms an essential part of the lipid-rich membranes in various tissues, including the skin surface and the liver, and has been studied for its potential benefits in skincare, dietary supplements, and vaccine adjuvant systems.
The relationships of groups of organisms as reflected by their genetic makeup.
Vaccines or candidate vaccines used to prevent infection with RESPIRATORY SYNCYTIAL VIRUSES.
Established cell cultures that have the potential to propagate indefinitely.
Deoxyribonucleic acid that makes up the genetic material of viruses.
Protection conferred on a host by inoculation with one strain or component of a microorganism that prevents infection when later challenged with a similar strain. Most commonly the microorganism is a virus.
Vaccines or candidate vaccines used to prevent infection with Japanese B encephalitis virus (ENCEPHALITIS VIRUS, JAPANESE).
Administration of a vaccine to large populations in order to elicit IMMUNITY.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Vaccines or candidate vaccines used to prevent conception.
Vaccines or candidate vaccines derived from edible plants. Transgenic plants (PLANTS, TRANSGENIC) are used as recombinant protein production systems and the edible plant tissue functions as an oral vaccine.
A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
The relationship between an elicited ADAPTIVE IMMUNE RESPONSE and the dose of the vaccine administered.
A highly contagious infectious disease caused by MORBILLIVIRUS, common among children but also seen in the nonimmune of any age, in which the virus enters the respiratory tract via droplet nuclei and multiplies in the epithelial cells, spreading throughout the MONONUCLEAR PHAGOCYTE SYSTEM.
The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES.
Vaccines for the prevention of diseases caused by various species of Rickettsia.
An acute, highly contagious, often fatal infectious disease caused by an orthopoxvirus characterized by a biphasic febrile course and distinctive progressive skin eruptions. Vaccination has succeeded in eradicating smallpox worldwide. (Dorland, 28th ed)
Emergency care or treatment given to a person who suddenly becomes ill or injured before full medical services become available.
Inbred C57BL mice are a strain of laboratory mice that have been produced by many generations of brother-sister matings, resulting in a high degree of genetic uniformity and homozygosity, making them widely used for biomedical research, including studies on genetics, immunology, cancer, and neuroscience.
Nonsusceptibility to the pathogenic effects of foreign microorganisms or antigenic substances as a result of antibody secretions of the mucous membranes. Mucosal epithelia in the gastrointestinal, respiratory, and reproductive tracts produce a form of IgA (IMMUNOGLOBULIN A, SECRETORY) that serves to protect these ports of entry into the body.
Vaccines or candidate vaccines used to prevent infection with parainfluenza viruses in humans and animals.
Infection with any of the rotaviruses. Specific infections include human infantile diarrhea, neonatal calf diarrhea, and epidemic diarrhea of infant mice.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 5 and neuraminidase 1. The H5N1 subtype, frequently referred to as the bird flu virus, is endemic in wild birds and very contagious among both domestic (POULTRY) and wild birds. It does not usually infect humans, but some cases have been reported.
A subtype of INFLUENZA A VIRUS comprised of the surface proteins hemagglutinin 3 and neuraminidase 2. The H3N2 subtype was responsible for the Hong Kong flu pandemic of 1968.
Species of the genus INFLUENZAVIRUS B that cause HUMAN INFLUENZA and other diseases primarily in humans. Antigenic variation is less extensive than in type A viruses (INFLUENZA A VIRUS) and consequently there is no basis for distinct subtypes or variants. Epidemics are less likely than with INFLUENZA A VIRUS and there have been no pandemics. Previously only found in humans, Influenza B virus has been isolated from seals which may constitute the animal reservoir from which humans are exposed.
Vaccines or candidate vaccines used to prevent PSEUDORABIES (Aujeszky's disease), a herpesvirus of swine and other animals.
Substances elaborated by viruses that have antigenic activity.
Membrane glycoproteins from influenza viruses which are involved in hemagglutination, virus attachment, and envelope fusion. Fourteen distinct subtypes of HA glycoproteins and nine of NA glycoproteins have been identified from INFLUENZA A VIRUS; no subtypes have been identified for Influenza B or Influenza C viruses.
Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)
The process of keeping pharmaceutical products in an appropriate location.
Acute VIRAL CNS INFECTION affecting mammals, including humans. It is caused by RABIES VIRUS and usually spread by contamination with virus-laden saliva of bites inflicted by rabid animals. Important animal vectors include the dog, cat, bat, fox, raccoon, skunk, and wolf.
A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
Virus diseases caused by the ORTHOMYXOVIRIDAE.
The term "United States" in a medical context often refers to the country where a patient or study participant resides, and is not a medical term per se, but relevant for epidemiological studies, healthcare policies, and understanding differences in disease prevalence, treatment patterns, and health outcomes across various geographic locations.
Proteins found in any species of protozoan.
The type species of the genus INFLUENZAVIRUS A that causes influenza and other diseases in humans and animals. Antigenic variation occurs frequently between strains, allowing classification into subtypes and variants. Transmission is usually by aerosol (human and most non-aquatic hosts) or waterborne (ducks). Infected birds shed the virus in their saliva, nasal secretions, and feces.
Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS.
Infections with bacteria of the species NEISSERIA MENINGITIDIS.
Vaccines used in conjunction with diagnostic tests to differentiate vaccinated animals from carrier animals. Marker vaccines can be either a subunit or a gene-deleted vaccine.
A type of H. influenzae isolated most frequently from biotype I. Prior to vaccine availability, it was a leading cause of childhood meningitis.
Process of determining and distinguishing species of bacteria or viruses based on antigens they share.
Specialized cells of the hematopoietic system that have branch-like extensions. They are found throughout the lymphatic system, and in non-lymphoid tissues such as SKIN and the epithelia of the intestinal, respiratory, and reproductive tracts. They trap and process ANTIGENS, and present them to T-CELLS, thereby stimulating CELL-MEDIATED IMMUNITY. They are different from the non-hematopoietic FOLLICULAR DENDRITIC CELLS, which have a similar morphology and immune system function, but with respect to humoral immunity (ANTIBODY PRODUCTION).
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
The type species of the FLAVIVIRUS genus. Principal vector transmission to humans is by AEDES spp. mosquitoes.
An acute infectious disease caused by RUBULAVIRUS, spread by direct contact, airborne droplet nuclei, fomites contaminated by infectious saliva, and perhaps urine, and usually seen in children under the age of 15, although adults may also be affected. (From Dorland, 28th ed)
Elements of limited time intervals, contributing to particular results or situations.
Strains of Neisseria meningitidis which are the most common ones causing infections or disease in infants. Serogroup B strains are isolated most frequently in sporadic cases, and are less common in outbreaks and epidemics.
The non-susceptibility to infection of a large group of individuals in a population. A variety of factors can be responsible for herd immunity and this gives rise to the different definitions used in the literature. Most commonly, herd immunity refers to the case when, if most of the population is immune, infection of a single individual will not cause an epidemic. Also, in such immunized populations, susceptible individuals are not likely to become infected. Herd immunity can also refer to the case when unprotected individuals fail to contract a disease because the infecting organism has been banished from the population.
Vaccines or candidate vaccines used to prevent LYME DISEASE.
Layers of protein which surround the capsid in animal viruses with tubular nucleocapsids. The envelope consists of an inner layer of lipids and virus specified proteins also called membrane or matrix proteins. The outer layer consists of one or more types of morphological subunits called peplomers which project from the viral envelope; this layer always consists of glycoproteins.
Epidemics of infectious disease that have spread to many countries, often more than one continent, and usually affecting a large number of people.
The expelling of virus particles from the body. Important routes include the respiratory tract, genital tract, and intestinal tract. Virus shedding is an important means of vertical transmission (INFECTIOUS DISEASE TRANSMISSION, VERTICAL).
A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form.
Nonsusceptibility to the invasive or pathogenic effects of foreign microorganisms or to the toxic effect of antigenic substances.
Vaccines or candidate vaccines used to prevent or treat PSEUDOMONAS INFECTIONS.
The giving of drugs, chemicals, or other substances by mouth.
A fulminant infection of the meninges and subarachnoid fluid by the bacterium NEISSERIA MENINGITIDIS, producing diffuse inflammation and peri-meningeal venous thromboses. Clinical manifestations include FEVER, nuchal rigidity, SEIZURES, severe HEADACHE, petechial rash, stupor, focal neurologic deficits, HYDROCEPHALUS, and COMA. The organism is usually transmitted via nasopharyngeal secretions and is a leading cause of meningitis in children and young adults. Organisms from Neisseria meningitidis serogroups A, B, C, Y, and W-135 have been reported to cause meningitis. (From Adams et al., Principles of Neurology, 6th ed, pp689-701; Curr Opin Pediatr 1998 Feb;10(1):13-8)

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) gp120 peptides in HIV-1-infected individuals immunized with HIV-1 rgp120 or rgp160 compared with nonimmunized and uninfected controls. (1/1614)

The proliferative responses to a series of peptides constituting the human immunodeficiency virus type 1 (HIV-1) gp120 sequence were evaluated in 19 HIV-1-infected rgp160 vaccine recipients, 17 HIV-1-infected rgp120 vaccine recipients, 15 HIV-1-infected placebo recipients, and 18 HIV-1-uninfected controls. Many regions of the gp120 molecule were found to contribute proliferative epitopes, although there were clearly regions of relative dominance and silence. Vaccine recipients tended to have broader, more robust, and more frequent peptide recognition than the placebo recipients. Despite the considerable variability in the pattern of peptide recognition among individuals, there was a striking similarity between the rgp160 and rgp120 vaccinee groups as a whole. Low-risk HIV-1-uninfected individuals may react to a few peptides within the gp120 sequence as well, despite a lack of significant response to the whole gp120 protein.  (+info)

Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. (2/1614)

The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.  (+info)

Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. (3/1614)

The potential roles of adhesion molecules in the expansion of T cell-mediated immune responses in the periphery were examined using DNA immunogen constructs as model antigens. We coimmunized cDNA expression cassettes encoding the adhesion molecules intracellular adhesion molecule-1 (ICAM-1), lymphocyte function associated-3 (LFA-3), and vascular cell adhesion molecule-1 (VCAM-1) along with DNA immunogens, and we analyzed the resulting antigen-specific immune responses. We observed that antigen-specific T-cell responses can be enhanced by the coexpression of DNA immunogen and adhesion molecules ICAM-1 and LFA-3. Coexpression of ICAM-1 or LFA-3 molecules along with DNA immunogens resulted in a significant enhancement of T-helper cell proliferative responses. In addition, coimmunization with pCICAM-1 (and more moderately with pCLFA-3) resulted in a dramatic enhancement of CD8-restricted cytotoxic T-lymphocyte responses. Although VCAM-1 and ICAM-1 are similar in size, VCAM-1 coimmunization did not have any measurable effect on cell-mediated responses. These results suggest that ICAM-1 and LFA-3 provide direct T-cell costimulation. These observations are further supported by the finding that coinjection with ICAM-1 dramatically enhanced the level of interferon-gamma (IFN-gamma) and beta-chemokines macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and regulated on activation normal T-cell expression and secreted (RANTES) produced by stimulated T cells. Through comparative studies, we observed that ICAM-1/LFA-1 T-cell costimulatory pathways are independent of CD86/CD28 pathways and that they may synergistically expand T-cell responses in vivo.  (+info)

Rectal transmission of human immunodeficiency virus type 1 to chimpanzees. (4/1614)

Inoculation of chimpanzees with human immunodeficiency virus type 1 (HIV-1) has been used as a model system to define mechanisms of pathogenesis and to test protective efficacy of candidate HIV-1 vaccines. In most of these studies, the animals were inoculated intravenously. However, because HIV-1 is transmitted primarily across mucosal surfaces, future evaluations of vaccines should employ mucosal routes for administering infectious virus to immunized animals. To develop a model of rectal transmission of HIV-1, chimpanzees were exposed without trauma to 4 different HIV-1 strains at doses ranging from 200 to 10,000 TCIDs. Infection, characterized by seroconversion and repeated isolation of virus from lymphocytes, was established in 1 of 5 animals. This animal was sequentially inoculated with a subtype B and then an E strain and was infected with both strains. The results show that rectal exposure of adult chimpanzees to cell-free HIV-1 was not an efficient mode of transmission in this cohort.  (+info)

Mucosal vaccination strategies for women. (5/1614)

Women were immunized orally, rectally, or vaginally with a recombinant cholera toxin B-containing vaccine to determine which of these mucosal immunization routes generate the greatest levels of antibody in the female genital tract and rectum. ELISA was used to measure concentrations of cholera toxin B-specific IgA and IgG antibody in serum and secretions before and after three immunizations. Each immunization route similarly increased specific IgG in serum and specific IgA in saliva. Only the vaginal route increased IgA antibodies in genital tract secretions and could be shown to induce a local IgG response. However, vaginal immunization failed to produce antibody in the rectum. In a similar fashion, rectal immunization elicited highest concentrations of locally derived IgA and IgG antibody in the rectum but was ineffective for generating antibody in the genital tract. The data suggest that local immunization may induce the greatest immune responses in the female genital tract and rectum of humans.  (+info)

Detection of intracellular antigen-specific cytokines in human T cell populations. (6/1614)

Determination of antigen-specific cytokine responses of T lymphocytes after vaccination is made difficult by the low frequency of responder cells. In order to detect these responses, the profile of intracellular cytokines was analyzed using flow cytometry after antigenic expansion. Peripheral blood mononuclear cells were stimulated with antigens for 5 days, further expanded with interleukin (IL)-2, and then restimulated on day 10. Cytokine production was detected by intracellular staining with monoclonal antibodies after saponin-based permeabilization. Influenza expansion resulted in specific interferon-gamma (IFN-gamma) production of 6%-20%, with less IL-4 production (0%-2%). Tetanus toxoid resulted in even greater production. IL-4 and IFN-gamma were produced mainly by memory cells of the CD45RO+ phenotype. IFN-gamma production was contributed by both CD4 and CD8 populations. These methods were then applied to a clinical trial of a candidate human immunodeficiency virus type 1 vaccine. Antigen-specific increases in IFN-gamma were measured, which corresponded to antibody production, lymphoproliferation, and skin testing.  (+info)

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. (7/1614)

The role of antibody in protection against human immunodeficiency virus (HIV-1) has been difficult to study in animal models because most primary HIV-1 strains do not infect nonhuman primates. Using a chimeric simian/human immunodeficiency virus (SHIV) based on the envelope of a primary isolate (HIV-89.6), we performed passive-transfer experiments in rhesus macaques to study the role of anti-envelope antibodies in protection. Based on prior in vitro data showing neutralization synergy by antibody combinations, we evaluated HIV immune globulin (HIVIG), and human monoclonal antibodies (MAbs) 2F5 and 2G12 given alone, compared with the double combination 2F5/2G12 and the triple combination HIVIG/2F5/2G12. Antibodies were administered 24 h prior to intravenous challenge with the pathogenic SHIV-89.6PD. Six control monkeys displayed high plasma viremia, rapid CD4(+)-cell decline, and clinical AIDS within 14 weeks. Of six animals given HIVIG/2F5/2G12, three were completely protected; the remaining three animals became SHIV infected but displayed reduced plasma viremia and near normal CD4(+)-cell counts. One of three monkeys given 2F5/2G12 exhibited only transient evidence of infection; the other two had marked reductions in viral load. All monkeys that received HIVIG, 2F5, or 2G12 alone became infected and developed high-level plasma viremia. However, compared to controls, monkeys that received HIVIG or MAb 2G12 displayed a less profound drop in CD4(+) T cells and a more benign clinical course. These data indicate a general correlation between in vitro neutralization and protection and suggest that a vaccine that elicits neutralizing antibody should have a protective effect against HIV-1 infection or disease.  (+info)

Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. (8/1614)

Overcoming preexisting immunity to vaccinia virus in the adult population is a key requirement for development of otherwise potent recombinant vaccinia vaccines. Based on our observation that s.c. immunization with vaccinia induces cellular and antibody immunity to vaccinia only in systemic lymphoid tissue and not in mucosal sites, we hypothesized that the mucosal immune system remains naive to vaccinia and therefore amenable to immunization with recombinant vaccinia vectors despite earlier vaccinia exposure. We show that mucosal immunization of vaccinia-immune BALB/c mice with recombinant vaccinia expressing HIV gp160 induced specific serum antibody and strong HIV-specific cytotoxic T lymphocyte responses. These responses occurred not only in mucosal but also in systemic lymphoid tissue, whereas systemic immunization was ineffective under these circumstances. In this context, intrarectal immunization was more effective than intranasal immunization. Boosting with a second dose of recombinant vaccinia was also more effective via the mucosal route. The systemic HIV-specific cytotoxic T lymphocyte response was enhanced by coadministration of IL-12 at the mucosal site. These results also demonstrate the independent compartmentalization of the mucosal versus systemic immune systems and the asymmetric trafficking of lymphocytes between them. This approach to circumvent previous vaccinia immunity may be useful for induction of protective immunity against infectious diseases and cancer in the sizable populations with preexisting immunity to vaccinia from smallpox vaccination.  (+info)

An AIDS vaccine is a type of preventive vaccine that aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV), which causes acquired immunodeficiency syndrome (AIDS). The goal of an AIDS vaccine is to induce the production of immune cells and proteins that can recognize and eliminate HIV-infected cells, thereby preventing the establishment of a persistent infection.

Despite decades of research, there is still no licensed AIDS vaccine available. This is due in part to the unique challenges posed by HIV, which has a high mutation rate and can rapidly evolve to evade the immune system's defenses. However, several promising vaccine candidates are currently being tested in clinical trials around the world, and researchers continue to explore new approaches and strategies for developing an effective AIDS vaccine.

A vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease. It typically contains an agent that resembles the disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins, or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it encounters in the future.

Vaccines can be prophylactic (to prevent or ameliorate the effects of a future infection by a natural or "wild" pathogen), or therapeutic (to fight disease that is already present). The administration of vaccines is called vaccination. Vaccinations are generally administered through needle injections, but can also be administered by mouth or sprayed into the nose.

The term "vaccine" comes from Edward Jenner's 1796 use of cowpox to create immunity to smallpox. The first successful vaccine was developed in 1796 by Edward Jenner, who showed that milkmaids who had contracted cowpox did not get smallpox. He reasoned that exposure to cowpox protected against smallpox and tested his theory by injecting a boy with pus from a cowpox sore and then exposing him to smallpox, which the boy did not contract. The word "vaccine" is derived from Variolae vaccinae (smallpox of the cow), the term devised by Jenner to denote cowpox. He used it in 1798 during a conversation with a fellow physician and later in the title of his 1801 Inquiry.

A viral vaccine is a biological preparation that introduces your body to a specific virus in a way that helps your immune system build up protection against the virus without causing the illness. Viral vaccines can be made from weakened or inactivated forms of the virus, or parts of the virus such as proteins or sugars. Once introduced to the body, the immune system recognizes the virus as foreign and produces an immune response, including the production of antibodies. These antibodies remain in the body and provide immunity against future infection with that specific virus.

Viral vaccines are important tools for preventing infectious diseases caused by viruses, such as influenza, measles, mumps, rubella, polio, hepatitis A and B, rabies, rotavirus, chickenpox, shingles, and some types of cancer. Vaccination programs have led to the control or elimination of many infectious diseases that were once common.

It's important to note that viral vaccines are not effective against bacterial infections, and separate vaccines must be developed for each type of virus. Additionally, because viruses can mutate over time, it is necessary to update some viral vaccines periodically to ensure continued protection.

Synthetic vaccines are artificially produced, designed to stimulate an immune response and provide protection against specific diseases. Unlike traditional vaccines that are derived from weakened or killed pathogens, synthetic vaccines are created using synthetic components, such as synthesized viral proteins, DNA, or RNA. These components mimic the disease-causing agent and trigger an immune response without causing the actual disease. The use of synthetic vaccines offers advantages in terms of safety, consistency, and scalability in production, making them valuable tools for preventing infectious diseases.

Inactivated vaccines, also known as killed or non-live vaccines, are created by using a version of the virus or bacteria that has been grown in a laboratory and then killed or inactivated with chemicals, heat, or radiation. This process renders the organism unable to cause disease, but still capable of stimulating an immune response when introduced into the body.

Inactivated vaccines are generally considered safer than live attenuated vaccines since they cannot revert back to a virulent form and cause illness. However, they may require multiple doses or booster shots to maintain immunity because the immune response generated by inactivated vaccines is not as robust as that produced by live vaccines. Examples of inactivated vaccines include those for hepatitis A, rabies, and influenza (inactivated flu vaccine).

I could not find a specific medical definition for "Vaccines, DNA." However, I can provide you with some information about DNA vaccines.

DNA vaccines are a type of vaccine that uses genetically engineered DNA to stimulate an immune response in the body. They work by introducing a small piece of DNA into the body that contains the genetic code for a specific antigen (a substance that triggers an immune response). The cells of the body then use this DNA to produce the antigen, which prompts the immune system to recognize and attack it.

DNA vaccines have several advantages over traditional vaccines. They are relatively easy to produce, can be stored at room temperature, and can be designed to protect against a wide range of diseases. Additionally, because they use DNA to stimulate an immune response, DNA vaccines do not require the growth and culture of viruses or bacteria, which can make them safer than traditional vaccines.

DNA vaccines are still in the experimental stages, and more research is needed to determine their safety and effectiveness. However, they have shown promise in animal studies and are being investigated as a potential tool for preventing a variety of infectious diseases, including influenza, HIV, and cancer.

Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:

1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.

Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.

Bacterial vaccines are types of vaccines that are created using bacteria or parts of bacteria as the immunogen, which is the substance that triggers an immune response in the body. The purpose of a bacterial vaccine is to stimulate the immune system to develop protection against specific bacterial infections.

There are several types of bacterial vaccines, including:

1. Inactivated or killed whole-cell vaccines: These vaccines contain entire bacteria that have been killed or inactivated through various methods, such as heat or chemicals. The bacteria can no longer cause disease, but they still retain the ability to stimulate an immune response.
2. Subunit, protein, or polysaccharide vaccines: These vaccines use specific components of the bacterium, such as proteins or polysaccharides, that are known to trigger an immune response. By using only these components, the vaccine can avoid using the entire bacterium, which may reduce the risk of adverse reactions.
3. Live attenuated vaccines: These vaccines contain live bacteria that have been weakened or attenuated so that they cannot cause disease but still retain the ability to stimulate an immune response. This type of vaccine can provide long-lasting immunity, but it may not be suitable for people with weakened immune systems.

Bacterial vaccines are essential tools in preventing and controlling bacterial infections, reducing the burden of diseases such as tuberculosis, pneumococcal disease, meningococcal disease, and Haemophilus influenzae type b (Hib) disease. They work by exposing the immune system to a harmless form of the bacteria or its components, which triggers the production of antibodies and memory cells that can recognize and fight off future infections with that same bacterium.

It's important to note that while vaccines are generally safe and effective, they may cause mild side effects such as pain, redness, or swelling at the injection site, fever, or fatigue. Serious side effects are rare but can occur, so it's essential to consult with a healthcare provider before receiving any vaccine.

I believe there may be a slight confusion in your question. AIDS is a condition caused by the human immunodeficiency virus (HIV) infection, and it weakens the immune system, making people more susceptible to other infections and diseases. There is no vaccine for AIDS itself. However, there are vaccines being developed and tested to prevent HIV infection, which would help prevent AIDS from developing.

SAIDS is not a medical term. If you meant to ask about "HIV vaccines," I can provide a definition:

An HIV vaccine aims to stimulate the immune system to produce an effective response against the human immunodeficiency virus (HIV). An effective HIV vaccine would ideally prevent the initial infection or significantly reduce viral replication and disease progression in infected individuals. Currently, no licensed HIV vaccines are available, but research is ongoing to develop a protective vaccine against HIV infection.

Simian Immunodeficiency Virus (SIV) is a retrovirus that primarily infects African non-human primates and is the direct ancestor of Human Immunodeficiency Virus type 2 (HIV-2). It is similar to HIV in its structure, replication strategy, and ability to cause an immunodeficiency disease in its host. SIV infection in its natural hosts is typically asymptomatic and non-lethal, but it can cause AIDS-like symptoms in other primate species. Research on SIV in its natural hosts has provided valuable insights into the mechanisms of HIV pathogenesis and potential strategies for prevention and treatment of AIDS.

HIV antibodies are proteins produced by the immune system in response to the presence of HIV (Human Immunodeficiency Virus) in the body. These antibodies are designed to recognize and bind to specific parts of the virus, known as antigens, in order to neutralize or eliminate it.

There are several types of HIV antibodies that can be produced, including:

1. Anti-HIV-1 and anti-HIV-2 antibodies: These are antibodies that specifically target the HIV-1 and HIV-2 viruses, respectively.
2. Antibodies to HIV envelope proteins: These antibodies recognize and bind to the outer envelope of the virus, which is covered in glycoprotein spikes that allow the virus to attach to and enter host cells.
3. Antibodies to HIV core proteins: These antibodies recognize and bind to the interior of the viral particle, where the genetic material of the virus is housed.

The presence of HIV antibodies in the blood can be detected through a variety of tests, including enzyme-linked immunosorbent assay (ELISA) and Western blot. A positive test result for HIV antibodies indicates that an individual has been infected with the virus, although it may take several weeks or months after infection for the antibodies to become detectable.

"Macaca mulatta" is the scientific name for the Rhesus macaque, a species of monkey that is native to South, Central, and Southeast Asia. They are often used in biomedical research due to their genetic similarity to humans.

Vaccination is a simple, safe, and effective way to protect people against harmful diseases, before they come into contact with them. It uses your body's natural defenses to build protection to specific infections and makes your immune system stronger.

A vaccination usually contains a small, harmless piece of a virus or bacteria (or toxins produced by these germs) that has been made inactive or weakened so it won't cause the disease itself. This piece of the germ is known as an antigen. When the vaccine is introduced into the body, the immune system recognizes the antigen as foreign and produces antibodies to fight it.

If a person then comes into contact with the actual disease-causing germ, their immune system will recognize it and immediately produce antibodies to destroy it. The person is therefore protected against that disease. This is known as active immunity.

Vaccinations are important for both individual and public health. They prevent the spread of contagious diseases and protect vulnerable members of the population, such as young children, the elderly, and people with weakened immune systems who cannot be vaccinated or for whom vaccination is not effective.

A subunit vaccine is a type of vaccine that contains a specific piece or component of the microorganism (such as a protein, sugar, or part of the bacterial outer membrane), instead of containing the entire organism. This piece of the microorganism is known as an antigen, and it stimulates an immune response in the body, allowing the development of immunity against the targeted infection without introducing the risk of disease associated with live vaccines.

Subunit vaccines offer several advantages over other types of vaccines. They are generally safer because they do not contain live or weakened microorganisms, making them suitable for individuals with weakened immune systems or specific medical conditions that prevent them from receiving live vaccines. Additionally, subunit vaccines can be designed to focus on the most immunogenic components of a pathogen, potentially leading to stronger and more targeted immune responses.

Examples of subunit vaccines include the Hepatitis B vaccine, which contains a viral protein, and the Haemophilus influenzae type b (Hib) vaccine, which uses pieces of the bacterial polysaccharide capsule. These vaccines have been crucial in preventing serious infectious diseases and reducing associated complications worldwide.

Conjugate vaccines are a type of vaccine that combines a part of a bacterium with a protein or other substance to boost the body's immune response to the bacteria. The bacterial component is usually a polysaccharide, which is a long chain of sugars that makes up part of the bacterial cell wall.

By itself, a polysaccharide is not very immunogenic, meaning it does not stimulate a strong immune response. However, when it is conjugated or linked to a protein or other carrier molecule, it becomes much more immunogenic and can elicit a stronger and longer-lasting immune response.

Conjugate vaccines are particularly effective in protecting against bacterial infections that affect young children, such as Haemophilus influenzae type b (Hib) and pneumococcal disease. These vaccines have been instrumental in reducing the incidence of these diseases and their associated complications, such as meningitis and pneumonia.

Overall, conjugate vaccines work by mimicking a natural infection and stimulating the immune system to produce antibodies that can protect against future infections with the same bacterium. By combining a weakly immunogenic polysaccharide with a protein carrier, these vaccines can elicit a stronger and more effective immune response, providing long-lasting protection against bacterial infections.

Simian Acquired Immunodeficiency Syndrome (SAIDS) is not recognized as a medical condition in humans. However, it is a disease that affects non-human primates like African green monkeys and sooty mangabeys. SAIDS is caused by the Simian Immunodeficiency Virus (SIV), which is similar to the Human Immunodeficiency Virus (HIV) that leads to Acquired Immunodeficiency Syndrome (AIDS) in humans.

In non-human primates, SIV infection can lead to a severe immunodeficiency state, characterized by the destruction of CD4+ T cells and impaired immune function, making the host susceptible to various opportunistic infections and cancers. However, it is important to note that most non-human primates infected with SIV do not develop SAIDS spontaneously, unlike humans who acquire HIV infection.

In summary, Simian Acquired Immunodeficiency Syndrome (SAIDS) is a disease affecting non-human primates due to Simian Immunodeficiency Virus (SIV) infection, characterized by immunodeficiency and susceptibility to opportunistic infections and cancers. It should not be confused with Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome (HIV/AIDS) in humans.

HIV-1 (Human Immunodeficiency Virus type 1) is a species of the retrovirus genus that causes acquired immunodeficiency syndrome (AIDS). It is primarily transmitted through sexual contact, exposure to infected blood or blood products, and from mother to child during pregnancy, childbirth, or breastfeeding. HIV-1 infects vital cells in the human immune system, such as CD4+ T cells, macrophages, and dendritic cells, leading to a decline in their numbers and weakening of the immune response over time. This results in the individual becoming susceptible to various opportunistic infections and cancers that ultimately cause death if left untreated. HIV-1 is the most prevalent form of HIV worldwide and has been identified as the causative agent of the global AIDS pandemic.

Secondary immunization, also known as "anamnestic response" or "booster," refers to the enhanced immune response that occurs upon re-exposure to an antigen, having previously been immunized or infected with the same pathogen. This response is characterized by a more rapid and robust production of antibodies and memory cells compared to the primary immune response. The secondary immunization aims to maintain long-term immunity against infectious diseases and improve vaccine effectiveness. It usually involves administering additional doses of a vaccine or booster shots after the initial series of immunizations, which helps reinforce the immune system's ability to recognize and combat specific pathogens.

Acquired Immunodeficiency Syndrome (AIDS) is a chronic, life-threatening condition caused by the Human Immunodeficiency Virus (HIV). AIDS is the most advanced stage of HIV infection, characterized by the significant weakening of the immune system, making the person more susceptible to various opportunistic infections and cancers.

The medical definition of AIDS includes specific criteria based on CD4+ T-cell count or the presence of certain opportunistic infections and diseases. According to the Centers for Disease Control and Prevention (CDC), a person with HIV is diagnosed with AIDS when:

1. The CD4+ T-cell count falls below 200 cells per cubic millimeter of blood (mm3) - a normal range is typically between 500 and 1,600 cells/mm3.
2. They develop one or more opportunistic infections or cancers that are indicative of advanced HIV disease, regardless of their CD4+ T-cell count.

Some examples of these opportunistic infections and cancers include:

* Pneumocystis pneumonia (PCP)
* Candidiasis (thrush) affecting the esophagus, trachea, or lungs
* Cryptococcal meningitis
* Toxoplasmosis of the brain
* Cytomegalovirus disease
* Kaposi's sarcoma
* Non-Hodgkin's lymphoma
* Invasive cervical cancer

It is important to note that with appropriate antiretroviral therapy (ART), people living with HIV can maintain their CD4+ T-cell counts, suppress viral replication, and prevent the progression to AIDS. Early diagnosis and consistent treatment are crucial for managing HIV and improving life expectancy and quality of life.

Malaria vaccines are biological preparations that induce immunity against malaria parasites, thereby preventing or reducing the severity of malaria disease. They typically contain antigens (proteins or other molecules derived from the parasite) that stimulate an immune response in the recipient, enabling their body to recognize and neutralize the pathogen upon exposure.

The most advanced malaria vaccine candidate is RTS,S/AS01 (Mosquirix), which targets the Plasmodium falciparum parasite's circumsporozoite protein (CSP). This vaccine has shown partial protection in clinical trials, reducing the risk of severe malaria and hospitalization in young children by about 30% over four years. However, it does not provide complete immunity, and additional research is ongoing to develop more effective vaccines against malaria.

Neutralization tests are a type of laboratory assay used in microbiology and immunology to measure the ability of a substance, such as an antibody or antitoxin, to neutralize the activity of a toxin or infectious agent. In these tests, the substance to be tested is mixed with a known quantity of the toxin or infectious agent, and the mixture is then incubated under controlled conditions. After incubation, the mixture is tested for residual toxicity or infectivity using a variety of methods, such as cell culture assays, animal models, or biochemical assays.

The neutralization titer is then calculated based on the highest dilution of the test substance that completely neutralizes the toxin or infectious agent. Neutralization tests are commonly used in the diagnosis and evaluation of immune responses to vaccines, as well as in the detection and quantification of toxins and other harmful substances.

Examples of neutralization tests include the serum neutralization test for measles antibodies, the plaque reduction neutralization test (PRNT) for dengue virus antibodies, and the cytotoxicity neutralization assay for botulinum neurotoxins.

HIV antigens refer to the proteins present on the surface or within the human immunodeficiency virus (HIV), which can stimulate an immune response in the infected individual. These antigens are recognized by the host's immune system, specifically by CD4+ T cells and antibodies, leading to their activation and production. Two significant HIV antigens are the HIV-1 p24 antigen and the gp120/gp41 envelope proteins. The p24 antigen is a capsid protein found within the viral particle, while the gp120/gp41 complex forms the viral envelope and facilitates viral entry into host cells. Detection of HIV antigens in clinical settings, such as in the ELISA or Western blot tests, helps diagnose HIV infection and monitor disease progression.

A gene product is the biochemical material, such as a protein or RNA, that is produced by the expression of a gene. Env, short for "envelope," refers to a type of gene product that is commonly found in enveloped viruses. The env gene encodes the viral envelope proteins, which are crucial for the virus's ability to attach to and enter host cells during infection. These envelope proteins typically form a coat around the exterior of the virus and interact with receptors on the surface of the host cell, triggering the fusion or endocytosis processes that allow the viral genome to enter the host cell.

Therefore, in medical terms, 'Gene Products, env' specifically refers to the proteins or RNA produced by the env gene in enveloped viruses, which play a critical role in the virus's infectivity and pathogenesis.

Neutralizing antibodies are a type of antibody that defends against pathogens such as viruses or bacteria by neutralizing their ability to infect cells. They do this by binding to specific regions on the surface proteins of the pathogen, preventing it from attaching to and entering host cells. This renders the pathogen ineffective and helps to prevent or reduce the severity of infection. Neutralizing antibodies can be produced naturally in response to an infection or vaccination, or they can be generated artificially for therapeutic purposes.

Papillomavirus vaccines are vaccines that have been developed to prevent infection by human papillomaviruses (HPV). HPV is a DNA virus that is capable of infecting the skin and mucous membranes. Certain types of HPV are known to cause cervical cancer, as well as other types of cancer such as anal, penile, vulvar, and oropharyngeal cancers. Other types of HPV can cause genital warts.

There are currently two papillomavirus vaccines that have been approved for use in the United States: Gardasil and Cervarix. Both vaccines protect against the two most common cancer-causing types of HPV (types 16 and 18), which together cause about 70% of cervical cancers. Gardasil also protects against the two most common types of HPV that cause genital warts (types 6 and 11).

Papillomavirus vaccines are given as a series of three shots over a period of six months. They are most effective when given to people before they become sexually active, as this reduces the risk of exposure to HPV. The Centers for Disease Control and Prevention (CDC) recommends that all boys and girls get vaccinated against HPV at age 11 or 12, but the vaccine can be given to people as young as age 9 and as old as age 26.

It is important to note that papillomavirus vaccines do not protect against all types of HPV, and they do not treat existing HPV infections or cervical cancer. They are intended to prevent new HPV infections and the cancers and other diseases that can be caused by HPV.

Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.

Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.

There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.

In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.

Meningococcal vaccines are vaccines that protect against Neisseria meningitidis, a type of bacteria that can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (bloodstream infection). There are several types of meningococcal vaccines available, including conjugate vaccines and polysaccharide vaccines. These vaccines work by stimulating the immune system to produce antibodies that can protect against the different serogroups of N. meningitidis, including A, B, C, Y, and W-135. The specific type of vaccine used and the number of doses required may depend on a person's age, health status, and other factors. Meningococcal vaccines are recommended for certain high-risk populations, such as infants, young children, adolescents, and people with certain medical conditions, as well as for travelers to areas where meningococcal disease is common.

HIV Envelope Protein gp120 is a glycoprotein that is a major component of the outer envelope of the Human Immunodeficiency Virus (HIV). It plays a crucial role in the viral infection process. The "gp" stands for glycoprotein.

The gp120 protein is responsible for binding to CD4 receptors on the surface of human immune cells, particularly T-helper cells or CD4+ cells. This binding initiates the fusion process that allows the virus to enter and infect the cell.

After attachment, a series of conformational changes occur in the gp120 and another envelope protein, gp41, leading to the formation of a bridge between the viral and cell membranes, which ultimately results in the virus entering the host cell.

The gp120 protein is also one of the primary targets for HIV vaccine design due to its critical role in the infection process and its surface location, making it accessible to the immune system. However, its high variability and ability to evade the immune response have posed significant challenges in developing an effective HIV vaccine.

HIV (Human Immunodeficiency Virus) infection is a viral illness that progressively attacks and weakens the immune system, making individuals more susceptible to other infections and diseases. The virus primarily infects CD4+ T cells, a type of white blood cell essential for fighting off infections. Over time, as the number of these immune cells declines, the body becomes increasingly vulnerable to opportunistic infections and cancers.

HIV infection has three stages:

1. Acute HIV infection: This is the initial stage that occurs within 2-4 weeks after exposure to the virus. During this period, individuals may experience flu-like symptoms such as fever, fatigue, rash, swollen glands, and muscle aches. The virus replicates rapidly, and the viral load in the body is very high.
2. Chronic HIV infection (Clinical latency): This stage follows the acute infection and can last several years if left untreated. Although individuals may not show any symptoms during this phase, the virus continues to replicate at low levels, and the immune system gradually weakens. The viral load remains relatively stable, but the number of CD4+ T cells declines over time.
3. AIDS (Acquired Immunodeficiency Syndrome): This is the most advanced stage of HIV infection, characterized by a severely damaged immune system and numerous opportunistic infections or cancers. At this stage, the CD4+ T cell count drops below 200 cells/mm3 of blood.

It's important to note that with proper antiretroviral therapy (ART), individuals with HIV infection can effectively manage the virus, maintain a healthy immune system, and significantly reduce the risk of transmission to others. Early diagnosis and treatment are crucial for improving long-term health outcomes and reducing the spread of HIV.

"Hepatitis B vaccines are vaccines that prevent infection caused by the hepatitis B virus. They work by introducing a small and harmless piece of the virus to your body, which triggers your immune system to produce antibodies to fight off the infection. These antibodies remain in your body and provide protection if you are exposed to the real hepatitis B virus in the future.

The hepatitis B vaccine is typically given as a series of three shots over a six-month period. It is recommended for all infants, children and adolescents who have not previously been vaccinated, as well as for adults who are at increased risk of infection, such as healthcare workers, people who inject drugs, and those with certain medical conditions.

It's important to note that hepatitis B vaccine does not provide protection against other types of viral hepatitis, such as hepatitis A or C."

A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.

The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.

Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.

A Pertussis vaccine is a type of immunization used to protect against pertussis, also known as whooping cough. It contains components that stimulate the immune system to produce antibodies against the bacteria that cause pertussis, Bordetella pertussis. There are two main types of pertussis vaccines: whole-cell pertussis (wP) vaccines and acellular pertussis (aP) vaccines. wP vaccines contain killed whole cells of B. pertussis, while aP vaccines contain specific components of the bacteria, such as pertussis toxin and other antigens. Pertussis vaccines are often combined with diphtheria and tetanus to form combination vaccines, such as DTaP (diphtheria, tetanus, and acellular pertussis) and TdaP (tetanus, diphtheria, and acellular pertussis). These vaccines are typically given to young children as part of their routine immunization schedule.

Immunization is defined medically as the process where an individual is made immune or resistant to an infectious disease, typically through the administration of a vaccine. The vaccine stimulates the body's own immune system to recognize and fight off the specific disease-causing organism, thereby preventing or reducing the severity of future infections with that organism.

Immunization can be achieved actively, where the person is given a vaccine to trigger an immune response, or passively, where antibodies are transferred to the person through immunoglobulin therapy. Immunizations are an important part of preventive healthcare and have been successful in controlling and eliminating many infectious diseases worldwide.

Haemophilus vaccines are vaccines that are designed to protect against Haemophilus influenzae type b (Hib), a bacterium that can cause serious infections such as meningitis, pneumonia, and epiglottitis. There are two main types of Hib vaccines:

1. Polysaccharide vaccine: This type of vaccine is made from the sugar coating (polysaccharide) of the bacterial cells. It is not effective in children under 2 years of age because their immune systems are not yet mature enough to respond effectively to this type of vaccine.
2. Conjugate vaccine: This type of vaccine combines the polysaccharide with a protein carrier, which helps to stimulate a stronger and more sustained immune response. It is effective in infants as young as 6 weeks old.

Hib vaccines are usually given as part of routine childhood immunizations starting at 2 months of age. They are administered through an injection into the muscle. The vaccine is safe and effective, with few side effects. Vaccination against Hib has led to a significant reduction in the incidence of Hib infections worldwide.

BCG (Bacillus Calmette-Guérin) vaccine is a type of immunization used primarily to prevent tuberculosis (TB). It contains a live but weakened strain of Mycobacterium bovis, which is related to the bacterium that causes TB in humans (Mycobacterium tuberculosis).

The BCG vaccine works by stimulating an immune response in the body, enabling it to better resist infection with TB bacteria if exposed in the future. It is often given to infants and children in countries where TB is common, and its use varies depending on the national immunization policies. The protection offered by the BCG vaccine is moderate and may not last for a very long time.

In addition to its use against TB, the BCG vaccine has also been investigated for its potential therapeutic role in treating bladder cancer and some other types of cancer. The mechanism of action in these cases is thought to be related to the vaccine's ability to stimulate an immune response against abnormal cells.

Poliovirus Vaccine, Inactivated (IPV) is a vaccine used to prevent poliomyelitis (polio), a highly infectious disease caused by the poliovirus. IPV contains inactivated (killed) polioviruses of all three poliovirus types. It works by stimulating an immune response in the body, but because the viruses are inactivated, they cannot cause polio. After vaccination, the immune system recognizes and responds to the inactivated viruses, producing antibodies that protect against future infection with wild, or naturally occurring, polioviruses. IPV is typically given as an injection in the leg or arm, and a series of doses are required for full protection. It is a safe and effective way to prevent polio and its complications.

Rabies vaccines are medical products that contain antigens of the rabies virus, which stimulate an immune response in individuals who receive them. The purpose of rabies vaccines is to prevent the development of rabies, a viral disease that is almost always fatal once symptoms appear.

There are two primary types of rabies vaccines available:

1. Pre-exposure prophylaxis (PrEP) vaccines: These vaccines are given to individuals who are at high risk of coming into contact with the rabies virus, such as veterinarians, animal handlers, and travelers visiting areas where rabies is common. The vaccine series typically consists of three doses given over a period of 28 days.
2. Post-exposure prophylaxis (PEP) vaccines: These vaccines are administered to individuals who have already been exposed to the rabies virus, usually through a bite or scratch from an infected animal. The vaccine series typically consists of four doses given over a period of 14 days, along with a dose of rabies immune globulin (RIG) to provide immediate protection while the immune system responds to the vaccine.

Both types of rabies vaccines are highly effective at preventing the disease, but it is essential to receive them as soon as possible after exposure or before potential exposure, as the virus can be fatal if left untreated.

Rotavirus vaccines are preventive measures used to protect against rotavirus infections, which are the leading cause of severe diarrhea and dehydration among infants and young children worldwide. These vaccines contain weakened or inactivated forms of the rotavirus, a pathogen that infects and causes symptoms by multiplying inside cells lining the small intestine.

The weakened or inactivated virus in the vaccine stimulates an immune response in the body, enabling it to recognize and fight off future rotavirus infections more effectively. The vaccines are usually administered orally, as a liquid droplet or on a sugar cube, to mimic natural infection through the gastrointestinal tract.

There are currently two licensed rotavirus vaccines available globally:

1. Rotarix (GlaxoSmithKline): This vaccine contains an attenuated (weakened) strain of human rotavirus and is given in a two-dose series, typically at 2 and 4 months of age.
2. RotaTeq (Merck): This vaccine contains five reassortant viruses, combining human and animal strains to provide broader protection. It is administered in a three-dose series, usually at 2, 4, and 6 months of age.

Rotavirus vaccines have been shown to significantly reduce the incidence of severe rotavirus gastroenteritis and related hospitalizations among infants and young children. The World Health Organization (WHO) recommends the inclusion of rotavirus vaccination in national immunization programs, particularly in countries with high child mortality rates due to diarrheal diseases.

"Intramuscular injections" refer to a medical procedure where a medication or vaccine is administered directly into the muscle tissue. This is typically done using a hypodermic needle and syringe, and the injection is usually given into one of the large muscles in the body, such as the deltoid (shoulder), vastus lateralis (thigh), or ventrogluteal (buttock) muscles.

Intramuscular injections are used for a variety of reasons, including to deliver medications that need to be absorbed slowly over time, to bypass stomach acid and improve absorption, or to ensure that the medication reaches the bloodstream quickly and directly. Common examples of medications delivered via intramuscular injection include certain vaccines, antibiotics, and pain relievers.

It is important to follow proper technique when administering intramuscular injections to minimize pain and reduce the risk of complications such as infection or injury to surrounding tissues. Proper site selection, needle length and gauge, and injection technique are all critical factors in ensuring a safe and effective intramuscular injection.

Cholera vaccines are preventive measures used to protect against the infection caused by the bacterium Vibrio cholerae. There are several types of cholera vaccines available, including:

1. Inactivated oral vaccine (ICCV): This vaccine contains killed whole-cell bacteria and is given in two doses, with each dose administered at least 14 days apart. It provides protection for up to six months and can be given to adults and children over the age of one year.
2. Live attenuated oral vaccine (LCV): This vaccine contains weakened live bacteria that are unable to cause disease but still stimulate an immune response. The most commonly used LCV is called CVD 103-HgR, which is given in a single dose and provides protection for up to three months. It can be given to adults and children over the age of six years.
3. Injectable cholera vaccine: This vaccine contains inactivated bacteria and is given as an injection. It is not widely available and its effectiveness is limited compared to oral vaccines.

Cholera vaccines are recommended for travelers visiting areas with known cholera outbreaks, particularly if they plan to eat food or drink water that may be contaminated. They can also be used in response to outbreaks to help control the spread of the disease. However, it is important to note that vaccination alone is not sufficient to prevent cholera infection and good hygiene practices, such as handwashing and safe food handling, should always be followed.

HIV (Human Immunodeficiency Virus) is a species of lentivirus (a subgroup of retrovirus) that causes HIV infection and over time, HIV infection can lead to AIDS (Acquired Immunodeficiency Syndrome). This virus attacks the immune system, specifically the CD4 cells, also known as T cells, which are a type of white blood cell that helps coordinate the body's immune response. As HIV destroys these cells, the body becomes more vulnerable to other infections and diseases. It is primarily spread through bodily fluids like blood, semen, vaginal fluids, and breast milk.

It's important to note that while there is no cure for HIV, with proper medical care, HIV can be controlled. Treatment for HIV is called antiretroviral therapy (ART). If taken as prescribed, this medicine reduces the amount of HIV in the body to a very low level, which keeps the immune system working and prevents illness. This treatment also greatly reduces the risk of transmission.

The "env" gene in the Human Immunodeficiency Virus (HIV) encodes for the envelope proteins gp120 and gp41, which are located on the surface of the viral particle. These proteins play a crucial role in the virus's ability to infect human cells.

The gp120 protein is responsible for binding to CD4 receptors and co-receptors (CCR5 or CXCR4) on the surface of host cells, primarily CD4+ T cells, dendritic cells, and macrophages. This interaction allows the virus to attach to and enter the host cell, initiating infection.

The gp41 protein then facilitates the fusion of the viral and host cell membranes, enabling the viral genetic material to be released into the host cell's cytoplasm. Once inside the host cell, HIV can integrate its genome into the host cell's DNA, leading to the production of new virus particles and the continued spread of infection.

Understanding the function of the env gene products is essential for developing effective HIV treatments and vaccines, as targeting these proteins can prevent viral entry and subsequent infection of host cells.

Typhoid-Paratyphoid vaccines are immunizations that protect against typhoid fever and paratyphoid fevers, which are caused by the Salmonella enterica serovars Typhi and Paratyphi, respectively. These vaccines contain inactivated or attenuated bacteria or specific antigens that stimulate an individual's immune system to develop immunity against these diseases without causing the illness itself. There are several types of typhoid-paratyphoid vaccines available, including:

1. Ty21a (oral live attenuated vaccine): This is a live but weakened form of the Salmonella Typhi bacteria. It is given orally in capsule form and requires a series of 4 doses taken every other day. The vaccine provides protection for about 5-7 years.
2. Vi polysaccharide (ViPS) typhoid vaccine: This vaccine contains purified Vi antigens from the Salmonella Typhi bacterium's outer capsular layer. It is given as an injection and provides protection for approximately 2-3 years.
3. Combined typhoid-paratyphoid A and B vaccines (Vi-rEPA): This vaccine combines Vi polysaccharide antigens from Salmonella Typhi and Paratyphi A and B. It is given as an injection and provides protection for about 3 years against typhoid fever and paratyphoid fevers A and B.
4. Typhoid conjugate vaccines (TCVs): These vaccines combine the Vi polysaccharide antigen from Salmonella Typhi with a protein carrier to enhance the immune response, particularly in children under 2 years of age. TCVs are given as an injection and provide long-lasting protection against typhoid fever.

It is important to note that none of these vaccines provides 100% protection, but they significantly reduce the risk of contracting typhoid or paratyphoid fevers. Additionally, good hygiene practices, such as handwashing and safe food handling, can further minimize the risk of infection.

The Smallpox vaccine is not a live virus vaccine but is instead made from a vaccinia virus, which is a virus related to the variola virus (the virus that causes smallpox). The vaccinia virus used in the vaccine does not cause smallpox, but it does cause a milder illness with symptoms such as a fever and a rash of pustules or blisters at the site of inoculation.

The smallpox vaccine was first developed by Edward Jenner in 1796 and is one of the oldest vaccines still in use today. It has been highly effective in preventing smallpox, which was once a major cause of death and disability worldwide. In fact, smallpox was declared eradicated by the World Health Organization (WHO) in 1980, thanks in large part to the widespread use of the smallpox vaccine.

Despite the eradication of smallpox, the smallpox vaccine is still used today in certain circumstances. For example, it may be given to laboratory workers who handle the virus or to military personnel who may be at risk of exposure to the virus. The vaccine may also be used as an emergency measure in the event of a bioterrorism attack involving smallpox.

It is important to note that the smallpox vaccine is not without risks and can cause serious side effects, including a severe allergic reaction (anaphylaxis), encephalitis (inflammation of the brain), and myocarditis (inflammation of the heart muscle). As a result, it is only given to people who are at high risk of exposure to the virus and who have been determined to be good candidates for vaccination by a healthcare professional.

A tuberculosis vaccine, also known as the BCG (Bacillus Calmette-Guérin) vaccine, is a type of immunization used to prevent tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The BCG vaccine contains a weakened strain of the bacteria that causes TB in cattle.

The BCG vaccine works by stimulating an immune response in the body, which helps to protect against severe forms of TB, such as TB meningitis and TB in children. However, it is not very effective at preventing pulmonary TB (TB that affects the lungs) in adults.

The BCG vaccine is not routinely recommended for use in the United States due to the low risk of TB infection in the general population. However, it may be given to people who are at high risk of exposure to TB, such as healthcare workers, laboratory personnel, and people traveling to countries with high rates of TB.

It is important to note that the BCG vaccine does not provide complete protection against TB and that other measures, such as testing and treatment for latent TB infection, are also important for controlling the spread of this disease.

The chickenpox vaccine, also known as varicella vaccine, is a preventive measure against the highly contagious viral infection caused by the varicella-zoster virus. The vaccine contains a live but weakened form of the virus, which stimulates the immune system to produce a response without causing the disease itself.

The chickenpox vaccine is typically given in two doses, with the first dose administered between 12 and 15 months of age and the second dose between 4 and 6 years of age. In some cases, the vaccine may be given to older children, adolescents, or adults who have not previously been vaccinated or who have never had chickenpox.

The chickenpox vaccine is highly effective at preventing severe cases of the disease and reducing the risk of complications such as bacterial infections, pneumonia, and encephalitis. It is also effective at preventing transmission of the virus to others.

Like any vaccine, the chickenpox vaccine can cause mild side effects such as soreness at the injection site, fever, or a mild rash. However, these side effects are generally mild and short-lived. Serious side effects are rare but may include allergic reactions or severe immune responses.

Overall, the chickenpox vaccine is a safe and effective way to prevent this common childhood disease and its potential complications.

The Diphtheria-Tetanus-Pertussis (DTaP) vaccine is a combination immunization that protects against three bacterial diseases: diphtheria, tetanus (lockjaw), and pertussis (whooping cough).

Diphtheria is an upper respiratory infection that can lead to breathing difficulties, heart failure, paralysis, or even death. Tetanus is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, leading to "lockjaw." Pertussis is a highly contagious respiratory infection characterized by severe coughing fits, which can make it difficult to breathe and may lead to pneumonia, seizures, or brain damage.

The DTaP vaccine contains inactivated toxins (toxoids) from the bacteria that cause these diseases. It is typically given as a series of five shots, with doses administered at 2 months, 4 months, 6 months, 15-18 months, and 4-6 years of age. The vaccine helps the immune system develop protection against the diseases without causing the actual illness.

It is important to note that there are other combination vaccines available that protect against these same diseases, such as DT (diphtheria and tetanus toxoids) and Tdap (tetanus, diphtheria, and acellular pertussis), which contain higher doses of the diphtheria and pertussis components. These vaccines are recommended for different age groups and may be used as booster shots to maintain immunity throughout adulthood.

HIV Envelope Protein gp160 is a precursor protein that is cleaved to form the two envelope glycoproteins, gp120 and gp41, on the surface of the Human Immunodeficiency Virus (HIV). The gp160 protein plays a crucial role in the viral life cycle as it mediates the attachment and fusion of the virus to the host cell membrane during infection.

The gp160 protein is composed of an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain contains several important regions that are involved in receptor binding and fusion activation. After the virus infects a host cell, the gp160 protein is cleaved by a protease enzyme into two separate proteins: gp120 and gp41.

The gp120 protein remains on the surface of the viral envelope and functions as the primary binding site for the CD4 receptor on the host cell surface, while gp41 spans the viral membrane and mediates the fusion of the viral and host cell membranes. Together, these proteins facilitate the entry of the viral genome into the host cell, which is a critical step in the HIV replication cycle.

"Gene products, GAG" refer to the proteins that are produced by the GAG (Group-specific Antigen) gene found in retroviruses, such as HIV (Human Immunodeficiency Virus). These proteins play a crucial role in the structure and function of the viral particle or virion.

The GAG gene encodes for a polyprotein that is cleaved by a protease into several individual proteins, including matrix (MA), capsid (CA), and nucleocapsid (NC) proteins. These proteins are involved in the formation of the viral core, which encloses the viral RNA genome and associated enzymes required for replication.

The MA protein is responsible for binding to the host cell membrane during viral entry, while the CA protein forms the capsid shell that surrounds the viral RNA and NC protein. The NC protein binds to the viral RNA and helps to package it into the virion during assembly. Overall, GAG gene products are essential for the life cycle of retroviruses and are important targets for antiretroviral therapy in HIV-infected individuals.

CD8-positive T-lymphocytes, also known as CD8+ T cells or cytotoxic T cells, are a type of white blood cell that plays a crucial role in the adaptive immune system. They are named after the CD8 molecule found on their surface, which is a protein involved in cell signaling and recognition.

CD8+ T cells are primarily responsible for identifying and destroying virus-infected cells or cancerous cells. When activated, they release cytotoxic granules that contain enzymes capable of inducing apoptosis (programmed cell death) in the target cells. They also produce cytokines such as interferon-gamma, which can help coordinate the immune response and activate other immune cells.

CD8+ T cells are generated in the thymus gland and are a type of T cell, which is a lymphocyte that matures in the thymus and plays a central role in cell-mediated immunity. They recognize and respond to specific antigens presented on the surface of infected or cancerous cells in conjunction with major histocompatibility complex (MHC) class I molecules.

Overall, CD8+ T cells are an essential component of the immune system's defense against viral infections and cancer.

A genetic vector is a vehicle, often a plasmid or a virus, that is used to introduce foreign DNA into a host cell as part of genetic engineering or gene therapy techniques. The vector contains the desired gene or genes, along with regulatory elements such as promoters and enhancers, which are needed for the expression of the gene in the target cells.

The choice of vector depends on several factors, including the size of the DNA to be inserted, the type of cell to be targeted, and the efficiency of uptake and expression required. Commonly used vectors include plasmids, adenoviruses, retroviruses, and lentiviruses.

Plasmids are small circular DNA molecules that can replicate independently in bacteria. They are often used as cloning vectors to amplify and manipulate DNA fragments. Adenoviruses are double-stranded DNA viruses that infect a wide range of host cells, including human cells. They are commonly used as gene therapy vectors because they can efficiently transfer genes into both dividing and non-dividing cells.

Retroviruses and lentiviruses are RNA viruses that integrate their genetic material into the host cell's genome. This allows for stable expression of the transgene over time. Lentiviruses, a subclass of retroviruses, have the advantage of being able to infect non-dividing cells, making them useful for gene therapy applications in post-mitotic tissues such as neurons and muscle cells.

Overall, genetic vectors play a crucial role in modern molecular biology and medicine, enabling researchers to study gene function, develop new therapies, and modify organisms for various purposes.

The Mumps Vaccine is a biological preparation intended to induce immunity against mumps, a contagious viral infection that primarily affects the salivary glands. The vaccine contains live attenuated (weakened) mumps virus, which stimulates the immune system to develop a protective response without causing the disease.

There are two types of mumps vaccines available:

1. The Jeryl Lynn strain is used in the United States and is part of the Measles, Mumps, and Rubella (MMR) vaccine and the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. This strain is derived from a clinical isolate obtained from the throat washings of a child with mumps in 1963.
2. The Urabe AM9 strain was used in some countries but has been discontinued in many places due to an increased risk of meningitis as a rare complication.

The MMR vaccine is typically given to children at 12-15 months of age and again at 4-6 years of age, providing long-lasting immunity against mumps in most individuals. The vaccine has significantly reduced the incidence of mumps and its complications worldwide.

Viral load refers to the amount or quantity of virus (like HIV, Hepatitis C, SARS-CoV-2) present in an individual's blood or bodily fluids. It is often expressed as the number of virus copies per milliliter of blood or fluid. Monitoring viral load is important in managing and treating certain viral infections, as a higher viral load may indicate increased infectivity, disease progression, or response to treatment.

Vaccinia virus is a large, complex DNA virus that belongs to the Poxviridae family. It is the virus used in the production of the smallpox vaccine. The vaccinia virus is not identical to the variola virus, which causes smallpox, but it is closely related and provides cross-protection against smallpox infection.

The vaccinia virus has a unique replication cycle that occurs entirely in the cytoplasm of infected cells, rather than in the nucleus like many other DNA viruses. This allows the virus to evade host cell defenses and efficiently produce new virions. The virus causes the formation of pocks or lesions on the skin, which contain large numbers of virus particles that can be transmitted to others through close contact.

Vaccinia virus has also been used as a vector for the delivery of genes encoding therapeutic proteins, vaccines against other infectious diseases, and cancer therapies. However, the use of vaccinia virus as a vector is limited by its potential to cause adverse reactions in some individuals, particularly those with weakened immune systems or certain skin conditions.

Hepatitis A vaccines are inactivated or live attenuated viral vaccines that are administered to prevent infection and illness caused by the hepatitis A virus. The vaccine contains antigens that stimulate an immune response in the body, leading to the production of antibodies that protect against future infection with the virus.

The inactivated hepatitis A vaccine is made from viruses that have been chemically treated to destroy their ability to cause disease while preserving their ability to stimulate an immune response. This type of vaccine is typically given in two doses, six months apart, and provides long-term protection against the virus.

The live attenuated hepatitis A vaccine contains a weakened form of the virus that is unable to cause illness but can still stimulate an immune response. This type of vaccine is given as a single dose and provides protection against the virus for at least 20 years.

Hepatitis A vaccines are recommended for people who are at increased risk of infection, including travelers to areas where hepatitis A is common, men who have sex with men, people who use injection drugs, and people with chronic liver disease or clotting factor disorders. The vaccine is also recommended for children in certain states and communities where hepatitis A is endemic.

An immunization schedule is a series of planned dates when a person, usually a child, should receive specific vaccines in order to be fully protected against certain preventable diseases. The schedule is developed based on scientific research and recommendations from health organizations such as the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).

The immunization schedule outlines which vaccines are recommended, the number of doses required, the age at which each dose should be given, and the minimum amount of time that must pass between doses. The schedule may vary depending on factors such as the individual's age, health status, and travel plans.

Immunization schedules are important for ensuring that individuals receive timely protection against vaccine-preventable diseases, and for maintaining high levels of immunity in populations, which helps to prevent the spread of disease. It is important to follow the recommended immunization schedule as closely as possible to ensure optimal protection.

Immunologic adjuvants are substances that are added to a vaccine to enhance the body's immune response to the antigens contained in the vaccine. They work by stimulating the immune system and promoting the production of antibodies and activating immune cells, such as T-cells and macrophages, which help to provide a stronger and more sustained immune response to the vaccine.

Immunologic adjuvants can be derived from various sources, including bacteria, viruses, and chemicals. Some common examples include aluminum salts (alum), oil-in-water emulsions (such as MF59), and bacterial components (such as lipopolysaccharide or LPS).

The use of immunologic adjuvants in vaccines can help to improve the efficacy of the vaccine, particularly for vaccines that contain weak or poorly immunogenic antigens. They can also help to reduce the amount of antigen needed in a vaccine, which can be beneficial for vaccines that are difficult or expensive to produce.

It's important to note that while adjuvants can enhance the immune response to a vaccine, they can also increase the risk of adverse reactions, such as inflammation and pain at the injection site. Therefore, the use of immunologic adjuvants must be carefully balanced against their potential benefits and risks.

The Measles-Mumps-Rubella (MMR) vaccine is a combination immunization that protects against three infectious diseases: measles, mumps, and rubella. It contains live attenuated viruses of each disease, which stimulate an immune response in the body similar to that produced by natural infection but do not cause the diseases themselves.

The MMR vaccine is typically given in two doses, the first at 12-15 months of age and the second at 4-6 years of age. It is highly effective in preventing these diseases, with over 90% effectiveness reported after a single dose and near 100% effectiveness after the second dose.

Measles is a highly contagious viral disease that can cause fever, rash, cough, runny nose, and red, watery eyes. It can also lead to serious complications such as pneumonia, encephalitis (inflammation of the brain), and even death.

Mumps is a viral infection that primarily affects the salivary glands, causing swelling and tenderness in the cheeks and jaw. It can also cause fever, headache, muscle aches, and fatigue. Mumps can lead to serious complications such as deafness, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and inflammation of the testicles or ovaries.

Rubella, also known as German measles, is a viral infection that typically causes a mild fever, rash, and swollen lymph nodes. However, if a pregnant woman becomes infected with rubella, it can cause serious birth defects such as hearing impairment, heart defects, and developmental delays in the fetus.

The MMR vaccine is an important tool in preventing these diseases and protecting public health.

Streptococcal vaccines are immunizations designed to protect against infections caused by Streptococcus bacteria. These vaccines contain antigens, which are substances that trigger an immune response and help the body recognize and fight off specific types of Streptococcus bacteria. There are several different types of streptococcal vaccines available or in development, including:

1. Pneumococcal conjugate vaccine (PCV): This vaccine protects against Streptococcus pneumoniae, a type of bacteria that can cause pneumonia, meningitis, and other serious infections. PCV is recommended for all children under 2 years old, as well as older children and adults with certain medical conditions.
2. Pneumococcal polysaccharide vaccine (PPSV): This vaccine also protects against Streptococcus pneumoniae, but it is recommended for adults 65 and older, as well as younger people with certain medical conditions.
3. Streptococcus pyogenes vaccine: This vaccine is being developed to protect against Group A Streptococcus (GAS), which can cause a variety of infections, including strep throat, skin infections, and serious diseases like rheumatic fever and toxic shock syndrome. There are several different GAS vaccine candidates in various stages of development.
4. Streptococcus agalactiae vaccine: This vaccine is being developed to protect against Group B Streptococcus (GBS), which can cause serious infections in newborns, pregnant women, and older adults with certain medical conditions. There are several different GBS vaccine candidates in various stages of development.

Overall, streptococcal vaccines play an important role in preventing bacterial infections and reducing the burden of disease caused by Streptococcus bacteria.

Molecular sequence data refers to the specific arrangement of molecules, most commonly nucleotides in DNA or RNA, or amino acids in proteins, that make up a biological macromolecule. This data is generated through laboratory techniques such as sequencing, and provides information about the exact order of the constituent molecules. This data is crucial in various fields of biology, including genetics, evolution, and molecular biology, allowing for comparisons between different organisms, identification of genetic variations, and studies of gene function and regulation.

Anthrax vaccines are biological preparations designed to protect against anthrax, a potentially fatal infectious disease caused by the bacterium Bacillus anthracis. Anthrax can affect both humans and animals, and it is primarily transmitted through contact with contaminated animal products or, less commonly, through inhalation of spores.

There are two types of anthrax vaccines currently available:

1. Anthrax Vaccine Adsorbed (AVA): This vaccine is licensed for use in the United States and is approved for pre-exposure prophylaxis in high-risk individuals, such as military personnel and laboratory workers who handle the bacterium. AVA contains a cell-free filtrate of cultured B. anthracis cells that have been chemically treated to render them non-infectious. The vaccine works by stimulating the production of antibodies against protective antigens (PA) present in the bacterial culture.
2. Recombinant Anthrax Vaccine (rPA): This vaccine, also known as BioThrax, is a newer generation anthrax vaccine that was approved for use in the United States in 2015. It contains only the recombinant protective antigen (rPA) of B. anthracis, which is produced using genetic engineering techniques. The rPA vaccine has been shown to be as effective as AVA in generating an immune response and offers several advantages, including a more straightforward manufacturing process, fewer side effects, and a longer shelf life.

Both vaccines require multiple doses for initial immunization, followed by periodic booster shots to maintain protection. Anthrax vaccines are generally safe and effective at preventing anthrax infection; however, they may cause mild to moderate side effects, such as soreness at the injection site, fatigue, and muscle aches. Severe allergic reactions are rare but possible.

It is important to note that anthrax vaccines do not provide immediate protection against anthrax infection. They require several weeks to stimulate an immune response, so they should be administered before potential exposure to the bacterium. In cases of known or suspected exposure to anthrax, antibiotics are used as a primary means of preventing and treating the disease.

Dengue vaccines are designed to protect against dengue fever, a mosquito-borne viral disease that can cause severe flu-like symptoms and potentially life-threatening complications. Dengue is caused by four distinct serotypes of the virus (DENV-1, DENV-2, DENV-3, and DENV-4), and infection with one serotype does not provide immunity against the others.

The first licensed dengue vaccine, Dengvaxia (CYD-TDV), is a chimeric yellow fever-dengue tetravalent vaccine developed by Sanofi Pasteur. It is approved for use in several countries and has demonstrated efficacy against dengue fever caused by all four serotypes in clinical trials. However, the vaccine has raised concerns about the risk of severe disease in individuals who have not been previously exposed to dengue. As a result, it is recommended primarily for people with a documented past dengue infection or living in areas with high dengue prevalence and where the benefits outweigh the risks.

Another dengue vaccine candidate, Takeda's TAK-003 (also known as TDV), is a live attenuated tetravalent dengue vaccine that has shown efficacy against all four serotypes in clinical trials. It was granted approval by the European Medicines Agency (EMA) and several other countries for use in individuals aged 4-16 years old, living in endemic areas.

Research and development of additional dengue vaccine candidates are ongoing to address concerns about safety, efficacy, and accessibility, particularly for at-risk populations in low- and middle-income countries where dengue is most prevalent.

CD4-positive T-lymphocytes, also known as CD4+ T cells or helper T cells, are a type of white blood cell that plays a crucial role in the immune response. They express the CD4 receptor on their surface and help coordinate the immune system's response to infectious agents such as viruses and bacteria.

CD4+ T cells recognize and bind to specific antigens presented by antigen-presenting cells, such as dendritic cells or macrophages. Once activated, they can differentiate into various subsets of effector cells, including Th1, Th2, Th17, and Treg cells, each with distinct functions in the immune response.

CD4+ T cells are particularly important in the immune response to HIV (human immunodeficiency virus), which targets and destroys these cells, leading to a weakened immune system and increased susceptibility to opportunistic infections. The number of CD4+ T cells is often used as a marker of disease progression in HIV infection, with lower counts indicating more advanced disease.

Virosomes are artificially constructed spherical vesicles composed of lipids and viral envelope proteins. They are used as a delivery system for vaccines and other therapeutic agents. In the context of vaccines, virosomes can be used to present viral antigens to the immune system in a way that mimics a natural infection, thereby inducing a strong immune response.

Virosome-based vaccines have several advantages over traditional vaccines. For example, they are non-infectious, meaning they do not contain live or attenuated viruses, which makes them safer for certain populations such as immunocompromised individuals. Additionally, virosomes can be engineered to target specific cells in the body, leading to more efficient uptake and presentation of antigens to the immune system.

Virosome-based vaccines have been developed for a variety of diseases, including influenza, hepatitis A, and HIV. While they are not yet widely used, they show promise as a safe and effective alternative to traditional vaccine approaches.

Cytotoxic T-lymphocytes, also known as CD8+ T cells, are a type of white blood cell that plays a central role in the cell-mediated immune system. They are responsible for identifying and destroying virus-infected cells and cancer cells. When a cytotoxic T-lymphocyte recognizes a specific antigen presented on the surface of an infected or malignant cell, it becomes activated and releases toxic substances such as perforins and granzymes, which can create pores in the target cell's membrane and induce apoptosis (programmed cell death). This process helps to eliminate the infected or malignant cells and prevent the spread of infection or cancer.

"Genes x Environment" (GxE) is a term used in the field of genetics to describe the interaction between genetic factors and environmental influences on the development, expression, and phenotypic outcome of various traits, disorders, or diseases. This concept recognizes that both genes and environment play crucial roles in shaping an individual's health and characteristics, and that these factors do not act independently but rather interact with each other in complex ways.

GxE interactions can help explain why some individuals with a genetic predisposition for a particular disorder may never develop the condition, while others without such a predisposition might. The environmental factors involved in GxE interactions can include lifestyle choices (such as diet and exercise), exposure to toxins or pollutants, social experiences, and other external conditions that can influence gene expression and overall health outcomes.

Understanding GxE interactions is essential for developing personalized prevention and treatment strategies, as it allows healthcare providers to consider both genetic and environmental factors when assessing an individual's risk for various disorders or diseases.

Cellular immunity, also known as cell-mediated immunity, is a type of immune response that involves the activation of immune cells, such as T lymphocytes (T cells), to protect the body against infected or damaged cells. This form of immunity is important for fighting off infections caused by viruses and intracellular bacteria, as well as for recognizing and destroying cancer cells.

Cellular immunity involves a complex series of interactions between various immune cells and molecules. When a pathogen infects a cell, the infected cell displays pieces of the pathogen on its surface in a process called antigen presentation. This attracts T cells, which recognize the antigens and become activated. Activated T cells then release cytokines, chemicals that help coordinate the immune response, and can directly attack and kill infected cells or help activate other immune cells to do so.

Cellular immunity is an important component of the adaptive immune system, which is able to learn and remember specific pathogens in order to mount a faster and more effective response upon subsequent exposure. This form of immunity is also critical for the rejection of transplanted organs, as the immune system recognizes the transplanted tissue as foreign and attacks it.

Viral hepatitis vaccines are vaccines that prevent infection caused by various hepatitis viruses, including hepatitis A and B. These vaccines contain antigens that stimulate the immune system to produce antibodies that protect against infection with the corresponding virus. The vaccines are typically administered through injection and may require multiple doses for full protection.

The hepatitis A vaccine is made from inactivated hepatitis A virus, while the hepatitis B vaccine is made from recombinant hepatitis B surface antigen. Both vaccines have been shown to be highly effective in preventing infection and reducing the risk of complications associated with viral hepatitis, such as liver disease and liver cancer.

It's important to note that there are no vaccines available for other types of viral hepatitis, such as hepatitis C, D, or E. Prevention strategies for these types of viral hepatitis typically involve measures to reduce exposure to the virus, such as safe injection practices and avoiding high-risk behaviors like sharing needles or having unprotected sex with infected individuals.

Poliovirus Vaccine, Oral (OPV) is a vaccine used to prevent poliomyelitis (polio). It contains live attenuated (weakened) polioviruses, which stimulate an immune response in the body and provide protection against all three types of wild, infectious polioviruses. OPV is given by mouth, usually in drops, and it replicates in the gastrointestinal tract, where it induces a strong immune response. This response not only protects the individual who receives the vaccine but also helps to stop the spread of poliovirus in the community, providing indirect protection (herd immunity) to those who are not vaccinated. OPV is safe, effective, and easy to administer, making it an important tool for global polio eradication efforts. However, due to the risk of vaccine-associated paralytic polio (VAPP), inactivated poliovirus vaccine (IPV) is recommended for routine immunization in some countries.

The Yellow Fever Vaccine is a vaccine that protects against the yellow fever virus, which is transmitted to humans through the bites of infected mosquitoes. The vaccine contains live, weakened yellow fever virus, and it works by stimulating the immune system to produce an immune response that provides protection against the disease.

The yellow fever vaccine is recommended for people who are traveling to areas where yellow fever is common, including parts of Africa and South America. It is also required for entry into some countries in these regions. The vaccine is generally safe and effective, but it can cause mild side effects such as headache, muscle pain, and fever in some people. Serious side effects are rare, but may include allergic reactions or infection with the weakened virus used in the vaccine.

It's important to note that yellow fever vaccine may not be recommended for certain individuals, including infants younger than 6 months, pregnant women, people with weakened immune systems, and those with a history of severe allergic reaction to a previous dose of the vaccine or any component of the vaccine. It is always best to consult with a healthcare provider before receiving any vaccination.

Bacterial antibodies are a type of antibodies produced by the immune system in response to an infection caused by bacteria. These antibodies are proteins that recognize and bind to specific antigens on the surface of the bacterial cells, marking them for destruction by other immune cells. Bacterial antibodies can be classified into several types based on their structure and function, including IgG, IgM, IgA, and IgE. They play a crucial role in the body's defense against bacterial infections and provide immunity to future infections with the same bacteria.

A plague vaccine is a type of immunization used to protect against the bacterial infection caused by Yersinia pestis, the causative agent of plague. The vaccine contains killed or weakened forms of the bacteria, which stimulate the immune system to produce antibodies and activate immune cells that can recognize and fight off the infection if the person is exposed to the bacteria in the future.

There are several types of plague vaccines available, including whole-cell killed vaccines, live attenuated vaccines, and subunit vaccines. The choice of vaccine depends on various factors, such as the target population, the route of exposure (e.g., respiratory or cutaneous), and the desired duration of immunity.

Plague vaccines have been used for many years to protect military personnel and individuals at high risk of exposure to plague, such as laboratory workers and people living in areas where plague is endemic. However, their use is not widespread, and they are not currently recommended for general use in the United States or other developed countries.

It's important to note that while plague vaccines can provide some protection against the disease, they are not 100% effective, and other measures such as antibiotics and insect control are also important for preventing and treating plague infections.

Clinical trials are research studies that involve human participants and are designed to evaluate the safety and efficacy of new medical treatments, drugs, devices, or behavioral interventions. The purpose of clinical trials is to determine whether a new intervention is safe, effective, and beneficial for patients, as well as to compare it with currently available treatments. Clinical trials follow a series of phases, each with specific goals and criteria, before a new intervention can be approved by regulatory authorities for widespread use.

Clinical trials are conducted according to a protocol, which is a detailed plan that outlines the study's objectives, design, methodology, statistical analysis, and ethical considerations. The protocol is developed and reviewed by a team of medical experts, statisticians, and ethicists, and it must be approved by an institutional review board (IRB) before the trial can begin.

Participation in clinical trials is voluntary, and participants must provide informed consent before enrolling in the study. Informed consent involves providing potential participants with detailed information about the study's purpose, procedures, risks, benefits, and alternatives, as well as their rights as research subjects. Participants can withdraw from the study at any time without penalty or loss of benefits to which they are entitled.

Clinical trials are essential for advancing medical knowledge and improving patient care. They help researchers identify new treatments, diagnostic tools, and prevention strategies that can benefit patients and improve public health. However, clinical trials also pose potential risks to participants, including adverse effects from experimental interventions, time commitment, and inconvenience. Therefore, it is important for researchers to carefully design and conduct clinical trials to minimize risks and ensure that the benefits outweigh the risks.

An amino acid sequence is the specific order of amino acids in a protein or peptide molecule, formed by the linking of the amino group (-NH2) of one amino acid to the carboxyl group (-COOH) of another amino acid through a peptide bond. The sequence is determined by the genetic code and is unique to each type of protein or peptide. It plays a crucial role in determining the three-dimensional structure and function of proteins.

A fungal vaccine is a biological preparation that provides active acquired immunity against fungal infections. It contains one or more fungal antigens, which are substances that can stimulate an immune response, along with adjuvants to enhance the immune response. The goal of fungal vaccines is to protect against invasive fungal diseases, especially in individuals with weakened immune systems, such as those undergoing chemotherapy, organ transplantation, or HIV/AIDS treatment.

Fungal vaccines can work by inducing both humoral and cell-mediated immunity. Humoral immunity involves the production of antibodies that recognize and neutralize fungal antigens, while cell-mediated immunity involves the activation of T cells to directly attack infected cells.

Currently, there are no licensed fungal vaccines available for human use, although several candidates are in various stages of development and clinical trials. Some examples include vaccines against Candida albicans, Aspergillus fumigatus, Cryptococcus neoformans, and Pneumocystis jirovecii.

Cross reactions, in the context of medical diagnostics and immunology, refer to a situation where an antibody or a immune response directed against one antigen also reacts with a different antigen due to similarities in their molecular structure. This can occur in allergy testing, where a person who is allergic to a particular substance may have a positive test result for a different but related substance because of cross-reactivity between them. For example, some individuals who are allergic to birch pollen may also have symptoms when eating certain fruits, such as apples, due to cross-reactive proteins present in both.

Rubella vaccine is a preventive measure used to immunize individuals against rubella, also known as German measles. It contains inactivated or weakened forms of the rubella virus that stimulate an immune response when introduced into the body. The two types of rubella vaccines available are:

1. Live Attenuated Rubella Vaccine (RAV): This vaccine contains a weakened form of the rubella virus, which triggers an immune response without causing the disease. It is the most commonly used rubella vaccine and is often combined with measles and mumps vaccines to create the Measles-Mumps-Rubella (MMR) or Measles-Mumps-Rubella-Varicella (MMRV) vaccines.

2. Inactivated Rubella Vaccine: This vaccine contains a killed rubella virus, which is less commonly used but can still provide immunity against the disease.

The Centers for Disease Control and Prevention (CDC) recommends that children receive one dose of MMR vaccine at 12-15 months of age and another dose at 4-6 years of age. This schedule ensures optimal protection against rubella and other diseases included in the vaccines.

It is important to note that pregnant women should not receive the rubella vaccine, as it can potentially harm the developing fetus. Women who are planning to become pregnant should ensure they have had their rubella immunization before conceiving.

Acellular vaccines are a type of vaccine that contain one or more antigens but do not contain whole cell parts or components of the pathogen. They are designed to produce an immune response in the body that is specific to the antigen(s) contained within the vaccine, while minimizing the risk of adverse reactions associated with whole cell vaccines.

Acellular vaccines are often produced using recombinant DNA technology, where a specific gene from the pathogen is inserted into a different organism (such as yeast or bacteria) that can produce large quantities of the antigen. The antigen is then purified and used to create the vaccine.

One example of an acellular vaccine is the DTaP vaccine, which is used to protect against diphtheria, tetanus, and pertussis (whooping cough). This vaccine contains only a small portion of the pertussis bacterium, along with purified versions of the toxins produced by the bacteria. By contrast, whole cell pertussis vaccines contain entire killed bacteria, which can cause more frequent and severe side effects.

Overall, acellular vaccines offer a safer and more targeted approach to immunization than whole cell vaccines, while still providing effective protection against infectious diseases.

Viremia is a medical term that refers to the presence of viruses in the bloodstream. It occurs when a virus successfully infects a host and replicates within the body's cells, releasing new viral particles into the blood. This condition can lead to various clinical manifestations depending on the specific virus involved and the immune response of the infected individual. Some viral infections result in asymptomatic viremia, while others can cause severe illness or even life-threatening conditions. The detection of viremia is crucial for diagnosing certain viral infections and monitoring disease progression or treatment effectiveness.

An epitope is a specific region on an antigen (a substance that triggers an immune response) that is recognized and bound by an antibody or a T-cell receptor. In the case of T-lymphocytes, which are a type of white blood cell that plays a central role in cell-mediated immunity, epitopes are typically presented on the surface of infected cells in association with major histocompatibility complex (MHC) molecules.

T-lymphocytes recognize and respond to epitopes through their T-cell receptors (TCRs), which are membrane-bound proteins that can bind to specific epitopes presented on the surface of infected cells. There are two main types of T-lymphocytes: CD4+ T-cells, also known as helper T-cells, and CD8+ T-cells, also known as cytotoxic T-cells.

CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, which are typically expressed on the surface of professional antigen-presenting cells such as dendritic cells, macrophages, and B-cells. CD4+ T-cells help to coordinate the immune response by producing cytokines that activate other immune cells.

CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules, which are expressed on the surface of almost all nucleated cells. CD8+ T-cells are able to directly kill infected cells by releasing cytotoxic granules that contain enzymes that can induce apoptosis (programmed cell death) in the target cell.

In summary, epitopes are specific regions on antigens that are recognized and bound by T-lymphocytes through their T-cell receptors. CD4+ T-cells recognize epitopes presented in the context of MHC class II molecules, while CD8+ T-cells recognize epitopes presented in the context of MHC class I molecules.

Salmonella vaccines are immunizations that are developed to protect against Salmonella infections, which are caused by bacteria of the Salmonella enterica species. These vaccines typically contain antigens or weakened forms of the Salmonella bacteria that stimulate an immune response in the body, enabling it to recognize and fight off future Salmonella infections.

There are two main types of Salmonella vaccines:

1. Live Attenuated Vaccines: These vaccines contain weakened (attenuated) forms of the Salmonella bacteria that can still replicate but at a much slower rate and with reduced virulence compared to the wild-type bacteria. Examples include Ty21a, a live oral typhoid vaccine, and χ 144, an experimental live oral vaccine against nontyphoidal Salmonella serovars.
2. Inactivated (Killed) Vaccines: These vaccines contain killed Salmonella bacteria or their components, such as proteins or polysaccharides. They cannot replicate and are generally considered safer than live attenuated vaccines. However, they may not stimulate as strong an immune response compared to live vaccines. An example is the Vi polysaccharide vaccine against typhoid fever.

Salmonella vaccines are primarily used for preventing Salmonella infections in humans and animals, particularly those that cause typhoid fever and nontyphoidal Salmonella (NTS) infections. Vaccination is an essential component of controlling Salmonella infections, especially in areas with poor sanitation and hygiene, where the risk of exposure to Salmonella bacteria is higher.

BALB/c is an inbred strain of laboratory mouse that is widely used in biomedical research. The strain was developed at the Institute of Cancer Research in London by Henry Baldwin and his colleagues in the 1920s, and it has since become one of the most commonly used inbred strains in the world.

BALB/c mice are characterized by their black coat color, which is determined by a recessive allele at the tyrosinase locus. They are also known for their docile and friendly temperament, making them easy to handle and work with in the laboratory.

One of the key features of BALB/c mice that makes them useful for research is their susceptibility to certain types of tumors and immune responses. For example, they are highly susceptible to developing mammary tumors, which can be induced by chemical carcinogens or viral infection. They also have a strong Th2-biased immune response, which makes them useful models for studying allergic diseases and asthma.

BALB/c mice are also commonly used in studies of genetics, neuroscience, behavior, and infectious diseases. Because they are an inbred strain, they have a uniform genetic background, which makes it easier to control for genetic factors in experiments. Additionally, because they have been bred in the laboratory for many generations, they are highly standardized and reproducible, making them ideal subjects for scientific research.

"Drug design" is the process of creating and developing a new medication or therapeutic agent to treat or prevent a specific disease or condition. It involves identifying potential targets within the body, such as proteins or enzymes that are involved in the disease process, and then designing small molecules or biologics that can interact with these targets to produce a desired effect.

The drug design process typically involves several stages, including:

1. Target identification: Researchers identify a specific molecular target that is involved in the disease process.
2. Lead identification: Using computational methods and high-throughput screening techniques, researchers identify small molecules or biologics that can interact with the target.
3. Lead optimization: Researchers modify the chemical structure of the lead compound to improve its ability to interact with the target, as well as its safety and pharmacokinetic properties.
4. Preclinical testing: The optimized lead compound is tested in vitro (in a test tube or petri dish) and in vivo (in animals) to evaluate its safety and efficacy.
5. Clinical trials: If the preclinical testing is successful, the drug moves on to clinical trials in humans to further evaluate its safety and efficacy.

The ultimate goal of drug design is to create a new medication that is safe, effective, and can be used to improve the lives of patients with a specific disease or condition.

T-lymphocytes, also known as T-cells, are a type of white blood cell that plays a key role in the adaptive immune system's response to infection. They are produced in the bone marrow and mature in the thymus gland. There are several different types of T-cells, including CD4+ helper T-cells, CD8+ cytotoxic T-cells, and regulatory T-cells (Tregs).

CD4+ helper T-cells assist in activating other immune cells, such as B-lymphocytes and macrophages. They also produce cytokines, which are signaling molecules that help coordinate the immune response. CD8+ cytotoxic T-cells directly kill infected cells by releasing toxic substances. Regulatory T-cells help maintain immune tolerance and prevent autoimmune diseases by suppressing the activity of other immune cells.

T-lymphocytes are important in the immune response to viral infections, cancer, and other diseases. Dysfunction or depletion of T-cells can lead to immunodeficiency and increased susceptibility to infections. On the other hand, an overactive T-cell response can contribute to autoimmune diseases and chronic inflammation.

Virus-like particles (VLPs) are nanostructures that mimic the organization and conformation of authentic viruses but lack the genetic material required for replication. VLPs can be produced from one or more viral proteins, which can be derived from various expression systems including bacteria, yeast, insect, or mammalian cells.

VLP-based vaccines are a type of vaccine that uses these virus-like particles to induce an immune response in the body. These vaccines can be designed to target specific viruses or other pathogens and have been shown to be safe and effective in inducing both humoral and cellular immunity.

VLPs resemble authentic viruses in their structure, size, and antigenic properties, making them highly immunogenic. They can be designed to present specific epitopes or antigens from a pathogen, which can stimulate the immune system to produce antibodies and activate T-cells that recognize and attack the pathogen.

VLP vaccines have been developed for several viruses, including human papillomavirus (HPV), hepatitis B virus (HBV), and respiratory syncytial virus (RSV). They offer several advantages over traditional vaccines, such as a strong immune response, safety, and stability.

Ebola vaccines are medical products designed to confer immunity against the Ebola virus, a deadly pathogen that causes hemorrhagic fever. Several Ebola vaccine candidates have been developed and tested in clinical trials, with some showing promising results. The most advanced Ebola vaccine is rVSV-ZEBOV, which has been shown to be highly effective in preventing the disease in clinical trials. It uses a weakened version of the vesicular stomatitis virus (VSV) to deliver a protein from the Ebola virus surface, triggering an immune response that protects against infection. Other Ebola vaccine candidates use different approaches, such as delivering Ebola virus genes using a harmless adenovirus vector or using inactivated whole Ebola viruses. These vaccines are still in development and have not yet been approved for widespread use.

Influenza, also known as the flu, is a highly contagious viral infection that attacks the respiratory system of humans. It is caused by influenza viruses A, B, or C and is characterized by the sudden onset of fever, chills, headache, muscle pain, sore throat, cough, runny nose, and fatigue. Influenza can lead to complications such as pneumonia, bronchitis, and ear infections, and can be particularly dangerous for young children, older adults, pregnant women, and people with weakened immune systems or chronic medical conditions. The virus is spread through respiratory droplets produced when an infected person coughs, sneezes, or talks, and can also survive on surfaces for a period of time. Influenza viruses are constantly changing, which makes it necessary to get vaccinated annually to protect against the most recent and prevalent strains.

A "gene product" is a general term that refers to the biochemical material or molecule produced by a gene after it has been transcribed and translated. This can include proteins, RNA molecules, or other types of functional genetic material.

In the context of "nef," this refers to a specific protein encoded by the nef gene found in the human immunodeficiency virus (HIV), which causes AIDS. The nef gene is one of the nine genes present in the HIV genome, and it encodes for a protein that plays a crucial role in the viral replication cycle and the pathogenesis of HIV infection.

The nef protein has multiple functions, including downregulation of CD4 receptors on the surface of infected cells, which helps the virus evade the immune response. It also enhances viral infectivity and modulates various cell signaling pathways to promote viral replication and survival. The nef gene product is an important target for HIV research and potential therapeutic interventions.

Virus replication is the process by which a virus produces copies or reproduces itself inside a host cell. This involves several steps:

1. Attachment: The virus attaches to a specific receptor on the surface of the host cell.
2. Penetration: The viral genetic material enters the host cell, either by invagination of the cell membrane or endocytosis.
3. Uncoating: The viral genetic material is released from its protective coat (capsid) inside the host cell.
4. Replication: The viral genetic material uses the host cell's machinery to produce new viral components, such as proteins and nucleic acids.
5. Assembly: The newly synthesized viral components are assembled into new virus particles.
6. Release: The newly formed viruses are released from the host cell, often through lysis (breaking) of the cell membrane or by budding off the cell membrane.

The specific mechanisms and details of virus replication can vary depending on the type of virus. Some viruses, such as DNA viruses, use the host cell's DNA polymerase to replicate their genetic material, while others, such as RNA viruses, use their own RNA-dependent RNA polymerase or reverse transcriptase enzymes. Understanding the process of virus replication is important for developing antiviral therapies and vaccines.

Attenuated vaccines consist of live microorganisms that have been weakened (attenuated) through various laboratory processes so they do not cause disease in the majority of recipients but still stimulate an immune response. The purpose of attenuation is to reduce the virulence or replication capacity of the pathogen while keeping it alive, allowing it to retain its antigenic properties and induce a strong and protective immune response.

Examples of attenuated vaccines include:

1. Sabin oral poliovirus vaccine (OPV): This vaccine uses live but weakened polioviruses to protect against all three strains of the disease-causing poliovirus. The weakened viruses replicate in the intestine and induce an immune response, which provides both humoral (antibody) and cell-mediated immunity.
2. Measles, mumps, and rubella (MMR) vaccine: This combination vaccine contains live attenuated measles, mumps, and rubella viruses. It is given to protect against these three diseases and prevent their spread in the population.
3. Varicella (chickenpox) vaccine: This vaccine uses a weakened form of the varicella-zoster virus, which causes chickenpox. By introducing this attenuated virus into the body, it stimulates an immune response that protects against future infection with the wild-type virus.
4. Yellow fever vaccine: This live attenuated vaccine is used to prevent yellow fever, a viral disease transmitted by mosquitoes in tropical and subtropical regions of Africa and South America. The vaccine contains a weakened form of the yellow fever virus that cannot cause the disease but still induces an immune response.
5. Bacillus Calmette-Guérin (BCG) vaccine: This live attenuated vaccine is used to protect against tuberculosis (TB). It contains a weakened strain of Mycobacterium bovis, which does not cause TB in humans but stimulates an immune response that provides some protection against the disease.

Attenuated vaccines are generally effective at inducing long-lasting immunity and can provide robust protection against targeted diseases. However, they may pose a risk for individuals with weakened immune systems, as the attenuated viruses or bacteria could potentially cause illness in these individuals. Therefore, it is essential to consider an individual's health status before administering live attenuated vaccines.

Animal disease models are specialized animals, typically rodents such as mice or rats, that have been genetically engineered or exposed to certain conditions to develop symptoms and physiological changes similar to those seen in human diseases. These models are used in medical research to study the pathophysiology of diseases, identify potential therapeutic targets, test drug efficacy and safety, and understand disease mechanisms.

The genetic modifications can include knockout or knock-in mutations, transgenic expression of specific genes, or RNA interference techniques. The animals may also be exposed to environmental factors such as chemicals, radiation, or infectious agents to induce the disease state.

Examples of animal disease models include:

1. Mouse models of cancer: Genetically engineered mice that develop various types of tumors, allowing researchers to study cancer initiation, progression, and metastasis.
2. Alzheimer's disease models: Transgenic mice expressing mutant human genes associated with Alzheimer's disease, which exhibit amyloid plaque formation and cognitive decline.
3. Diabetes models: Obese and diabetic mouse strains like the NOD (non-obese diabetic) or db/db mice, used to study the development of type 1 and type 2 diabetes, respectively.
4. Cardiovascular disease models: Atherosclerosis-prone mice, such as ApoE-deficient or LDLR-deficient mice, that develop plaque buildup in their arteries when fed a high-fat diet.
5. Inflammatory bowel disease models: Mice with genetic mutations affecting intestinal barrier function and immune response, such as IL-10 knockout or SAMP1/YitFc mice, which develop colitis.

Animal disease models are essential tools in preclinical research, but it is important to recognize their limitations. Differences between species can affect the translatability of results from animal studies to human patients. Therefore, researchers must carefully consider the choice of model and interpret findings cautiously when applying them to human diseases.

Staphylococcal vaccines are immunizations that are developed to protect against infections caused by the Staphylococcus bacteria, particularly Staphylococcus aureus. These vaccines typically contain components of the bacterial cell wall or toxins that stimulate an immune response in the body, leading to the production of antibodies that can recognize and neutralize the bacteria if they invade the body in the future.

There are currently no licensed staphylococcal vaccines available for use in humans, although several candidates are in various stages of development. These vaccines aim to prevent a range of staphylococcal infections, including skin and soft tissue infections, pneumonia, bloodstream infections, and toxic shock syndrome.

It's important to note that while antibiotics can be effective against staphylococcal infections, the bacteria have become increasingly resistant to these drugs over time, making vaccines an important area of research and development for preventing and controlling the spread of these infections.

Diphtheria-Tetanus-acellular Pertussis (DTaP) vaccines are a type of combination vaccine that protect against three serious diseases caused by bacteria: diphtheria, tetanus, and pertussis (also known as whooping cough).

Diphtheria is a highly contagious respiratory infection that can cause breathing difficulties, heart failure, paralysis, and even death. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, which can be severe enough to cause broken bones or suffocation. Pertussis is a highly contagious respiratory infection that causes severe coughing fits, making it difficult to breathe, eat, or drink.

The "a" in DTaP stands for "acellular," which means that the pertussis component of the vaccine contains only parts of the bacteria, rather than the whole cells used in older vaccines. This reduces the risk of side effects associated with the whole-cell pertussis vaccine while still providing effective protection against the disease.

DTaP vaccines are typically given as a series of five shots, starting at 2 months of age and ending at 4-6 years of age. Booster doses may be recommended later in life to maintain immunity. DTaP vaccines are an essential part of routine childhood immunization schedules and have significantly reduced the incidence of these diseases worldwide.

I'm sorry for any confusion, but "International Cooperation" is not a medical term. It refers to the collaboration and exchange of resources and information between countries or international organizations in various fields, including politics, economics, culture, environment, and security, among others. In the context of healthcare and medicine, international cooperation can involve joint research projects, sharing of data and clinical trial results, collaborative efforts to combat global health issues (such as infectious diseases or chronic conditions), capacity building in low-resource settings, and standardizing medical practices and guidelines across countries.

Cytomegalovirus (CMV) vaccines are medical products being developed to prevent or ameliorate infection and disease caused by the human cytomegalovirus. CMV is a type of herpesvirus that can cause serious health problems in people with weakened immune systems, such as those undergoing organ transplantation, people living with HIV/AIDS, and newborns infected with the virus before birth (congenital CMV infection).

There are currently no approved vaccines for CMV. However, several vaccine candidates are being investigated in clinical trials to evaluate their safety, immunogenicity, and efficacy. These vaccine candidates use various approaches, such as:

1. Live-attenuated viruses: These vaccines contain weakened forms of the virus that can stimulate an immune response without causing disease. An example is the Towne vaccine, which has been studied in clinical trials for several decades.
2. Recombinant proteins: These vaccines use specific viral proteins to induce an immune response. For instance, a glycoprotein B (gB) subunit vaccine has shown promising results in phase II clinical trials.
3. Virus-like particles (VLPs): VLPs mimic the structure of the virus but do not contain any viral genetic material. They can be used to induce an immune response without causing infection.
4. DNA vaccines: These vaccines use plasmids containing CMV genes to stimulate an immune response. A DNA vaccine encoding the CMV phosphoprotein 65 (pp65) has been tested in clinical trials.
5. mRNA vaccines: Similar to DNA vaccines, mRNA vaccines use genetic material to induce an immune response. Moderna Therapeutics is developing an mRNA vaccine candidate for CMV.

The development of a safe and effective CMV vaccine remains a significant public health priority, as CMV infection can lead to severe complications in vulnerable populations.

Immunization programs, also known as vaccination programs, are organized efforts to administer vaccines to populations or communities in order to protect individuals from vaccine-preventable diseases. These programs are typically implemented by public health agencies and involve the planning, coordination, and delivery of immunizations to ensure that a high percentage of people are protected against specific infectious diseases.

Immunization programs may target specific age groups, such as infants and young children, or populations at higher risk of certain diseases, such as travelers, healthcare workers, or individuals with weakened immune systems. The goals of immunization programs include controlling and eliminating vaccine-preventable diseases, reducing the morbidity and mortality associated with these diseases, and protecting vulnerable populations from outbreaks and epidemics.

Immunization programs may be delivered through a variety of settings, including healthcare facilities, schools, community centers, and mobile clinics. They often involve partnerships between government agencies, healthcare providers, non-governmental organizations, and communities to ensure that vaccines are accessible, affordable, and acceptable to the populations they serve. Effective immunization programs require strong leadership, adequate funding, robust data systems, and ongoing monitoring and evaluation to assess their impact and identify areas for improvement.

Immunoglobulin G (IgG) is a type of antibody, which is a protective protein produced by the immune system in response to foreign substances like bacteria or viruses. IgG is the most abundant type of antibody in human blood, making up about 75-80% of all antibodies. It is found in all body fluids and plays a crucial role in fighting infections caused by bacteria, viruses, and toxins.

IgG has several important functions:

1. Neutralization: IgG can bind to the surface of bacteria or viruses, preventing them from attaching to and infecting human cells.
2. Opsonization: IgG coats the surface of pathogens, making them more recognizable and easier for immune cells like neutrophils and macrophages to phagocytose (engulf and destroy) them.
3. Complement activation: IgG can activate the complement system, a group of proteins that work together to help eliminate pathogens from the body. Activation of the complement system leads to the formation of the membrane attack complex, which creates holes in the cell membranes of bacteria, leading to their lysis (destruction).
4. Antibody-dependent cellular cytotoxicity (ADCC): IgG can bind to immune cells like natural killer (NK) cells and trigger them to release substances that cause target cells (such as virus-infected or cancerous cells) to undergo apoptosis (programmed cell death).
5. Immune complex formation: IgG can form immune complexes with antigens, which can then be removed from the body through various mechanisms, such as phagocytosis by immune cells or excretion in urine.

IgG is a critical component of adaptive immunity and provides long-lasting protection against reinfection with many pathogens. It has four subclasses (IgG1, IgG2, IgG3, and IgG4) that differ in their structure, function, and distribution in the body.

The Diphtheria-Tetanus vaccine, also known as the DT vaccine or Td vaccine (if diphtheria toxoid is not included), is a combination vaccine that protects against two potentially serious bacterial infections: diphtheria and tetanus.

Diphtheria is a respiratory infection that can cause breathing difficulties, heart problems, and nerve damage. Tetanus, also known as lockjaw, is a bacterial infection that affects the nervous system and causes muscle stiffness and spasms, particularly in the jaw and neck.

The vaccine contains small amounts of inactivated toxins (toxoids) from the bacteria that cause diphtheria and tetanus. When the vaccine is administered, it stimulates the immune system to produce antibodies that provide protection against these diseases.

In addition to protecting against diphtheria and tetanus, some formulations of the vaccine may also include protection against pertussis (whooping cough), polio, or hepatitis B. The DTaP vaccine is a similar combination vaccine that includes protection against diphtheria, tetanus, and pertussis, but uses acellular pertussis components instead of the whole-cell pertussis component used in the DT vaccine.

The Diphtheria-Tetanus vaccine is typically given as a series of shots in childhood, with booster shots recommended every 10 years to maintain immunity. It is an important part of routine childhood vaccination and is also recommended for adults who have not received the full series of shots or whose protection has waned over time.

Poliovirus vaccines are preparations used for active immunization against poliomyelitis, a highly infectious disease caused by the poliovirus. The two types of poliovirus vaccines available are:

1. Inactivated Poliovirus Vaccine (IPV): This vaccine contains inactivated (killed) poliovirus strains of all three serotypes. IPV is typically administered through an injection, usually in combination with other vaccines. It provides a strong immune response and does not carry the risk of vaccine-associated paralytic polio (VAPP), which is a rare but serious adverse event associated with the oral poliovirus vaccine (OPV).

2. Oral Poliovirus Vaccine (OPV): This vaccine contains live attenuated (weakened) poliovirus strains of all three serotypes. OPV is administered orally and induces both humoral and intestinal immunity, which helps prevent the spread of the virus in a community. However, there is a small risk of VAPP associated with this vaccine, especially after multiple doses. In rare cases, the weakened virus can revert to its virulent form and cause paralytic polio in the vaccinated individual or their close contacts.

Both IPV and OPV have been instrumental in global efforts to eradicate polio. The World Health Organization (WHO) recommends using IPV in routine immunization programs, while using OPV during supplementary immunization activities in areas with a high risk of poliovirus transmission.

Intranasal administration refers to the delivery of medication or other substances through the nasal passages and into the nasal cavity. This route of administration can be used for systemic absorption of drugs or for localized effects in the nasal area.

When a medication is administered intranasally, it is typically sprayed or dropped into the nostril, where it is absorbed by the mucous membranes lining the nasal cavity. The medication can then pass into the bloodstream and be distributed throughout the body for systemic effects. Intranasal administration can also result in direct absorption of the medication into the local tissues of the nasal cavity, which can be useful for treating conditions such as allergies, migraines, or pain in the nasal area.

Intranasal administration has several advantages over other routes of administration. It is non-invasive and does not require needles or injections, making it a more comfortable option for many people. Additionally, intranasal administration can result in faster onset of action than oral administration, as the medication bypasses the digestive system and is absorbed directly into the bloodstream. However, there are also some limitations to this route of administration, including potential issues with dosing accuracy and patient tolerance.

Escherichia coli (E. coli) vaccines are designed to protect against infections caused by various strains of the E. coli bacterium. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, which stimulate an immune response when introduced into the body. The immune system learns to recognize and fight off the specific strain of E. coli used in the vaccine, providing protection against future infections with that strain.

There are several types of E. coli vaccines available or in development, including:

1. Shiga toxin-producing E. coli (STEC) vaccines: These vaccines protect against STEC strains, such as O157:H7 and non-O157 STECs, which can cause severe illness, including hemorrhagic colitis and hemolytic uremic syndrome (HUS).
2. Enterotoxigenic E. coli (ETEC) vaccines: These vaccines target ETEC strains that are a common cause of traveler's diarrhea in people visiting areas with poor sanitation.
3. Enteropathogenic E. coli (EPEC) vaccines: EPEC strains can cause persistent diarrhea, especially in young children in developing countries. Vaccines against these strains are still in the research and development stage.
4. Extraintestinal pathogenic E. coli (ExPEC) vaccines: These vaccines aim to protect against ExPEC strains that can cause urinary tract infections, sepsis, and meningitis.

It is important to note that different E. coli vaccines are designed for specific purposes and may not provide cross-protection against other strains or types of E. coli infections.

West Nile Virus (WNV) vaccines are immunizations that are designed to protect against the West Nile virus, which is a single-stranded RNA virus that belongs to the family Flaviviridae. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly those of the Culex species.

There are currently no licensed WNV vaccines available for human use in the United States or Europe. However, there are several veterinary vaccines that have been developed and approved for use in horses and other animals, such as birds and geese. These vaccines work by stimulating the immune system to produce antibodies against the virus, which can help prevent infection and reduce the severity of symptoms in animals that do become infected.

Human WNV vaccine candidates are in various stages of development and testing. Some of these vaccines use inactivated or weakened forms of the virus, while others use only a portion of the viral protein to stimulate an immune response. While these vaccines have shown promise in clinical trials, further research is needed to determine their safety and effectiveness in larger populations before they can be approved for widespread use.

Hemagglutination inhibition (HI) tests are a type of serological assay used in medical laboratories to detect and measure the amount of antibodies present in a patient's serum. These tests are commonly used to diagnose viral infections, such as influenza or HIV, by identifying the presence of antibodies that bind to specific viral antigens and prevent hemagglutination (the agglutination or clumping together of red blood cells).

In an HI test, a small amount of the patient's serum is mixed with a known quantity of the viral antigen, which has been treated to attach to red blood cells. If the patient's serum contains antibodies that bind to the viral antigen, they will prevent the antigen from attaching to the red blood cells and inhibit hemagglutination. The degree of hemagglutination inhibition can be measured and used to estimate the amount of antibody present in the patient's serum.

HI tests are relatively simple and inexpensive to perform, but they have some limitations. For example, they may not detect early-stage infections before the body has had a chance to produce antibodies, and they may not be able to distinguish between different strains of the same virus. Nonetheless, HI tests remain an important tool for diagnosing viral infections and monitoring immune responses to vaccination or infection.

Shigella vaccines are immunizations that are developed to protect against Shigella infection, which is caused by the bacterium Shigella spp. These vaccines aim to stimulate the immune system to produce an immune response (the production of antibodies and activation of immune cells) that will provide protection against future Shigella infections.

There are currently no licensed Shigella vaccines available for use, although several candidate vaccines are in various stages of development and clinical trials. These vaccines typically contain inactivated or attenuated (weakened) forms of the bacteria, or specific components of the bacteria that can stimulate an immune response.

Shigella infection can cause a range of symptoms, including diarrhea, fever, abdominal cramps, and tenesmus (the strong, frequent urge to have a bowel movement). In severe cases, it can lead to complications such as dehydration, seizures, and hemolytic-uremic syndrome (HUS), which is a serious condition that can cause kidney failure. Shigella infection is most commonly transmitted through contaminated food or water, or direct contact with an infected person's feces.

Antibody formation, also known as humoral immune response, is the process by which the immune system produces proteins called antibodies in response to the presence of a foreign substance (antigen) in the body. This process involves several steps:

1. Recognition: The antigen is recognized and bound by a type of white blood cell called a B lymphocyte or B cell, which then becomes activated.
2. Differentiation: The activated B cell undergoes differentiation to become a plasma cell, which is a type of cell that produces and secretes large amounts of antibodies.
3. Antibody production: The plasma cells produce and release antibodies, which are proteins made up of four polypeptide chains (two heavy chains and two light chains) arranged in a Y-shape. Each antibody has two binding sites that can recognize and bind to specific regions on the antigen called epitopes.
4. Neutralization or elimination: The antibodies bind to the antigens, neutralizing them or marking them for destruction by other immune cells. This helps to prevent the spread of infection and protect the body from harmful substances.

Antibody formation is an important part of the adaptive immune response, which allows the body to specifically recognize and respond to a wide variety of pathogens and foreign substances.

The Herpes Zoster vaccine, also known as the shingles vaccine, is a preventive measure against the reactivation of the varicella-zoster virus (VZV) in individuals who have previously had chickenpox. The vaccine contains a live but weakened form of VZV that boosts the immune system's ability to recognize and fight off the virus, thereby reducing the risk of developing shingles and its complications. It is typically administered as a single dose for people aged 50 and older, or as a two-dose series for those aged 19 and older who have weakened immune systems.

Humoral immunity is a type of immune response in which the body produces proteins called antibodies that circulate in bodily fluids such as blood and help to protect against infection. This form of immunity involves the interaction between antigens (foreign substances that trigger an immune response) and soluble factors, including antibodies, complement proteins, and cytokines.

When a pathogen enters the body, it is recognized as foreign by the immune system, which triggers the production of specific antibodies to bind to and neutralize or destroy the pathogen. These antibodies are produced by B cells, a type of white blood cell that is part of the adaptive immune system.

Humoral immunity provides protection against extracellular pathogens, such as bacteria and viruses, that exist outside of host cells. It is an important component of the body's defense mechanisms and plays a critical role in preventing and fighting off infections.

Polysorbates are a type of nonionic surfactant (a compound that lowers the surface tension between two substances, such as oil and water) commonly used in pharmaceuticals, foods, and cosmetics. They are derived from sorbitol and reacted with ethylene oxide to create a polyoxyethylene structure. The most common types of polysorbates used in medicine are polysorbate 20, polysorbate 40, and polysorbate 60, which differ in the number of oxyethylene groups in their molecular structure.

Polysorbates are often added to pharmaceutical formulations as emulsifiers, solubilizers, or stabilizers. They help to improve the solubility and stability of drugs that are otherwise insoluble in water, allowing for better absorption and bioavailability. Polysorbates can also prevent the aggregation and precipitation of proteins in injectable formulations.

In addition to their use in pharmaceuticals, polysorbates are also used as emulsifiers in food products such as ice cream, salad dressings, and baked goods. They help to mix oil and water-based ingredients together and prevent them from separating. In cosmetics, polysorbates are used as surfactants, solubilizers, and stabilizers in a variety of personal care products.

It is important to note that some people may have allergic reactions to polysorbates, particularly those with sensitivities to sorbitol or other ingredients used in their production. Therefore, it is essential to carefully consider the potential risks and benefits of using products containing polysorbates in individuals who may be at risk for adverse reactions.

A Brucella vaccine is a type of immunization used to protect against brucellosis, an infectious disease caused by bacteria of the genus Brucella. The most commonly used vaccine is the Brucella melitensis Rev-1 strain, which is administered to sheep and goats to prevent the spread of the disease to humans through contaminated food and animal contact.

The Brucella vaccine works by stimulating the immune system to produce a protective response against the bacteria. When the vaccinated animal encounters the actual bacterial infection, their immune system is better prepared to fight it off and prevent the development of clinical disease.

It's important to note that the Brucella vaccine is not approved for use in humans due to the risk of severe side effects and the possibility of causing a false positive result on brucellosis diagnostic tests. Therefore, it should only be administered to animals under the supervision of a veterinarian.

An epitope is a specific region on the surface of an antigen (a molecule that can trigger an immune response) that is recognized by an antibody, B-cell receptor, or T-cell receptor. It is also commonly referred to as an antigenic determinant. Epitopes are typically composed of linear amino acid sequences or conformational structures made up of discontinuous amino acids in the antigen. They play a crucial role in the immune system's ability to differentiate between self and non-self molecules, leading to the targeted destruction of foreign substances like viruses and bacteria. Understanding epitopes is essential for developing vaccines, diagnostic tests, and immunotherapies.

Tetanus toxoid is a purified and inactivated form of the tetanus toxin, which is derived from the bacterium Clostridium tetani. It is used as a vaccine to induce active immunity against tetanus, a potentially fatal disease caused by this toxin. The toxoid is produced through a series of chemical treatments that modify the toxic properties of the tetanus toxin while preserving its antigenic qualities. This allows the immune system to recognize and develop protective antibodies against the toxin without causing illness. Tetanus toxoid is often combined with diphtheria and/or pertussis toxoids in vaccines such as DTaP, Tdap, and Td.

Herpesvirus vaccines are immunizations designed to protect against infections caused by herpesviruses. These viruses include herpes simplex virus type 1 (HSV-1), which primarily causes oral herpes, and herpes simplex virus type 2 (HSV-2), which primarily causes genital herpes. Additionally, other herpesviruses such as varicella-zoster virus (VZV), which causes chickenpox and shingles, and cytomegalovirus (CMV), which can cause serious complications in newborns and immunocompromised individuals, are also targeted by herpesvirus vaccines.

Herpesvirus vaccines work by exposing the immune system to a weakened or inactivated form of the virus, or to specific viral proteins, which triggers an immune response. This response includes the production of antibodies and activation of T-cells that recognize and attack the virus if it enters the body in the future.

Currently, there are vaccines available for HSV-1 and HSV-2, but they are not widely used. The only FDA-approved herpesvirus vaccine is for VZV, which is marketed as Varivax and prevents chickenpox and reduces the risk of shingles. There are also several experimental vaccines in development for other herpesviruses, including HSV-1, HSV-2, and CMV.

An "injection, intradermal" refers to a type of injection where a small quantity of a substance is introduced into the layer of skin between the epidermis and dermis, using a thin gauge needle. This technique is often used for diagnostic or research purposes, such as conducting allergy tests or administering immunizations in a way that stimulates a strong immune response. The injection site typically produces a small, raised bump (wheal) that disappears within a few hours. It's important to note that intradermal injections should be performed by trained medical professionals to minimize the risk of complications.

Leishmaniasis vaccines do not currently exist for human use, despite extensive research efforts. However, the concept and goal of a leishmaniasis vaccine refer to a potential prophylactic treatment that would prevent or significantly reduce the risk of contracting Leishmania infections, which cause various clinical manifestations of the disease.

Leishmaniasis is a vector-borne neglected tropical disease caused by protozoan parasites of the Leishmania genus, transmitted through the bite of infected female sandflies. The disease has diverse clinical presentations, ranging from self-healing cutaneous lesions (localized cutaneous leishmaniasis) to destructive mucocutaneous forms (mucocutaneous leishmaniasis) and potentially fatal visceral leishmaniasis, also known as kala-azar.

The development of an effective vaccine against Leishmania infections is challenging due to the complexity of the parasite's life cycle, genetic diversity, and the variety of clinical outcomes it can cause. Several vaccine candidates have been investigated, primarily focusing on inducing cell-mediated immunity, particularly a Th1 response. These candidates include:

1. First-generation vaccines: These are whole-parasite or live-attenuated vaccines, such as Leishmania major (Lm) strain Friedlin and Leishmania tarentolae. Although these vaccines have shown promising results in animal models, their use in humans is limited due to safety concerns.
2. Second-generation vaccines: These involve subunit or recombinant protein vaccines, which utilize specific antigens from the parasite to stimulate an immune response. Examples include Leishmania antigens such as Leishmania major stress-inducible protein 1 (LiSP1), Leishmania donovani A2, and Leishmania infantum nucleoside hydrolase (LiNH36).
3. Third-generation vaccines: These are DNA or RNA/mRNA vaccines that encode specific antigens from the parasite to stimulate an immune response. Examples include plasmid DNA vaccines encoding Leishmania major HSP70 and Leishmania donovani A2.
4. Adjuvant systems: To enhance the immunogenicity of these vaccine candidates, various adjuvants are being explored, such as saponins (QS-21), cytokines (GM-CSF), and TLR agonists (CpG oligodeoxynucleotides).

Despite significant progress in developing Leishmania vaccines, no licensed vaccine is currently available for human use. Further research is required to optimize the formulation, delivery, and safety of these vaccine candidates to ensure their effectiveness against various Leishmania species and clinical manifestations.

'Influenza A Virus, H1N1 Subtype' is a specific subtype of the influenza A virus that causes flu in humans and animals. It contains certain proteins called hemagglutinin (H) and neuraminidase (N) on its surface, with this subtype specifically having H1 and N1 antigens. The H1N1 strain is well-known for causing the 2009 swine flu pandemic, which was a global outbreak of flu that resulted in significant morbidity and mortality. This subtype can also cause seasonal flu, although the severity and symptoms may vary. It is important to note that influenza viruses are constantly changing, and new strains or subtypes can emerge over time, requiring regular updates to vaccines to protect against them.

Aluminum hydroxide is a medication that contains the active ingredient aluminum hydroxide, which is an inorganic compound. It is commonly used as an antacid to neutralize stomach acid and relieve symptoms of acid reflux and heartburn. Aluminum hydroxide works by reacting with the acid in the stomach to form a physical barrier that prevents the acid from backing up into the esophagus.

In addition to its use as an antacid, aluminum hydroxide is also used as a phosphate binder in patients with kidney disease. It works by binding to phosphate in the gut and preventing it from being absorbed into the bloodstream, which can help to control high phosphate levels in the body.

Aluminum hydroxide is available over-the-counter and by prescription in various forms, including tablets, capsules, and liquid suspensions. It is important to follow the dosage instructions carefully and to talk to a healthcare provider if symptoms persist or worsen.

Genetic variation refers to the differences in DNA sequences among individuals and populations. These variations can result from mutations, genetic recombination, or gene flow between populations. Genetic variation is essential for evolution by providing the raw material upon which natural selection acts. It can occur within a single gene, between different genes, or at larger scales, such as differences in the number of chromosomes or entire sets of chromosomes. The study of genetic variation is crucial in understanding the genetic basis of diseases and traits, as well as the evolutionary history and relationships among species.

Bacterial antigens are substances found on the surface or produced by bacteria that can stimulate an immune response in a host organism. These antigens can be proteins, polysaccharides, teichoic acids, lipopolysaccharides, or other molecules that are recognized as foreign by the host's immune system.

When a bacterial antigen is encountered by the host's immune system, it triggers a series of responses aimed at eliminating the bacteria and preventing infection. The host's immune system recognizes the antigen as foreign through the use of specialized receptors called pattern recognition receptors (PRRs), which are found on various immune cells such as macrophages, dendritic cells, and neutrophils.

Once a bacterial antigen is recognized by the host's immune system, it can stimulate both the innate and adaptive immune responses. The innate immune response involves the activation of inflammatory pathways, the recruitment of immune cells to the site of infection, and the production of antimicrobial peptides.

The adaptive immune response, on the other hand, involves the activation of T cells and B cells, which are specific to the bacterial antigen. These cells can recognize and remember the antigen, allowing for a more rapid and effective response upon subsequent exposures.

Bacterial antigens are important in the development of vaccines, as they can be used to stimulate an immune response without causing disease. By identifying specific bacterial antigens that are associated with virulence or pathogenicity, researchers can develop vaccines that target these antigens and provide protection against infection.

Alum compounds are a type of double sulfate salt, typically consisting of aluminum sulfate and another metal sulfate. The most common variety is potassium alum, or potassium aluminum sulfate (KAl(SO4)2·12H2O). Alum compounds have a wide range of uses, including water purification, tanning leather, dyeing and printing textiles, and as a food additive for baking powder and pickling. They are also used in medicine as astringents to reduce bleeding and swelling, and to soothe skin irritations. Alum compounds have the ability to make proteins in living cells become more stable, which can be useful in medical treatments.

Herpes simplex virus vaccines are types of vaccines that are being developed to prevent infections caused by the herpes simplex viruses (HSV), which include HSV-1 and HSV-2. These viruses can cause painful blisters or sores on the skin or mucous membranes, such as those found inside the mouth or genitals.

There are currently no approved vaccines for HSV-1 or HSV-2, although several candidates are in various stages of development. The goal of an HSV vaccine is to stimulate the immune system to produce a strong and durable response that can prevent infection with the virus or reduce the severity and frequency of outbreaks in people who are already infected.

HSV vaccines typically work by introducing a harmless piece of the virus, such as a protein or a weakened or killed virus, to the body. This triggers the immune system to produce antibodies and activate immune cells that can recognize and attack the virus if it enters the body in the future. Some HSV vaccine candidates are designed to stimulate both arms of the immune system (humoral and cell-mediated immunity), while others focus on one or the other.

While there is no cure for herpes simplex virus infections, a successful vaccine could help prevent the spread of the virus and reduce the burden of disease.

Diphtheria toxoid is a modified form of the diphtheria toxin that has been made harmless but still stimulates an immune response. It is used in vaccines to provide immunity against diphtheria, a serious bacterial infection that can cause breathing difficulties, heart failure, and paralysis. The toxoid is typically combined with other components in a vaccine, such as tetanus toxoid and pertussis vaccine, to form a combination vaccine that protects against multiple diseases.

The diphtheria toxoid is made by treating the diphtheria toxin with formaldehyde, which modifies the toxin's structure and makes it nontoxic while still retaining its ability to stimulate an immune response. When the toxoid is introduced into the body through vaccination, the immune system recognizes it as a foreign substance and produces antibodies against it. These antibodies then provide protection against future infections with the diphtheria bacteria.

The diphtheria toxoid vaccine is usually given as part of a routine childhood immunization schedule, starting at 2 months of age. Booster shots are recommended throughout childhood and adolescence, and adults may also need booster shots if they have not received them previously or if their immune status has changed.

Squalene is a organic compound that is a polyunsaturated triterpene. It is a natural component of human skin surface lipids and sebum, where it plays a role in maintaining the integrity and permeability barrier of the stratum corneum. Squalene is also found in various plant and animal tissues, including olive oil, wheat germ oil, and shark liver oil.

In the body, squalene is an intermediate in the biosynthesis of cholesterol and other sterols. It is produced in the liver and transported to other tissues via low-density lipoproteins (LDLs). Squalene has been studied for its potential health benefits due to its antioxidant properties, as well as its ability to modulate immune function and reduce the risk of certain types of cancer. However, more research is needed to confirm these potential benefits.

Phylogeny is the evolutionary history and relationship among biological entities, such as species or genes, based on their shared characteristics. In other words, it refers to the branching pattern of evolution that shows how various organisms have descended from a common ancestor over time. Phylogenetic analysis involves constructing a tree-like diagram called a phylogenetic tree, which depicts the inferred evolutionary relationships among organisms or genes based on molecular sequence data or other types of characters. This information is crucial for understanding the diversity and distribution of life on Earth, as well as for studying the emergence and spread of diseases.

Respiratory Syncytial Virus (RSV) vaccines are immunizations designed to protect against the RSV infection, which is a major cause of respiratory tract illnesses in infants and young children worldwide. The virus can also cause serious illness in older adults and people with weakened immune systems.

There are currently no approved RSV vaccines available on the market, although several candidates are in various stages of development and clinical trials. Most of the vaccine candidates are aimed at preventing severe lower respiratory tract disease caused by RSV infection in infants and young children.

RSV vaccines typically work by stimulating the immune system to produce antibodies against the virus, which can help prevent infection or reduce the severity of symptoms if infection occurs. Some vaccine candidates use live-attenuated viruses, while others use inactivated viruses or viral proteins to induce an immune response.

While RSV vaccines have shown promise in clinical trials, developing a safe and effective vaccine has proven challenging due to the risk of vaccine-associated enhanced respiratory disease (VAERD), a rare but serious complication that can occur when certain types of RSV vaccines are given to people who have previously been infected with the virus. Therefore, ongoing research is focused on developing vaccines that can safely and effectively protect against RSV infection while minimizing the risk of VAERD.

A cell line is a culture of cells that are grown in a laboratory for use in research. These cells are usually taken from a single cell or group of cells, and they are able to divide and grow continuously in the lab. Cell lines can come from many different sources, including animals, plants, and humans. They are often used in scientific research to study cellular processes, disease mechanisms, and to test new drugs or treatments. Some common types of human cell lines include HeLa cells (which come from a cancer patient named Henrietta Lacks), HEK293 cells (which come from embryonic kidney cells), and HUVEC cells (which come from umbilical vein endothelial cells). It is important to note that cell lines are not the same as primary cells, which are cells that are taken directly from a living organism and have not been grown in the lab.

Viral DNA refers to the genetic material present in viruses that consist of DNA as their core component. Deoxyribonucleic acid (DNA) is one of the two types of nucleic acids that are responsible for storing and transmitting genetic information in living organisms. Viruses are infectious agents much smaller than bacteria that can only replicate inside the cells of other organisms, called hosts.

Viral DNA can be double-stranded (dsDNA) or single-stranded (ssDNA), depending on the type of virus. Double-stranded DNA viruses have a genome made up of two complementary strands of DNA, while single-stranded DNA viruses contain only one strand of DNA.

Examples of dsDNA viruses include Adenoviruses, Herpesviruses, and Poxviruses, while ssDNA viruses include Parvoviruses and Circoviruses. Viral DNA plays a crucial role in the replication cycle of the virus, encoding for various proteins necessary for its multiplication and survival within the host cell.

Cross-protection is a term used in immunology and vaccinology that refers to the ability of a vaccine or natural infection with one strain of a microorganism (such as a virus or bacteria) to provide protection against other, related strains. This occurs because the immune response elicited by the initial exposure also recognizes and targets certain common features present in the related strains.

In the context of vaccines, cross-protection can be an important factor in designing broadly protective vaccines that can cover multiple strains or serotypes of a pathogen, thus reducing the need for individual vaccines against each strain. However, the degree of cross-protection can vary depending on the specific microorganisms and antigens involved.

It's important to note that cross-protection is not always complete or long-lasting, and additional research may be needed to fully understand its mechanisms and limitations.

Japanese Encephalitis (JE) vaccines are immunobiological preparations used for active immunization against Japanese Encephalitis, a viral infection transmitted through the bite of infected mosquitoes. The vaccines contain inactivated or live attenuated strains of the JE virus. They work by stimulating the immune system to produce antibodies and T-cells that provide protection against the virus. There are several types of JE vaccines available, including inactivated Vero cell-derived vaccine, live attenuated SA14-14-2 vaccine, and inactivated mouse brain-derived vaccine. These vaccines have been shown to be effective in preventing JE and are recommended for use in individuals traveling to or living in areas where the disease is endemic.

Mass vaccination is a coordinated effort to administer vaccine doses to a large portion of a population in a short amount of time. This strategy is often used during outbreaks of infectious diseases, such as influenza or measles, to quickly build up community immunity (herd immunity) and reduce the spread of the disease. Mass vaccination campaigns can also be implemented as part of public health initiatives to control or eliminate vaccine-preventable diseases in a population. These campaigns typically involve mobilizing healthcare workers, volunteers, and resources to reach and vaccinate as many people as possible, often through mobile clinics, community centers, and other accessible locations.

An Enzyme-Linked Immunosorbent Assay (ELISA) is a type of analytical biochemistry assay used to detect and quantify the presence of a substance, typically a protein or peptide, in a liquid sample. It takes its name from the enzyme-linked antibodies used in the assay.

In an ELISA, the sample is added to a well containing a surface that has been treated to capture the target substance. If the target substance is present in the sample, it will bind to the surface. Next, an enzyme-linked antibody specific to the target substance is added. This antibody will bind to the captured target substance if it is present. After washing away any unbound material, a substrate for the enzyme is added. If the enzyme is present due to its linkage to the antibody, it will catalyze a reaction that produces a detectable signal, such as a color change or fluorescence. The intensity of this signal is proportional to the amount of target substance present in the sample, allowing for quantification.

ELISAs are widely used in research and clinical settings to detect and measure various substances, including hormones, viruses, and bacteria. They offer high sensitivity, specificity, and reproducibility, making them a reliable choice for many applications.

A contraceptive vaccine is a type of immunocontraception that uses the immune system to prevent pregnancy. It is a relatively new field of research and development, and there are currently no licensed contraceptive vaccines available on the market. However, several experimental vaccines are in various stages of preclinical and clinical testing.

Contraceptive vaccines work by stimulating the immune system to produce antibodies against specific proteins or hormones that play a critical role in reproduction. By neutralizing these targets, the vaccine can prevent fertilization or inhibit the implantation of a fertilized egg in the uterus.

For example, one approach is to develop vaccines that target the zona pellucida (ZP), a glycoprotein layer surrounding mammalian eggs. Antibodies generated against ZP proteins can prevent sperm from binding and fertilizing the egg. Another strategy is to create vaccines that generate antibodies against hormones such as human chorionic gonadotropin (hCG), a hormone produced during pregnancy. By blocking hCG, the vaccine can prevent the maintenance of pregnancy and induce a miscarriage.

While contraceptive vaccines have shown promise in preclinical studies, several challenges remain before they can be widely adopted. These include issues related to safety, efficacy, duration of protection, and public acceptance. Additionally, there are concerns about the potential for accidental cross-reactivity with other proteins or hormones, leading to unintended side effects.

Overall, contraceptive vaccines represent a promising area of research that could provide long-acting, reversible, and user-friendly contraception options in the future. However, further studies are needed to address the remaining challenges and ensure their safe and effective use.

Edible vaccines are a relatively new concept in the field of immunization, whereby vaccine antigens are produced in edible plant material. The idea is to create an easy-to-deliver, cost-effective, and potentially more accessible way to protect against various diseases, especially in developing countries.

The process involves genetically modifying plants to express the desired vaccine antigen within their tissues. Once the plant has been grown and harvested, the edible material containing the antigen can be consumed directly, stimulating an immune response in the consumer. This approach bypasses the need for traditional methods of vaccine production, such as fermentation or egg-based manufacturing, and eliminates the need for sterile injection equipment and cold storage during transportation and distribution.

Examples of edible vaccines that have been explored include those targeting infectious diseases like cholera, hepatitis B, and influenza, among others. However, it is important to note that this area of vaccine development still faces several challenges, including ensuring consistent antigen expression, maintaining stability during storage and preparation, and addressing potential public concerns regarding genetically modified organisms (GMOs) used in the production process.

Whoopering Cough, also known as Pertussis, is a highly contagious respiratory infection caused by the bacterium Bordetella pertussis. It is characterized by severe coughing fits followed by a high-pitched "whoop" sound during inspiration. The disease can affect people of all ages, but it is most dangerous for babies and young children. Symptoms typically develop within 5 to 10 days after exposure and include runny nose, low-grade fever, and a mild cough. After a week or two, the cough becomes more severe and is often followed by vomiting and exhaustion. Complications can be serious, especially in infants, and may include pneumonia, seizures, brain damage, or death. Treatment usually involves antibiotics to kill the bacteria and reduce the severity of symptoms. Vaccination is available and recommended for the prevention of whooping cough.

Active immunotherapy, also known as active immunization or vaccination, is a type of medical treatment that stimulates the immune system to develop an adaptive response against specific antigens, thereby providing protection against future exposures to those antigens. This is typically achieved through the administration of vaccines, which contain either weakened or inactivated pathogens, or components of pathogens (such as proteins or sugars), along with adjuvants that enhance the immune response. The goal of active immunotherapy is to induce long-term immunity by generating memory T and B cells, which can quickly recognize and respond to subsequent infections or reinfections with the targeted pathogen.

In contrast to passive immunotherapy, where preformed antibodies or immune cells are directly administered to a patient for immediate but temporary protection, active immunotherapy relies on the recipient's own immune system to mount a specific and durable response against the antigen of interest. This approach has been instrumental in preventing and controlling various infectious diseases, such as measles, mumps, rubella, polio, hepatitis B, and influenza, among others. Additionally, active immunotherapy is being explored as a potential strategy for treating cancer and other chronic diseases by targeting disease-specific antigens or modulating the immune system to enhance its ability to recognize and eliminate abnormal cells.

Antigens are substances (usually proteins) found on the surface of cells, or viruses, that can be recognized by the immune system and stimulate an immune response. In the context of protozoa, antigens refer to the specific proteins or other molecules found on the surface of these single-celled organisms that can trigger an immune response in a host organism.

Protozoa are a group of microscopic eukaryotic organisms that include a diverse range of species, some of which can cause diseases in humans and animals. When a protozoan infects a host, the host's immune system recognizes the protozoan antigens as foreign and mounts an immune response to eliminate the infection. This response involves the activation of various types of immune cells, such as T-cells and B-cells, which recognize and target the protozoan antigens.

Understanding the nature of protozoan antigens is important for developing vaccines and other immunotherapies to prevent or treat protozoan infections. For example, researchers have identified specific antigens on the surface of the malaria parasite that are recognized by the human immune system and have used this information to develop vaccine candidates. However, many protozoan infections remain difficult to prevent or treat, and further research is needed to identify new targets for vaccines and therapies.

Vaccine potency is a measure of the ability of a vaccine to induce an immune response in the recipient, typically measured by its ability to stimulate the production of antibodies or activate immune cells. It is usually expressed as the amount of antigen contained in the vaccine or the dose required to produce a specific level of immunity in a certain percentage of vaccinated individuals.

Potency testing is an important part of vaccine manufacturing and quality control, as it helps ensure that each batch of vaccine contains sufficient levels of active ingredients to provide protection against the targeted disease. Vaccine potency may be affected by various factors, including the age and health status of the recipient, the route of administration, and the storage and handling conditions of the vaccine.

Measles, also known as rubeola, is a highly infectious viral disease that primarily affects the respiratory system. It is caused by the measles virus, which belongs to the family Paramyxoviridae and the genus Morbillivirus. The virus is transmitted through direct contact with infected individuals or through airborne droplets released during coughing and sneezing.

The classic symptoms of measles include:

1. Fever: A high fever (often greater than 104°F or 40°C) usually appears before the onset of the rash, lasting for about 4-7 days.
2. Cough: A persistent cough is common and may become severe.
3. Runny nose: A runny or blocked nose is often present during the early stages of the illness.
4. Red eyes (conjunctivitis): Inflammation of the conjunctiva, the mucous membrane that covers the inner surface of the eyelids and the white part of the eye, can cause redness and irritation.
5. Koplik's spots: These are small, irregular, bluish-white spots with a red base that appear on the inside lining of the cheeks, usually 1-2 days before the rash appears. They are considered pathognomonic for measles, meaning their presence confirms the diagnosis.
6. Rash: The characteristic measles rash typically starts on the face and behind the ears, then spreads downward to the neck, trunk, arms, and legs. It consists of flat red spots that may merge together, forming irregular patches. The rash usually lasts for 5-7 days before fading.

Complications from measles can be severe and include pneumonia, encephalitis (inflammation of the brain), and ear infections. In rare cases, measles can lead to serious long-term complications or even death, particularly in young children, pregnant women, and individuals with weakened immune systems.

Vaccination is an effective way to prevent measles. The measles vaccine is typically administered as part of the Measles, Mumps, and Rubella (MMR) vaccine, which provides immunity against all three diseases.

Interferon-gamma (IFN-γ) is a soluble cytokine that is primarily produced by the activation of natural killer (NK) cells and T lymphocytes, especially CD4+ Th1 cells and CD8+ cytotoxic T cells. It plays a crucial role in the regulation of the immune response against viral and intracellular bacterial infections, as well as tumor cells. IFN-γ has several functions, including activating macrophages to enhance their microbicidal activity, increasing the presentation of major histocompatibility complex (MHC) class I and II molecules on antigen-presenting cells, stimulating the proliferation and differentiation of T cells and NK cells, and inducing the production of other cytokines and chemokines. Additionally, IFN-γ has direct antiproliferative effects on certain types of tumor cells and can enhance the cytotoxic activity of immune cells against infected or malignant cells.

Rickettsial vaccines are vaccines that are designed to protect against rickettsial infections, which are diseases caused by bacteria of the genus Rickettsia. These bacteria are transmitted to humans through the bites of infected arthropods such as ticks, fleas, and lice.

Rickettsial vaccines typically contain whole-cell or subunit antigens of the rickettsial bacteria, which stimulate the immune system to produce antibodies and activate T cells that can recognize and eliminate the pathogen if it infects the body in the future.

Examples of rickettsial vaccines include those for typhus fever, Rocky Mountain spotted fever, and scrub typhus. These vaccines have been shown to be effective in preventing or reducing the severity of these diseases, but they are not widely available or used due to various factors such as limited demand, production challenges, and safety concerns.

It's important to note that rickettsial vaccines may carry some risks and side effects, including allergic reactions, local reactions at the injection site, and in rare cases, systemic reactions. Therefore, it is essential to consult with a healthcare provider before receiving any vaccine, including rickettsial vaccines.

Smallpox is a severe, contagious, and fatal infectious disease caused by the variola virus. It's characterized by fever, malaise, prostration, headache, and backache; followed by a distinctive rash with flat, red spots that turn into small blisters filled with clear fluid, then pus, and finally crust, scab, and fall off after about two weeks, leaving permanent scarring. There are two clinical forms of smallpox: variola major and variola minor. Variola major is the severe and most common form, with a mortality rate of 30% or higher. Variola minor is a less common presentation with milder symptoms and a lower mortality rate of about 1%.

Smallpox was declared eradicated by the World Health Organization (WHO) in 1980 following a successful global vaccination campaign, and routine smallpox vaccination has since been discontinued. However, due to concerns about bioterrorism, military personnel and some healthcare workers may still receive smallpox vaccinations as a precautionary measure.

First Aid is the immediate and temporary treatment or care given to a sick, injured, or wounded person until full medical services become available. It can include simple procedures like cleaning and dressing wounds, administering CPR (Cardiopulmonary Resuscitation), preventing shock, or placing a splint on a broken bone. The goal of first aid is to preserve life, prevent further harm, and promote recovery.

C57BL/6 (C57 Black 6) is an inbred strain of laboratory mouse that is widely used in biomedical research. The term "inbred" refers to a strain of animals where matings have been carried out between siblings or other closely related individuals for many generations, resulting in a population that is highly homozygous at most genetic loci.

The C57BL/6 strain was established in 1920 by crossing a female mouse from the dilute brown (DBA) strain with a male mouse from the black strain. The resulting offspring were then interbred for many generations to create the inbred C57BL/6 strain.

C57BL/6 mice are known for their robust health, longevity, and ease of handling, making them a popular choice for researchers. They have been used in a wide range of biomedical research areas, including studies of cancer, immunology, neuroscience, cardiovascular disease, and metabolism.

One of the most notable features of the C57BL/6 strain is its sensitivity to certain genetic modifications, such as the introduction of mutations that lead to obesity or impaired glucose tolerance. This has made it a valuable tool for studying the genetic basis of complex diseases and traits.

Overall, the C57BL/6 inbred mouse strain is an important model organism in biomedical research, providing a valuable resource for understanding the genetic and molecular mechanisms underlying human health and disease.

Mucosal immunity refers to the immune system's defense mechanisms that are specifically adapted to protect the mucous membranes, which line various body openings such as the respiratory, gastrointestinal, and urogenital tracts. These membranes are constantly exposed to foreign substances, including potential pathogens, and therefore require a specialized immune response to maintain homeostasis and prevent infection.

Mucosal immunity is primarily mediated by secretory IgA (SIgA) antibodies, which are produced by B cells in the mucosa-associated lymphoid tissue (MALT). These antibodies can neutralize pathogens and prevent them from adhering to and invading the epithelial cells that line the mucous membranes.

In addition to SIgA, other components of the mucosal immune system include innate immune cells such as macrophages, dendritic cells, and neutrophils, which can recognize and respond to pathogens through pattern recognition receptors (PRRs). T cells also play a role in mucosal immunity, particularly in the induction of cell-mediated immunity against viruses and other intracellular pathogens.

Overall, mucosal immunity is an essential component of the body's defense system, providing protection against a wide range of potential pathogens while maintaining tolerance to harmless antigens present in the environment.

Parainfluenza vaccines are vaccines that are designed to protect against parainfluenza virus infections, which are a common cause of respiratory illnesses such as croup, bronchitis, and pneumonia. There are four types of parainfluenza viruses (PIV 1-4), and they are spread from person to person through respiratory droplets.

Currently, there are no licensed vaccines available for parainfluenza viruses in the United States. However, researchers have been working on developing vaccines against PIV1 and PIV3, which are the most common causes of severe lower respiratory tract illnesses in infants and young children.

There are two main types of parainfluenza vaccines that have been developed: live-attenuated vaccines and inactivated vaccines. Live-attenuated vaccines contain weakened strains of the virus, while inactivated vaccines contain killed viruses. Both types of vaccines have shown promise in clinical trials, but further research is needed to determine their safety and effectiveness in larger populations.

Overall, parainfluenza vaccines are an important area of research, as they could help prevent serious respiratory illnesses in young children and other vulnerable populations.

According to the World Health Organization (WHO), Rotavirus is the most common cause of severe diarrhea among children under 5 years of age. It is responsible for around 215,000 deaths among children in this age group each year.

Rotavirus infection causes inflammation of the stomach and intestines, resulting in symptoms such as vomiting, watery diarrhea, and fever. The virus is transmitted through the fecal-oral route, often through contaminated hands, food, or water. It can also be spread through respiratory droplets when an infected person coughs or sneezes.

Rotavirus infections are highly contagious and can spread rapidly in communities, particularly in settings where children are in close contact with each other, such as child care centers and schools. The infection is usually self-limiting and resolves within a few days, but severe cases can lead to dehydration and require hospitalization.

Prevention measures include good hygiene practices, such as handwashing with soap and water, safe disposal of feces, and rotavirus vaccination. The WHO recommends the inclusion of rotavirus vaccines in national immunization programs to reduce the burden of severe diarrhea caused by rotavirus infection.

"Influenza A Virus, H5N1 Subtype" is a specific subtype of the Influenza A virus that is often found in avian species (birds) and can occasionally infect humans. The "H5N1" refers to the specific proteins (hemagglutinin and neuraminidase) found on the surface of the virus. This subtype has caused serious infections in humans, with high mortality rates, especially in cases where people have had close contact with infected birds. It does not commonly spread from person to person, but there is concern that it could mutate and adapt to efficiently transmit between humans, which would potentially cause a pandemic.

"Influenza A Virus, H3N2 Subtype" is a specific subtype of the influenza A virus that causes respiratory illness and is known to circulate in humans and animals, including birds and pigs. The "H3N2" refers to the two proteins on the surface of the virus: hemagglutinin (H) and neuraminidase (N). In this subtype, the H protein is of the H3 variety and the N protein is of the N2 variety. This subtype has been responsible for several influenza epidemics and pandemics in humans, including the 1968 Hong Kong flu pandemic. It is one of the influenza viruses that are monitored closely by public health authorities due to its potential to cause significant illness and death, particularly in high-risk populations such as older adults, young children, and people with certain underlying medical conditions.

Influenza B virus is one of the primary types of influenza viruses that cause seasonal flu in humans. It's an enveloped, negative-sense, single-stranded RNA virus belonging to the family Orthomyxoviridae.

Influenza B viruses are typically found only in humans and circulate widely during the annual flu season. They mutate at a slower rate than Influenza A viruses, which means that immunity developed against one strain tends to provide protection against similar strains in subsequent seasons. However, they can still cause significant illness, especially among young children, older adults, and people with certain chronic medical conditions.

Influenza B viruses are divided into two lineages: Victoria and Yamagata. Vaccines are developed each year to target the most likely strains of Influenza A and B viruses that will circulate in the upcoming flu season.

Pseudorabies vaccines are vaccines used to protect swine against the Pseudorabies virus, also known as Aujeszky's disease. This viral disease can affect the nervous system of pigs and other animals, causing symptoms such as fever, loss of appetite, difficulty breathing, and neurological issues. It can also lead to significant economic losses in the swine industry due to reproductive failures and mortality.

Pseudorabies vaccines contain attenuated (weakened) or inactivated (killed) forms of the Pseudorabies virus. These vaccines work by stimulating the pig's immune system to produce antibodies against the virus, providing protection against infection. However, it is important to note that these vaccines do not provide complete sterilizing immunity, meaning that vaccinated animals may still become infected and shed the virus if exposed to the wild-type strain.

Pseudorabies vaccines are typically administered to young pigs through injection, and revaccination may be necessary to maintain immunity. These vaccines have played a crucial role in controlling and eradicating Pseudorabies from swine populations in many countries. However, it is important to follow proper vaccine handling, storage, and administration procedures to ensure their effectiveness and safety.

An antigen is any substance that can stimulate an immune response, particularly the production of antibodies. Viral antigens are antigens that are found on or produced by viruses. They can be proteins, glycoproteins, or carbohydrates present on the surface or inside the viral particle.

Viral antigens play a crucial role in the immune system's recognition and response to viral infections. When a virus infects a host cell, it may display its antigens on the surface of the infected cell. This allows the immune system to recognize and target the infected cells for destruction, thereby limiting the spread of the virus.

Viral antigens are also important targets for vaccines. Vaccines typically work by introducing a harmless form of a viral antigen to the body, which then stimulates the production of antibodies and memory T-cells that can recognize and respond quickly and effectively to future infections with the actual virus.

It's worth noting that different types of viruses have different antigens, and these antigens can vary between strains of the same virus. This is why there are often different vaccines available for different viral diseases, and why flu vaccines need to be updated every year to account for changes in the circulating influenza virus strains.

Hemagglutinin (HA) glycoproteins are surface proteins found on influenza viruses. They play a crucial role in the virus's ability to infect and spread within host organisms.

The HAs are responsible for binding to sialic acid receptors on the host cell's surface, allowing the virus to attach and enter the cell. After endocytosis, the viral and endosomal membranes fuse, releasing the viral genome into the host cell's cytoplasm.

There are several subtypes of hemagglutinin (H1-H18) identified so far, with H1, H2, and H3 being common in human infections. The significant antigenic differences among these subtypes make them important targets for the development of influenza vaccines. However, due to their high mutation rate, new vaccine formulations are often required to match the circulating virus strains.

In summary, hemagglutinin glycoproteins on influenza viruses are essential for host cell recognition and entry, making them important targets for diagnosis, prevention, and treatment of influenza infections.

Papillomavirus infections are a group of diseases caused by various types of human papillomaviruses (HPVs). These viruses infect the skin and mucous membranes, and can cause benign growths such as warts or papillomas, as well as malignant growths like cervical cancer.

There are more than 100 different types of HPVs, and they can be classified into low-risk and high-risk types based on their potential to cause cancer. Low-risk HPV types, such as HPV-6 and HPV-11, commonly cause benign genital warts and respiratory papillomas. High-risk HPV types, such as HPV-16 and HPV-18, are associated with an increased risk of developing cancer, including cervical, anal, penile, vulvar, and oropharyngeal cancers.

HPV infections are typically transmitted through sexual contact, and most sexually active individuals will acquire at least one HPV infection during their lifetime. In many cases, the immune system is able to clear the virus without any symptoms or long-term consequences. However, persistent high-risk HPV infections can lead to the development of cancer over time.

Prevention measures for HPV infections include vaccination against high-risk HPV types, safe sex practices, and regular screening for cervical cancer in women. The HPV vaccine is recommended for both boys and girls aged 11-12 years old, and can also be given to older individuals up to age 45 who have not previously been vaccinated or who have not completed the full series of shots.

Poliomyelitis, also known as polio, is a highly infectious disease caused by a virus that invades the body through the mouth, usually from contaminated water or food. The virus multiplies in the intestine and can invade the nervous system, causing paralysis.

The medical definition of Poliomyelitis includes:

1. An acute viral infection caused by the poliovirus.
2. Characterized by inflammation of the gray matter of the spinal cord (poliomyelitis), leading to muscle weakness, and in some cases, paralysis.
3. The disease primarily affects children under 5 years of age.
4. Transmission occurs through the fecal-oral route or, less frequently, by respiratory droplets.
5. The virus enters the body via the mouth, multiplies in the intestines, and can invade the nervous system.
6. There are three types of poliovirus (types 1, 2, and 3), each capable of causing paralytic polio.
7. Infection with one type does not provide immunity to the other two types.
8. The disease has no cure, but vaccination can prevent it.
9. Two types of vaccines are available: inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV).
10. Rare complications of OPV include vaccine-associated paralytic polio (VAPP) and circulating vaccine-derived polioviruses (cVDPVs).

"Drug storage" refers to the proper handling, maintenance, and preservation of medications in a safe and suitable environment to ensure their effectiveness and safety until they are used. Proper drug storage includes:

1. Protecting drugs from light, heat, and moisture: Exposure to these elements can degrade the quality and potency of medications. Therefore, it is recommended to store most drugs in a cool, dry place, away from direct sunlight.

2. Keeping drugs out of reach of children and pets: Medications should be stored in a secure location, such as a locked cabinet or medicine chest, to prevent accidental ingestion or harm to young children and animals.

3. Following storage instructions on drug labels and packaging: Some medications require specific storage conditions, such as refrigeration or protection from freezing. Always follow the storage instructions provided by the manufacturer or pharmacist.

4. Regularly inspecting drugs for signs of degradation or expiration: Check medications for changes in color, consistency, or odor, and discard any that have expired or show signs of spoilage.

5. Storing drugs separately from one another: Keep different medications separate to prevent cross-contamination, incorrect dosing, or accidental mixing of incompatible substances.

6. Avoiding storage in areas with high humidity or temperature fluctuations: Bathrooms, kitchens, and garages are generally not ideal for storing medications due to their exposure to moisture, heat, and temperature changes.

Proper drug storage is crucial for maintaining the safety, efficacy, and stability of medications. Improper storage can lead to reduced potency, increased risk of adverse effects, or even life-threatening situations. Always consult a healthcare professional or pharmacist for specific storage instructions and recommendations.

Rabies is a viral zoonotic disease that is typically transmitted through the saliva of infected animals, usually by a bite or scratch. The virus infects the central nervous system, causing encephalopathy and ultimately leading to death in both humans and animals if not treated promptly and effectively.

The rabies virus belongs to the Rhabdoviridae family, with a negative-sense single-stranded RNA genome. It is relatively fragile and cannot survive for long outside of its host, but it can be transmitted through contact with infected tissue or nerve cells.

Initial symptoms of rabies in humans may include fever, headache, and general weakness or discomfort. As the disease progresses, more specific symptoms appear, such as insomnia, anxiety, confusion, partial paralysis, excitation, hallucinations, agitation, hypersalivation (excessive saliva production), difficulty swallowing, and hydrophobia (fear of water).

Once clinical signs of rabies appear, the disease is almost always fatal. However, prompt post-exposure prophylaxis with rabies vaccine and immunoglobulin can prevent the onset of the disease if administered promptly after exposure. Preventive vaccination is also recommended for individuals at high risk of exposure to the virus, such as veterinarians, animal handlers, and travelers to areas where rabies is endemic.

A dose-response relationship in immunology refers to the quantitative relationship between the dose or amount of an antigen (a substance that triggers an immune response) and the magnitude or strength of the resulting immune response. Generally, as the dose of an antigen increases, the intensity and/or duration of the immune response also increase, up to a certain point. This relationship helps in determining the optimal dosage for vaccines and immunotherapies, ensuring sufficient immune activation while minimizing potential adverse effects.

Orthomyxoviridae is a family of viruses that includes influenza A, B, and C viruses, which can cause respiratory infections in humans. Orthomyxoviridae infections are typically characterized by symptoms such as fever, cough, sore throat, runny or stuffy nose, muscle or body aches, headaches, and fatigue.

Influenza A and B viruses can cause seasonal epidemics of respiratory illness that occur mainly during the winter months in temperate climates. Influenza A viruses can also cause pandemics, which are global outbreaks of disease that occur when a new strain of the virus emerges to which there is little or no immunity in the human population.

Influenza C viruses are less common and typically cause milder illness than influenza A and B viruses. They do not cause epidemics and are not usually included in seasonal flu vaccines.

Orthomyxoviridae infections can be prevented through vaccination, good respiratory hygiene (such as covering the mouth and nose when coughing or sneezing), hand washing, and avoiding close contact with sick individuals. Antiviral medications may be prescribed to treat influenza A and B infections, particularly for people at high risk of complications, such as older adults, young children, pregnant women, and people with certain underlying medical conditions.

I'm sorry for any confusion, but "United States" is a geopolitical entity, specifically the name of the country consisting of 50 states, and it is not a medical term or concept. Therefore, I can't provide a medical definition for it. If you have any questions related to health, medicine, or biology, I would be happy to try to help answer those!

I'm sorry for any confusion, but "Protozoan Proteins" is not a specific medical or scientific term. Protozoa are single-celled eukaryotic organisms, and proteins are large biological molecules consisting of one or more chains of amino acid residues. Therefore, "Protozoan Proteins" generally refers to the various types of proteins found in protozoa.

However, if you're looking for information about proteins specific to certain protozoan parasites with medical relevance (such as Plasmodium falciparum, which causes malaria), I would be happy to help! Please provide more context or specify the particular protozoan of interest.

Influenza A virus is defined as a negative-sense, single-stranded, segmented RNA virus belonging to the family Orthomyxoviridae. It is responsible for causing epidemic and pandemic influenza in humans and is also known to infect various animal species, such as birds, pigs, horses, and seals. The viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), are the primary targets for antiviral drugs and vaccines. There are 18 different HA subtypes and 11 known NA subtypes, which contribute to the diversity and antigenic drift of Influenza A viruses. The zoonotic nature of this virus allows for genetic reassortment between human and animal strains, leading to the emergence of novel variants with pandemic potential.

A disease outbreak is defined as the occurrence of cases of a disease in excess of what would normally be expected in a given time and place. It may affect a small and localized group or a large number of people spread over a wide area, even internationally. An outbreak may be caused by a new agent, a change in the agent's virulence or host susceptibility, or an increase in the size or density of the host population.

Outbreaks can have significant public health and economic impacts, and require prompt investigation and control measures to prevent further spread of the disease. The investigation typically involves identifying the source of the outbreak, determining the mode of transmission, and implementing measures to interrupt the chain of infection. This may include vaccination, isolation or quarantine, and education of the public about the risks and prevention strategies.

Examples of disease outbreaks include foodborne illnesses linked to contaminated food or water, respiratory infections spread through coughing and sneezing, and mosquito-borne diseases such as Zika virus and West Nile virus. Outbreaks can also occur in healthcare settings, such as hospitals and nursing homes, where vulnerable populations may be at increased risk of infection.

Meningococcal infections are caused by the bacterium Neisseria meningitidis, also known as meningococcus. These infections can take several forms, but the most common are meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicemia (bloodstream infection). Meningococcal infections are contagious and can spread through respiratory droplets or close contact with an infected person. They can be serious and potentially life-threatening, requiring prompt medical attention and treatment with antibiotics. Symptoms of meningococcal meningitis may include fever, headache, stiff neck, and sensitivity to light, while symptoms of septicemia may include fever, chills, rash, and severe muscle pain. Vaccination is available to prevent certain strains of meningococcal disease.

A marker vaccine, also known as a "test vaccine" or "immunization tag," is a type of vaccine that not only provides immunity against a particular disease but also contains an antigen that can be detected in bodily fluids (such as blood) after vaccination. This allows for the confirmation of a successful vaccination and the development of immune response in an individual.

Marker vaccines are particularly useful in situations where it is essential to confirm whether a person has been vaccinated or not, such as in disease eradication programs, public health monitoring, or in cases where vaccine-induced immunity needs to be distinguished from natural immunity (due to previous infection). The marker component of the vaccine can be detected through various methods like serological assays or molecular techniques.

An example of a marker vaccine is the oral poliovirus vaccine (OPV), which contains live attenuated polioviruses. After vaccination, the shedding of the weakened viruses in the stool can be detected and used to monitor the effectiveness of immunization campaigns aimed at eradicating polio globally.

Haemophilus influenzae type b (Hib) is a bacterial subtype that can cause serious infections, particularly in children under 5 years of age. Although its name may be confusing, Hib is not the cause of influenza (the flu). It is defined medically as a gram-negative, coccobacillary bacterium that is a member of the family Pasteurellaceae.

Hib is responsible for several severe and potentially life-threatening infections such as meningitis (inflammation of the membranes surrounding the brain and spinal cord), epiglottitis (swelling of the tissue located at the base of the tongue that can block the windpipe), pneumonia, and bacteremia (bloodstream infection).

Before the introduction of the Hib vaccine in the 1980s and 1990s, Haemophilus influenzae type b was a leading cause of bacterial meningitis in children under 5 years old. Since then, the incidence of invasive Hib disease has decreased dramatically in vaccinated populations.

Serotyping is a laboratory technique used to classify microorganisms, such as bacteria and viruses, based on the specific antigens or proteins present on their surface. It involves treating the microorganism with different types of antibodies and observing which ones bind to its surface. Each distinct set of antigens corresponds to a specific serotype, allowing for precise identification and characterization of the microorganism. This technique is particularly useful in epidemiology, vaccine development, and infection control.

Dendritic cells (DCs) are a type of immune cell that play a critical role in the body's defense against infection and cancer. They are named for their dendrite-like projections, which they use to interact with and sample their environment. DCs are responsible for processing antigens (foreign substances that trigger an immune response) and presenting them to T cells, a type of white blood cell that plays a central role in the immune system's response to infection and cancer.

DCs can be found throughout the body, including in the skin, mucous membranes, and lymphoid organs. They are able to recognize and respond to a wide variety of antigens, including those from bacteria, viruses, fungi, and parasites. Once they have processed an antigen, DCs migrate to the lymph nodes, where they present the antigen to T cells. This interaction activates the T cells, which then go on to mount a targeted immune response against the invading pathogen or cancerous cells.

DCs are a diverse group of cells that can be divided into several subsets based on their surface markers and function. Some DCs, such as Langerhans cells and dermal DCs, are found in the skin and mucous membranes, where they serve as sentinels for invading pathogens. Other DCs, such as plasmacytoid DCs and conventional DCs, are found in the lymphoid organs, where they play a role in activating T cells and initiating an immune response.

Overall, dendritic cells are essential for the proper functioning of the immune system, and dysregulation of these cells has been implicated in a variety of diseases, including autoimmune disorders and cancer.

Immunotherapy is a type of medical treatment that uses the body's own immune system to fight against diseases, such as cancer. It involves the use of substances (like vaccines, medications, or immune cells) that stimulate or suppress the immune system to help it recognize and destroy harmful disease-causing cells or agents, like tumor cells.

Immunotherapy can work in several ways:

1. Activating the immune system: Certain immunotherapies boost the body's natural immune responses, helping them recognize and attack cancer cells more effectively.
2. Suppressing immune system inhibitors: Some immunotherapies target and block proteins or molecules that can suppress the immune response, allowing the immune system to work more efficiently against diseases.
3. Replacing or enhancing specific immune cells: Immunotherapy can also involve administering immune cells (like T-cells) that have been genetically engineered or modified to recognize and destroy cancer cells.

Immunotherapies have shown promising results in treating various types of cancer, autoimmune diseases, and allergies. However, they can also cause side effects, as an overactive immune system may attack healthy tissues and organs. Therefore, careful monitoring is necessary during immunotherapy treatment.

Yellow fever virus (YFV) is an single-stranded RNA virus belonging to the Flaviviridae family, genus Flavivirus. It is primarily transmitted to humans through the bite of infected mosquitoes, most commonly Aedes and Haemagogus species. The virus is named for the jaundice that can occur in some patients, giving their skin and eyes a yellowish color.

Yellow fever is endemic in tropical regions of Africa and South America, with outbreaks occurring when large numbers of people are infected. After an incubation period of 3 to 6 days, symptoms typically begin with fever, chills, headache, back pain, and muscle aches. In more severe cases, the infection can progress to cause bleeding, organ failure, and death.

Prevention measures include vaccination, mosquito control, and personal protective measures such as wearing long sleeves and using insect repellent in areas where yellow fever is endemic or outbreaks are occurring.

Mumps is a viral infection that primarily affects the parotid salivary glands, causing them to swell and become painful. The medical definition of mumps is: "An acute infectious disease, caused by the mumps virus, characterized by painful enlargement of one or more of the salivary glands, especially the parotids."

The infection spreads easily through respiratory droplets or direct contact with an infected person's saliva. Symptoms typically appear 16-18 days after exposure and include fever, headache, muscle aches, tiredness, and swollen, tender salivary glands. Complications of mumps are rare but can be serious and include meningitis, encephalitis, deafness, and inflammation of the reproductive organs in males.

Prevention is through vaccination with the measles-mumps-rubella (MMR) vaccine, which is part of routine childhood immunization schedules in many countries.

In the field of medicine, "time factors" refer to the duration of symptoms or time elapsed since the onset of a medical condition, which can have significant implications for diagnosis and treatment. Understanding time factors is crucial in determining the progression of a disease, evaluating the effectiveness of treatments, and making critical decisions regarding patient care.

For example, in stroke management, "time is brain," meaning that rapid intervention within a specific time frame (usually within 4.5 hours) is essential to administering tissue plasminogen activator (tPA), a clot-busting drug that can minimize brain damage and improve patient outcomes. Similarly, in trauma care, the "golden hour" concept emphasizes the importance of providing definitive care within the first 60 minutes after injury to increase survival rates and reduce morbidity.

Time factors also play a role in monitoring the progression of chronic conditions like diabetes or heart disease, where regular follow-ups and assessments help determine appropriate treatment adjustments and prevent complications. In infectious diseases, time factors are crucial for initiating antibiotic therapy and identifying potential outbreaks to control their spread.

Overall, "time factors" encompass the significance of recognizing and acting promptly in various medical scenarios to optimize patient outcomes and provide effective care.

Neisseria meningitidis, Serogroup B is a subtype of the bacterium Neisseria meningitidis, also known as meningococcus. This bacterium can cause serious infections such as meningitis (inflammation of the lining of the brain and spinal cord) and septicemia (blood poisoning).

Serogroup B is one of the five main serogroups of Neisseria meningitidis, which are classified based on the chemical structure of their capsular polysaccharides. Serogroup B strains are responsible for a significant proportion of invasive meningococcal disease cases in many parts of the world.

The availability of vaccines that protect against some but not all serogroups of Neisseria meningitidis has led to efforts to develop effective vaccines against Serogroup B strains, which have been challenging due to their chemical structure and variability. In recent years, several vaccines targeting Serogroup B have been developed and licensed for use in various countries.

Herd immunity, also known as community immunity or population immunity, is a form of indirect protection from infectious diseases that occurs when a large percentage of a population has become immune to an infection, either through vaccination or previous illness. This reduces the likelihood of infection for individuals who are not immune, especially those who cannot receive vaccines due to medical reasons. The more people in a community who are immune, the less likely the disease will spread and the entire community is protected, not just those who are immune.

A Lyme disease vaccine is not currently available on the market. However, in the past, there was a vaccine called Lymerix, which was a recombinant OspA (outer surface protein A) vaccine. It was approved by the FDA in 1998 for use in people aged 15 to 70 years to prevent Lyme disease caused by the bacterium Borrelia burgdorferi. However, due to low consumer demand and unfounded concerns about potential adverse events, the manufacturer voluntarily withdrew it from the market in 2002.

Currently, there is no licensed vaccine available for Lyme disease. Researchers are continuing to work on developing new vaccines, but none have yet been approved for use.

Viral envelope proteins are structural proteins found in the envelope that surrounds many types of viruses. These proteins play a crucial role in the virus's life cycle, including attachment to host cells, fusion with the cell membrane, and entry into the host cell. They are typically made up of glycoproteins and are often responsible for eliciting an immune response in the host organism. The exact structure and function of viral envelope proteins vary between different types of viruses.

A pandemic is a global outbreak of a disease that spreads easily from person to person across a large region, such as multiple continents or worldwide. It is declared by the World Health Organization (WHO) when the spread of a disease poses a significant threat to the global population due to its severity and transmissibility.

Pandemics typically occur when a new strain of virus emerges that has not been previously seen in humans, for which there is little or no pre-existing immunity. This makes it difficult to control the spread of the disease, as people do not have natural protection against it. Examples of pandemics include the 1918 Spanish flu pandemic and the more recent COVID-19 pandemic caused by the SARS-CoV-2 virus.

During a pandemic, healthcare systems can become overwhelmed, and there may be significant social and economic disruption as governments take measures to slow the spread of the disease, such as travel restrictions, quarantines, and lockdowns. Effective vaccines and treatments are critical in controlling the spread of pandemics and reducing their impact on public health.

Virus shedding refers to the release of virus particles by an infected individual, who can then transmit the virus to others through various means such as respiratory droplets, fecal matter, or bodily fluids. This occurs when the virus replicates inside the host's cells and is released into the surrounding environment, where it can infect other individuals. The duration of virus shedding varies depending on the specific virus and the individual's immune response. It's important to note that some individuals may shed viruses even before they show symptoms, making infection control measures such as hand hygiene, mask-wearing, and social distancing crucial in preventing the spread of infectious diseases.

Tetanus is a serious bacterial infection caused by the bacterium Clostridium tetani. The bacteria are found in soil, dust and manure and can enter the body through wounds, cuts or abrasions, particularly if they're not cleaned properly. The bacterium produces a toxin that affects the nervous system, causing muscle stiffness and spasms, often beginning in the jaw and face (lockjaw) and then spreading to the rest of the body.

Tetanus can be prevented through vaccination, and it's important to get vaccinated if you haven't already or if your immunization status is not up-to-date. If tetanus is suspected, medical attention should be sought immediately, as it can be a life-threatening condition if left untreated. Treatment typically involves administering tetanus immune globulin (TIG) to neutralize the toxin and antibiotics to kill the bacteria, as well as supportive care such as wound cleaning and management, and in some cases, mechanical ventilation may be necessary to assist with breathing.

Immunity, in medical terms, refers to the body's ability to resist or fight against harmful foreign substances or organisms such as bacteria, viruses, parasites, and fungi. This resistance is achieved through various mechanisms, including the production of antibodies, the activation of immune cells like T-cells and B-cells, and the release of cytokines and other chemical messengers that help coordinate the immune response.

There are two main types of immunity: innate immunity and adaptive immunity. Innate immunity is the body's first line of defense against infection and involves nonspecific mechanisms such as physical barriers (e.g., skin and mucous membranes), chemical barriers (e.g., stomach acid and enzymes), and inflammatory responses. Adaptive immunity, on the other hand, is specific to particular pathogens and involves the activation of T-cells and B-cells, which recognize and remember specific antigens (foreign substances that trigger an immune response). This allows the body to mount a more rapid and effective response to subsequent exposures to the same pathogen.

Immunity can be acquired through natural means, such as when a person recovers from an infection and develops immunity to that particular pathogen, or artificially, through vaccination. Vaccines contain weakened or inactivated forms of a pathogen or its components, which stimulate the immune system to produce a response without causing the disease. This response provides protection against future infections with that same pathogen.

There is no established medical definition for "Pseudomonas vaccines" as it generally refers to vaccines that are being developed to prevent infections caused by the bacterium *Pseudomonas aeruginosa*. This bacterium can cause various types of infections, particularly in individuals with weakened immune systems or underlying health conditions.

*Pseudomonas aeruginosa* is an opportunistic pathogen, which means it mainly causes infection in people who have weakened defenses. It's known for its ability to develop resistance to multiple antibiotics, making it a significant concern in healthcare settings.

Vaccines against *Pseudomonas aeruginosa* aim to stimulate the immune system to produce an immune response (the production of antibodies and activation of immune cells) that can protect against future infection by this bacterium. Several vaccine candidates are being researched, targeting various antigens on the surface of *Pseudomonas aeruginosa*. However, none have been licensed for widespread use yet.

In summary, 'Pseudomonas vaccines' refers to vaccines under development that aim to protect against infections caused by the bacterium *Pseudomonas aeruginosa*.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Meningococcal meningitis is a specific type of bacterial meningitis caused by the bacterium Neisseria meningitidis, also known as meningococcus. Meningitis refers to the inflammation of the meninges, which are the protective membranes covering the brain and spinal cord. When this inflammation is caused by the meningococcal bacteria, it is called meningococcal meningitis.

There are several serogroups of Neisseria meningitidis that can cause invasive disease, with the most common ones being A, B, C, W, and Y. The infection can spread through respiratory droplets or direct contact with an infected person's saliva or secretions, especially when they cough or sneeze.

Meningococcal meningitis is a serious and potentially life-threatening condition that requires immediate medical attention. Symptoms may include sudden onset of fever, severe headache, stiff neck, nausea, vomiting, confusion, and sensitivity to light. In some cases, a rash may also develop, characterized by small purple or red spots that do not blanch when pressed with a glass.

Prevention measures include vaccination against the different serogroups of Neisseria meningitidis, maintaining good personal hygiene, avoiding sharing utensils, cigarettes, or other items that may come into contact with an infected person's saliva, and promptly seeking medical care if symptoms develop.

... through its Action Cycling 200 and AIDS Vaccine 200 rides has donated a total of $2,781,090 for AIDS vaccine research and AIDS- ... The majority of these funds ($557,000) has gone towards AIDS vaccine research at Emory Vaccine Center. The ride also ... who has helped raise big bucks for AIDS research - and his company Pallotta announces end to AIDS Vaccine Rides: Even with ... 2.4 million to the Emory Vaccine Center, one of the world's leading vaccine research centers working to find an HIV vaccine. ...
"AIDS Vaccine Advocacy Coalition". AVAC. Retrieved 2008-12-08. "AIDS Vaccine Advocacy Coalition(AVAC)". Archived from the ... the International AIDS Vaccine Initiative, Until There's a Cure Foundation, Broadway Cares/Equity Fights AIDS, the Gill ... AVAC works to provide independent analysis, policy advocacy, public education and mobilisation to enhance AIDS vaccine research ... HIV vaccine research, Organizations established in 1995, HIV/AIDS organizations in the United States, Vaccination-related ...
... , also known as HIV Vaccine Awareness Day, is observed annually on May 18. HIV vaccine advocates mark the ... preventive HIV vaccine can limit and eventually eliminate the threat of AIDS." The first World AIDS Vaccine Day was observed on ... South African AIDS Vaccine Initiative (SAAVI) World AIDS Day Bill Clinton's commencement speech at Morgan State University AIDS ... International AIDS Vaccine Initiative The South Africa AIDS Vaccine Initiative (SAAVI) (Articles lacking in-text citations from ...
... to evaluate the challenges facing HIV/AIDS vaccine development and identify ways to jump-start research. The International AIDS ... The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership working to accelerate ... It also partners with civil society organizations and other entities to advocate jointly for the development of AIDS vaccines, ... To address major obstacles in AIDS vaccine development, IAVI partners with HIV researchers from around the world. Its ...
The Collaboration for AIDS Vaccine Discovery (CAVD) is an international network of scientists, research organizations, and ... Official website (Orphaned articles from August 2019, All orphaned articles, HIV/AIDS research organisations, HIV vaccine ... The CAVD was founded in 2006 when the Bill & Melinda Gates Foundation donated $287 million USD to promote HIV vaccine research ... The CAVD itself supports the Global HIV Vaccine Enterprise. The network comprises many individual institutions. "Gates ...
"Development of an AIDS vaccine: perspective from the South African AIDS Vaccine Initiative". BMJ: British Medical Journal. 329 ... HIV/AIDS research organisations, HIV vaccine research, HIV/AIDS in South Africa, Medical research institutes in South Africa, ... The South African AIDS Vaccine Initiative (SAAVI) was a South African organisation with the mission of coordinating the ... Faul, Michelle (20 June 2009). "South Africa launches AIDS vaccine trial but slashes research funding". washingtonexaminer.com ...
Vaccine. 22 (15-16): 1831-1835. doi:10.1016/j.vaccine.2004.01.028. PMID 15121291. Koprowski (1992). "AIDS and the Polio Vaccine ... The oral polio vaccine (OPV) AIDS hypothesis is a now-discredited hypothesis that the AIDS pandemic originated from live polio ... The second vaccine, an oral polio vaccine (OPV), is a live-attenuated vaccine, produced by the passage of the virus through non ... "The Origins of AIDS (2004) video". YouTube. "Les origines du SIDA". IMDb. 2 May 2004. Osterrieth PM (June 2001). "Vaccine could ...
"Nabel to Head AIDS Vaccine Institute". www.science.org. Retrieved 2022-02-11. "NIAID selects new director of the Vaccine ... The discovery, a potentially landmark one in the drive to find a vaccine for AIDS should it be validated and further improved. ... Anthony Fauci regarding research addressing HIV/AIDS. Recognizing the potential impact a vaccine could make in decreasing the ... Notable visits to Vaccine Research Center President George W. Bush visits the Vaccine Research Center President Barack Obama ...
Global Alliance for Vaccines and Immunization (GAVI) International AIDS Vaccine Initiative (IAVI) AIDS Vaccine Advocacy ... Viruses portal Cabotegravir COVID-19 vaccine HIV Vaccine Trials Network World AIDS Vaccine Day Gray GE, Laher F, Lazarus E, ... An HIV vaccine is a potential vaccine that could be either a preventive vaccine or a therapeutic vaccine, which means it would ... Vaccine Research Center (VRC)- Information concerning Preventive HIV vaccine research studies NIAID HIV vaccine site (DAIDS) ...
In 2005, DHVI became the home to the NIAID funded Center for HIV/AIDS Vaccine Immunology, a $350M grant to speed the ... DHVI investigators have been at the forefront in the battle against AIDS and specifically in the quest for an HIV vaccine. In ... development of an AIDS vaccine. Led by Barton Haynes, MD this effort has had a major effect on the progress of the entire field ... The vaccine strategy of the Duke CHAVI-ID is based on identifying and targeting novel HIV-1 vulnerabilities to B, T, and NK ...
Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise (2005) The Global HIV/AIDS Vaccine Enterprise: Scientific ... 18 January 2005 Global HIV/AIDS Vaccine Enterprise (2005). "The Global HIV/AIDS Vaccine Enterprise: Scientific Strategic Plan ... International AIDS Vaccine Initiative, French National Agency for Research on AIDS and Viral Hepatitis. In June 2003, a group ... The article asserted that current attempts to develop such a vaccine were insufficient and that a renewed HIV vaccine research ...
Doran, Bishop Kevin (14 January 2021). "Vaccines - an aid to forming conscience". The Irish Catholic. Retrieved 10 March 2023. ... Kelly, Michael (14 January 2021). "Vulnerable may die if people refuse vaccine - Bishop Doran". The Irish Catholic. Retrieved ... Doran warned that lives would be lost if significant numbers refused to take the COVID-19 vaccine. One of the most outspoken ...
Paediatric European Network for Treatment of AIDS (PENTA) Vaccines Group; Penta Steering, C.; Children's HIV Association (CHIVA ... Vaccine-naive is a lack of immunity, or immunologic memory, to a disease because the person has not been vaccinated. There are ... Vaccine-naive persons threaten what epidemiologists call herd immunity. This is because vaccinations provide not just ... Wallace, H. Shortages require practices to take extra measures to keep patients up-to-date on vaccines: Calling the shots. AAP ...
Trafton, Anne (4 February 2009). "Alum's $100 million gift targets AIDS vaccines". Archived from the original on 2009-02-05. ... In 2009, Ragon pledged to donate US $100 million over 10 years period for AIDS research through the Phillip T. and Susan M. ... "Businessman donates $100 million to AIDS research". Reuters. 4 February 2009. Retrieved 2020-11-23. "Mass General Receives $200 ... 200 million to Massachusetts General Hospital for a vaccine-research center. In 2022, Ragon received the Golden Plate Award of ...
The results of the trial found that the two experimental AIDS vaccines proved to yield the best immune response in patients. ... "New experiment with AIDS vaccines called encouraging". The Sacramento Bee. June 22, 1991. Retrieved January 10, 2021 - via ... "First human tests of AIDS vaccine slated". Auburn Journal. August 12, 1987. Retrieved January 10, 2021 - via newspapers.com. " ... In 2000, the National Institutes of Health (NIH) recruited him to create a vaccine evaluation clinic (Vaccine Research Center ...
Merck have tested the a few vaccines and some of the other proposals are being tested by International AIDS Vaccine Initiative ... organized by the Department of Biotechnology and International AIDS Vaccine Initiative for the development of HIV vaccines. He ... International AIDS Vaccine Initiative. 2 May 2007. Retrieved 19 October 2016. "Seminar by Prof. Raghavan Varadarajan". ... his team developed a number of immunogens which have been demonstrated to have positive effect as HIV-1 vaccines and he holds ...
"Understanding Long-term Nonprogressors". International AIDS Vaccine Initiative. Archived from the original on October 9, 2006. ... AIDS. 20 (5): 685-9. doi:10.1097/01.aids.0000216368.23325.bc. PMID 16514298. S2CID 27932324. Thorven, M; Grahn, A; Hedlund, KO ... "Mitochondrial DNA haplogroups influence AIDS progression". AIDS. 22 (18): 2429-39. doi:10.1097/QAD.0b013e32831940bb. ISSN 0269- ... Without the symptoms of AIDS, many LTNP patients may not know they are infected. Genetic traits that confer greater resistance ...
International AIDS Vaccine Initiative. 18 (3): 14-7. PMID 25401194. Plaza, David F; Gomez, Manuel; Patarroyo, Manuel (31 ... De Groot, Anne (1 December 2009). "Exploring the immunome: A brave new world for human vaccine development". Human Vaccines. 5 ... Human Vaccines & Immunotherapeutics. 14 (9): 2214-2216. doi:10.1080/21645515.2018.1476813. PMID 6183335. "The Human Vaccines ... The development of vaccines is also an application of immunome study as shown by Carlos F. Suárez and his colleagues. They were ...
T-cell vaccines underwent clinical trials for HIV/AIDS. As of July 2012[update] none have been approved. As December 2020, The ... A T-cell vaccine is a vaccine designed to induce protective T-cells. T-cell vaccines are designed to induce cellular immunity. ... Vaccines, All stub articles, COVID-19 vaccine stubs, Vaccine stubs). ... "T-cell Vaccines Could Treat Elusive Diseases". Commissioner, Office of the (2020-12-14). "FDA Takes Key Action in Fight Against ...
"Claim Covid-19 vaccine is giving people AIDS is False". The Ferret. 24 February 2022. Archived from the original on 8 February ... The Exposé has falsely linked the COVID-19 vaccines to AIDS, miscarriages, monkeypox and hepatitis. The website has also ... "Facebook yanks Bolsonaro video claiming vaccines cause AIDS". NBC News. Reuters. 26 October 2021. Archived from the original on ... "Facebook yanks Bolsonaro video claiming vaccines cause AIDS". Associated Press. Archived from the original on 22 October 2022. ...
"Building a better vaccine Hildegund Ertl and her Philadelphia researchers pursue a new way to conquer the AIDS virus, threats ... In interviews, Ertl has been cautious and critical when it comes to the development of vaccines for AIDS. Her research has ... "Study shows how some AIDS vaccines may harm". Reuters. 17 November 2007. Retrieved 12 February 2014. Dr. Ertl's page on The ... In 2007, Ertl helped create The Wistar Institute Vaccine Center. Ertl said that the vaccines the laboratories in the center are ...
Vaccines are being researched for AIDS and tuberculosis. Genes associated with type 1 diabetes and certain types of cancer have ...
... "oral polio vaccine AIDS hypothesis", which posited that the AIDS pandemic originated from live polio vaccines such as ... Albert Sabin Discredited HIV/AIDS origins theories Jonas Salk List of Polish people Poles Polio vaccine Wistar Institute ... 119-130 online Archived 2008-08-02 at the Wayback Machine Hilary Koprowski (1992). "AIDS and the polio vaccine". Science. 257 ( ... "Rabies Vaccine 2" Archived 2020-07-11 at the Wayback Machine, History of Vaccines, The College of Physicians of Philadelphia ( ...
In 2018 she was elected to the board of the International AIDS Vaccine Initiative. She is concerned about Donald Trump ... "Board of Directors". IAVI - International AIDS Vaccine Initiative. Archived from the original on 14 April 2017. Retrieved 14 ... In 2016 she was elected President of the International AIDS Society. She gave the opening address at the International AIDS ... She saw young people dying from HIV/AIDS and was frustrated that she couldn't help them. Her PhD was funded by the John E. ...
Later, Hilleman's vaccine was falsely blamed for igniting the AIDS epidemic. (See Wolf Szmuness) But, although the purified ... Both types of the vaccine, the plasma-derived vaccine (PDV) and recombinant vaccine (RV), seems to be able to elicit similar ... brands, Recombinant proteins, Subunit vaccines, Hepatitis vaccines, World Health Organization essential medicines (vaccines), ... The vaccine is given by injection into a muscle. Serious side effects from the hepatitis B vaccine are very uncommon. Pain may ...
Gage, Brandon (3 April 2022). "Anti-vax activist claims COVID-19 vaccines cause AIDS". Salon. Archived from the original on 3 ... Srikanth, Anagha (24 March 2021). "12 prominent people opposed to vaccines are responsible for two-thirds of anti-vaccine ... every fully vaccinated person over the age of 30 may have the equivalent of full-blown vaccine-induced immune suppressed AIDS ... During the course, Tenpenny explains her views on the immune system and vaccines, and Hunt instructs participants on how best ...
... particularly in the prevention of hepatitis and AIDS. Gust, Ian D.; Kahn, Patricia; Koff, Wayne C. (2007). AIDS Vaccine ... Gust's area of work is in the development of drugs and vaccines against viral diseases and he is best known for the development ... "Professor Ian Gust". Vaccine and Immunotherapy Technologies. Sir Mark Oliphant Conferences. 2008. Archived from the original on ... The most cited are: Gust, I.D. "Epidemiological patterns of hepatitis A in different parts of the world" (1992) Vaccine, 10 ( ...
Kendall, Don (June 20, 1981). "Vaccine to aid human, animal diseases". Nashua Telegraph. Associated Press. Retrieved June 2, ... This vaccine was the first one developed using genetic engineering. Bachrach retired in 1981. In 1982, he was elected to ... In turn, the bacterium produced a large amount of VP3, and the Bachrach team felt that this could lead to a vaccine against the ... The development of the foot-and-mouth disease vaccine, which was only effective against a single strain of the illness, taught ...
"Immune children aid malaria vaccine hunt". BBC News. May 22, 2014. Raj, Dipak K.; Nixon, Christian P.; Nixon, Christina E.; ... "Groundbreaking malaria vaccine discovery". April 22, 2020. "Punjab NRI's company to try its new malaria vaccine on Covid-19 ... "New Malaria Vaccine Shows Promise in Mice". www.science.org. "partnerships". ocean biomedical. "Brown Alpert Medical School ... Ocean Biomedical has worked on developing vaccines for tropical diseases such as malaria, as well as for emerging diseases like ...
AVAC (27 January 2015). "News from the HC-HIV front: it's raining meta (analyses)!". New York: AIDS Vaccine Advocacy Coalition ...
Current Trends Hepatitis B Vaccine: Evidence Confirming Lack of AIDS Transmission ... In addition, the rate of AIDS for HB vaccine recipients in CDC vaccine trials among homosexually active men in Denver and San ... In addition, epidemiologic monitoring of AIDS cases and high-risk groups confirms the lack of AIDS transmission by HB vaccine. ... Epidemiologic approaches to detect an association between HB vaccine and AIDS have included analysis of data on AIDS cases ...
Global HIV Vaccine Enterprise, the Partnership for AIDS Vaccine Evaluation, and the Center for HIV-AIDS Vaccine Immunology). ... AIDS Vaccine Development: Challenges and Opportunities. Emerging Infectious Diseases. 2007;13(11):1802. doi:10.3201/ ... Chen, R. T. (2007). AIDS Vaccine Development: Challenges and Opportunities. Emerging Infectious Diseases, 13(11), 1802. https ... AIDS Vaccine Development: Challenges and Opportunities. Volume 13, Number 11-November 2007 ...
... through its Action Cycling 200 and AIDS Vaccine 200 rides has donated a total of $2,781,090 for AIDS vaccine research and AIDS- ... The majority of these funds ($557,000) has gone towards AIDS vaccine research at Emory Vaccine Center. The ride also ... who has helped raise big bucks for AIDS research - and his company Pallotta announces end to AIDS Vaccine Rides: Even with ... 2.4 million to the Emory Vaccine Center, one of the worlds leading vaccine research centers working to find an HIV vaccine. ...
... an American lab has developed new vaccine candidates that appear promising enough to consider advancing into clinical trials ... Persistence yields progress in AIDS vaccine research. Date:. May 13, 2015. Source:. University of California, Santa Cruz. ... "Persistence yields progress in AIDS vaccine research." ScienceDaily. www.sciencedaily.com. /. releases. /. 2015. /. 05. /. ... Phil Berman has been working to develop an AIDS vaccine for nearly 30 years, first at the pioneering biotech company Genentech ...
... vaccines are causing cancer and vaccine-induced AIDS at an alarming rate during the February 2 episode of ... Vladimir Zelenko how the COVID-19 vaccines are causing AIDS. Its not an HIV-induced AIDS, but a similar one that weakens the ... vaccines are causing cancer and vaccine-induced AIDS at an alarming rate during the February 2 episode of "The Ben Armstrong ... VAIDS is basically AIDS given by a vaccine. "Think of it as your immune system not performing like its supposed to," Armstrong ...
... vaccines. This effort will support the research of AIDS investigators, including three SIV Vaccine Evaluation Units (SIV VEU), ... a Chimpanzee Unit, the National Cooperative Vaccine Evaluation Group (NCVDG), the AIDS Vaccine Evaluation Group (AVEG), and ... CORE IMMUNOLOGY LABORATORY FOR ASSESSMENT OF AIDS VACCINES INPRIMATES NIH GUIDE, Volume 21, Number 37, October 16, 1992 RFP: ... preclinical AIDS vaccine trials in primates. The purpose of this contract is to support the NIAID in its mission to stimulate ...
Without a vaccine the AIDS epidemic can still end, UNAIDS boss November 22, 2016 Health, In The Magazine, Interview, Society ... Over the years, the HIV/AIDS discussion has changed from tackling transmission to treatment and prevention. Worldwide, experts ...
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV : AIDS. ... The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-3109.. * Cited Here ... In that study, most participants (,70%) had received the ChAdOx1 vaccine, with less than one-quarter receiving mRNA vaccines [ ... People with HIV were underrepresented in coronavirus disease 2019 (COVID-19) vaccine clinical trials. We estimated vaccine ...
... *Download PDF Copy ... Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?. News-Medical, viewed 04 December 2023, ... Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?. News-Medical. 04 December 2023. ,https ... 2023, April 05). Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?. News-Medical. ...
Nasal Vaccine May Aid Fight Against New Viral Variants December 11, 2021. December 11, 2021. Eurasia Review 0 Comments ... While both vaccine injections and nasal vaccines increased levels of antibodies in the blood of mice, only the nasal vaccine ... If the nasal vaccines prove to be safe and efficient in humans, Iwasaki envisions them being used in conjunction with current ... Nasal vaccines, but not the shot, also induced antibodies that protected the animals against a variety of flu strains, not just ...
10m of UK Aid funding for research into vaccines to protect the world from deadly diseases. ... 462,462 for the development of a vaccine for the Zika virus from £ ... UK Aid funding for Nottingham research to develop Zika virus vaccine. Scientists in Nottingham have been awarded £462,462 for ... the development of a vaccine for the Zika virus from £10m of UK Aid funding for research into vaccines to protect the world ...
Vaccine czar Carlito Galvez Jr. on Friday said he will ask President Rodrigo Duterte to certify as urgent the measure seeking ... Galvez: Vaccine indemnity fund law to aid PH bid to get ample vaccine supply. By: Krissy Aguilar - Reporter / @KAguilarINQ ... MANILA, Philippines - Vaccine czar Carlito Galvez Jr. on Friday stressed the significance of passing a bill that would provide ... There will be a one week delay on the arrival of vaccines coming from the World Health Organization-led COVAX facility, but ...
... the intramural research program of the NIAID Vaccine Research Center; the IAVI NAC Center; Collaboration for AIDS Vaccine ... A series of new studies led by scientists at the Scripps Research Institute (TSRI) and the International AIDS Vaccine ... Researchers Harness Antibody Evolution on the Path to an AIDS Vaccine. Sep 9, 2016. Article ... "The reductionist vaccine approach were undertaking will hopefully not only lead to an HIV vaccine, but also could potentially ...
Previous message (by thread): [ExI] Vaccines for Alzheimers, AIDS, herpes *Next message (by thread): [ExI] Vaccines for ... Previous message (by thread): [ExI] Vaccines for Alzheimers, AIDS, herpes *Next message (by thread): [ExI] Vaccines for ... ExI] Vaccines for Alzheimers, AIDS, herpes. Rafal Smigrodzki rafal.smigrodzki at gmail.com Wed Nov 18 21:17:05 UTC 2009 * ... I would be extremely skeptical regarding the prospects for Alzheimers vaccine. The efforts to remove amyloid have proven to be ...
YiSheng BioPharma Announces Research Collaboration With The Scripps Research Institute In Developing New AIDS Vaccine - read ... We are very pleased to join forces with TSRI in exploring a more effective vaccine against AIDS, which remains a significant ... Under the terms of the agreement, the scientists at TSRI will evaluate the potential of PIKA adjuvant for AIDS vaccine ... "TSRI has gained a great deal of expertise in AIDS research which lays the groundwork in revolutionizing vaccine design strategy ...
Frontline workers explain the importance of receiving the COVID-19 vaccine. ... Why did you decide to get the vaccine? Louis Smith (he, him, his) PrEP & HIV Benefits Navigator and Linkage Navigator: I got ... Why was it important to you to receive the vaccine? Kyle Temple (he, him, his) Senior Director, Stonewall Project: Getting the ... What would you say to anyone who is hesitant about getting the vaccine? Vincent Crisostomo: Ive lived with HIV for over 33 ...
Find out how an AIDS vaccine could change the trajectory of the epidemic. Support vaccine research and development for a game- ... Discover the potential impact of an HIV/AIDS Vaccine in Kenya. Explore the modeling of the Kenyan epidemic and the effects of ... IAVI (2005) Modeling the impact of AIDS vaccines. International AIDS Vaccine Initiative, New York. ... Objective: To estimate the potential impact of an HIV/AIDS Vaccine in Kenya. Design: The Kenyan HIV/AIDS epidemic was modeled ...
The FDA will vote on whether to clear Pfizers COVID-19 vaccine for emergency use. Two lawsuits question how Facebook got so ... HORSLEY: Aid to state and local governments also provides a lot of bang for the buck; grants to small businesses, probably less ... Experts are going to weigh the benefits and the risks of clearing Pfizers COVID-19 vaccine for emergency use in the U.S. Now, ... The FDA has built a case that this vaccine should be authorized for emergency use. Now, the meeting starts at 9 a.m. Eastern ...
In many cases, vaccine eligibility is determined by states or local health authorities. At the federal level, the U.S. Centers ... As coronavirus vaccine distribution gathers pace across the U.S., there is limited consensus and some confusion as to which ... amfARs mission is to end the global AIDS epidemic through innovative research. ... People Living with HIV Should Be Prioritized for Coronavirus Vaccine. March 5, 2021 ...
The supply of vaccines will remain limited, and it may be challenging for people living with HIV to get an appointment. AFC ... the City of Chicago announced anyone 16 and older who is living with HIV will be eligible for COVID-19 vaccines after Monday, ... Are the COVID-19 vaccines safe for people with HIV? The safety of COVID-19 vaccines is a top priority. No steps were skipped ... Will the COVID-19 vaccine mess with my HIV medications? No, your HIV medications will not be affected by the vaccine. The COVID ...
New Streptococcus Vaccine to Aid Tilapia Producers in Indonesia. Health Economics Education & academia +3 more ... an inactivated vaccine that aids in the protection against Streptococcus agalactiae infections in tilapia and other susceptible ... AQUAVAC Strep Sa has been shown both by the strain survey and cross-protection studies to be the vaccine to use in Indonesia ... He noted that the vaccine the first of its kind in the industry was registered successfully in Brazil in late 2011 and ...
AIDS (acquired immune deficiency syndrome) is just the name used to describe a number of potentially life-threatening ... Vaccine effectiveness isnt really a measure of a vaccine, it is a measure of a vaccine recipients immune system performance ... But vaccine effectiveness isnt really a measure of a vaccine, it is a measure of a vaccine recipients immune system ... Uncovering The Truth: Examining The Fatal Link Between COVID Vaccines And A New Form of AIDS. by The Expose , Dec 27, 2022 , ...
AIDS Vaccine Science for Busy Advocates - Passive Immunization: An important piece of the puzzle. ...
What is HIV/Aids? Is HIV/AIDS a common infection? What are the symptoms of HIV/AIDS ? How is HIV transmitted? HIV/AIDS and ... When can we expect a vaccine against HIV/AIDS?. Unfortunately, it will be many years of research before an effective and safe ... pregnancy HIV/AIDS in the newborn How is HIV/AIDS diagnosed? Is there a treatment for HIV/AIDS ? How can people infected with ... When can we expect a vaccine against HIV/AIDS? Links and References ...
Envelope protein immunogens may improve DNA or live-vectored HIV vaccines by complementing antiviral cellular responses with ... Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge AIDS Res Hum ... Envelope protein immunogens may improve DNA or live-vectored HIV vaccines by complementing antiviral cellular responses with ... and allowed testing of whether gp120 vaccines that fail to raise neutralizing antibody can improve protection. Following the ...
Bidens Vaccine Patent Waiver Aids Chinas Race to Beat U.S. in Innovation. "It wont address the short-term problem of vaccine ... Waiving the patents on these vaccines will disincentivize future investment and development of vaccines and treatments. ... The vaccines saved thousands of lives, prevented countless sicknesses, and have already come close to ending the pandemic in ... It Wont Work: It will take manufacturers many months, possibly years, to build the facilities to produce vaccines even with ...
... vaccine stocks are taking a massive hit as investors price in the potential effect of oral medications for Covid-19 on this ... Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today Heres the big news thats taking vaccines stocks ... Vaccine Stocks: Why MRNA, VXRT, CVAC and NVAX Stocks Need a Band-Aid Today ... Indeed, vaccine stocks such as Moderna (NASDAQ:MRNA), Vaxart (NASDAQ:VXRT), CureVac (NASDAQ:CVAC) and Novavax (NASDAQ:NVAX) are ...
  • Frontline workers explain the importance of receiving the COVID-19 vaccine. (sfaf.org)
  • Global HIV Vaccine Enterprise, the Partnership for AIDS Vaccine Evaluation, and the Center for HIV-AIDS Vaccine Immunology). (cdc.gov)
  • On March 17, 2021, the City of Chicago announced anyone 16 and older who is living with HIV will be eligible for COVID-19 vaccines after Monday, March 29. (aidschicago.org)
  • These FDA-licensed vaccine products are available in the United States for the 2021-2022 flu season. (cdc.gov)
  • This is the only LAIV nasal spray vaccine available for use during the 2021-2022 season. (cdc.gov)
  • This is the only cell-based inactivated influenza vaccine that has been licensed by the FDA for using during the 2021-2022 flu season. (cdc.gov)
  • Coronavirus disease 2019 vaccine effectiveness among a popul. (lww.com)
  • People with HIV were underrepresented in coronavirus disease 2019 (COVID-19) vaccine clinical trials. (lww.com)
  • However, with the onset of the coronavirus disease 2019 (COVID-19) pandemic, and amid focus on vaccines as the only definitive method of durable control, a new study describes the possibility of producing a combined vaccine against both infections. (news-medical.net)
  • as the coronavirus disease 2019 (COVID-19) vaccines are distributed and administered globally, hesitancy towards the vaccine hinders the immunisation of a significant number of vulnerable populations , such as people living with HIV / AIDS . (bvsalud.org)
  • and (3) look for serologic markers of infection from the AIDS virus in vaccine recipients. (cdc.gov)
  • The latest results from this effort have Berman sounding optimistic about the prospects for a vaccine that can be effective in protecting against HIV infection. (sciencedaily.com)
  • Although the effect was small, RV 144 is still the only clinical trial in which a vaccine has shown any protective effect at all against HIV infection. (sciencedaily.com)
  • We estimated vaccine effectiveness (VE) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for the BNT162b2, mRNA-1273, and ChAdOx1 vaccines among a population-based cohort of people with HIV in Ontario, Canada. (lww.com)
  • If the nasal vaccines prove to be safe and efficient in humans, Iwasaki envisions them being used in conjunction with current vaccines and boosters that work system wide in order to add immune system reinforcements at the source of infection. (eurasiareview.com)
  • A series of new studies led by scientists at the Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) describe a potential vaccination strategy to jump-start the selection and evolution of broadly effective antibodies to prevent HIV infection. (infectioncontroltoday.com)
  • The cooperative research partnership represents a new opportunity for both organizations to create more effective and safe vaccine products against HIV infection. (biospace.com)
  • When used together with highly optimized HIV vaccine immunogens, PIKA could activate innate immune signaling and induce a more robust immune response that confers protection against HIV infection. (biospace.com)
  • It is important to understand that we do not yet know if the vaccines actually prevent infection from happening, or if they prevent transmission. (aidschicago.org)
  • The vaccines work exceptionally well at preventing people from getting really sick from COVID-19 infection. (aidschicago.org)
  • Vaccines allegedly help develop immunity by imitating an infection. (shtfplan.com)
  • Persons with AIDS have one crucial missing part of their immunity, the immune cells, called T cells, that can recognize and kill the infection. (ca.gov)
  • And yet, that's exactly what happened earlier this month when Moderna published protocols for a vaccine trail that excluded people "in an immunosuppressive or immunodeficient state, including human immunodeficiency virus infection. (aidsunited.org)
  • No vaccine is currently available to prevent HIV infection, the virus which causes AIDS, or to treat those who have it, but there are many medications available for those living with HIV to manage the virus . (huffpost.com)
  • There is currently no vaccine against HIV: and AIDS, if untreated, will lead to the death of more than 95% of infected individuals 10 years post-infection. (aphios.com)
  • Additionally, MEMA may use the funding for infection control measures at facilities administering vaccinations and for vaccine-related public information distribution. (supertalk.fm)
  • AUSTIN, Texas - The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus. (utexas.edu)
  • Today's paper describes findings that the vaccine keeps infection from spreading into the airways of mice, produces neutralizing antibodies and prompts a response in immune cells called memory T-cells. (utexas.edu)
  • Then the infection will progress to AIDS. (medlineplus.gov)
  • More than a quarter-century later, HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection. (aidsmap.com)
  • The third was the STEP trial, which closed in September 2007 - this vaccine, which had looked promising in animal studies, proved not only to have no effect in humans but actually to increase the likelihood of infection in a subset of participants. (aidsmap.com)
  • However many had the misconception that "HIV/AIDS does not influence Iran" and "I will not be infected with HIV/AIDS under any conditions" and 63.6% agreed that lack of religious and moral commitment could spread AIDS infection. (who.int)
  • The vaccines saved thousands of lives, prevented countless sicknesses, and have already come close to ending the pandemic in America. (house.gov)
  • President Donald Trump went off-topic during an address outside the White House on police reform Tuesday, declaring that the coronavirus pandemic will go away without a vaccine and that scientists have "come up with the AIDS vaccine. (huffpost.com)
  • WISCONSIN - Republican legislative leaders have indicated that they want oversight of how the state spends federal pandemic relief funds and distributes vaccines. (tmj4.com)
  • The heavy burden of the pandemic has been a strain on our resources, economy, healthcare system, and personal lives, but the new vaccines offer a strong response in our fight against COVID-19. (supertalk.fm)
  • During the COVID-19 pandemic, gloves should be worn when administering intranasal or oral vaccines. (cdc.gov)
  • The prevention and treatment of HIV/AIDS are important, but a long-term goal to deal with the pandemic should be focused on vaccination, says Professor Anna-Lise Williamson. (uct.ac.za)
  • Due to the COVID-19 pandemic, Rite Aids enables you to make either a physical appointment or a zoom appointment online for inquiries and questions. (appointments-system.org)
  • The AIDSVAX vaccine was based on the gp120 envelope protein. (sciencedaily.com)
  • One key to improving the vaccine, Berman said, came from independent lines of investigation pointing to the importance of antibodies that recognize a specific segment of gp120 known as the V1/V2 domain. (sciencedaily.com)
  • Eight months after vaccination, all animals were challenged intrarectally with the related, yet serologically distinct, SHIV-89.6P. The gp120 immunizations raised binding, but not neutralizing antibody for the challenge virus, and allowed testing of whether gp120 vaccines that fail to raise neutralizing antibody can improve protection. (nih.gov)
  • We conclude that gp120 inoculations that fail to raise neutralizing antibody do not improve the efficacy of Gag-Pol-Env DNA/MVA vaccines. (nih.gov)
  • Those vaccines included whole inactivated virus preparations, utilizing heat or formalin, or a recombinant envelope protein of HIV gp120. (aphios.com)
  • After 30 years of working on AIDS research, an American lab has developed new vaccine candidates that appear promising enough to consider advancing into clinical trials within the next two years. (sciencedaily.com)
  • His lab has developed new vaccine candidates that he said are promising enough to consider advancing into clinical trials within the next two years. (sciencedaily.com)
  • and (5) maintaining test result database and transferring data to the AIDS Vaccine Clinical Trials Network (AVCTN) Data Coordinating and Analysis Center (DCAC). (nih.gov)
  • Were people living with HIV included in clinical trials of the COVID-19 vaccines? (aidschicago.org)
  • AIDS United will continue to fight to ensure that all clinical trials for a COVID-19 vaccine include people living with HIV. (aidsunited.org)
  • The aim of the study conducted by scientists from the Dynamics of Immune Responses Unit (Institut Pasteur / Inserm / VRI), directed by Inserm research director Philippe Bousso, was to observe the effect of the HIV/AIDS vaccine candidate MVA-HIV - currently undergoing clinical trials by the French Vaccine Research Institute (VRI) and the ANRS - on the immune response. (inserm.fr)
  • The stabilized spike protein, known as the S-2P protein, also features in several other coronavirus vaccines currently in clinical trials. (utexas.edu)
  • The first two vaccines developed by her team are scheduled for clinical trials in the US later this year. (uct.ac.za)
  • Coming soon: news from IAS 2019 05 July 2019 The 10th International AIDS Society conference (IAS 2019) is being held. (aidsmap.com)
  • Epidemiologic approaches to detect an association between HB vaccine and AIDS have included analysis of data on AIDS cases reported to CDC concerning their receipt of HB vaccine and monitoring rates of AIDS in groups of homosexually active men who did or did not receive HB vaccine in the vaccine trials conducted by CDC in Denver, Colorado, and San Francisco, California. (cdc.gov)
  • To exclude those of us living with HIV from COVID-19 vaccine trials with no scientific basis is unconscionable. (aidsunited.org)
  • While this was a victory to those living with, impacted by, and vulnerable to HIV, we must continue to fight so that all other vaccine trials also include people living with HIV. (aidsunited.org)
  • All vaccines trials must include people living with HIV. (aidsunited.org)
  • VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection. (duke.edu)
  • There have only ever been four large phase III efficacy trials of HIV vaccines in humans. (aidsmap.com)
  • The field is in a period of retrenchment, conducting, in the main, smaller trials of novel vaccines and examining ways to improve the immunological efficacy of formulations already used. (aidsmap.com)
  • While two HIV vaccines failed to show protection in efficacy trials, Williamson still believes this is the only way to curb the spread of the virus. (uct.ac.za)
  • The third approach attempted to detect seroconversion to AIDS virus antibodies in paired sera of HB vaccine recipients. (cdc.gov)
  • Researchers believe that for an AIDS vaccine to be effective, it must stimulate the immune system to make "broadly neutralizing antibodies" that are effective against multiple strains of the virus. (sciencedaily.com)
  • We found that the vaccine that gave partial protection in the RV 144 trial had very little of the kind of carbohydrate required to bind these antibodies. (sciencedaily.com)
  • Unlike vaccines which elicit a system-wide immune response, IgA antibodies work locally on mucosal surfaces found in the nose, stomach, and lungs. (eurasiareview.com)
  • Nasal vaccines, but not the shot, also induced antibodies that protected the animals against a variety of flu strains, not just against the strain the vaccine was meant to protect against. (eurasiareview.com)
  • While both vaccine injections and nasal vaccines increased levels of antibodies in the blood of mice, only the nasal vaccine enabled IgA secretion into the lungs, where respiratory viruses need to lodge to infect the host, Iwasaki said. (eurasiareview.com)
  • A vaccine needs to elicit those rare antibodies, called "broadly neutralizing antibodies" (bnAbs), which fight a wide variety of strains of HIV-and it needs to elicit them quickly. (infectioncontroltoday.com)
  • Envelope protein immunogens may improve DNA or live-vectored HIV vaccines by complementing antiviral cellular responses with Env antibodies. (nih.gov)
  • Earlier this year, SFAF received approval from the California Department of Public Health to administer the COVID-19 vaccine. (sfaf.org)
  • Should people with HIV consider getting the COVID-19 vaccine? (aidschicago.org)
  • People living with HIV can take the COVID-19 vaccine, no matter what their viral load or CD4 count. (aidschicago.org)
  • Will the COVID-19 vaccine mess with my HIV medications? (aidschicago.org)
  • People with HIV should keep taking their HIV medicines when they receive a COVID-19 vaccine. (aidschicago.org)
  • Are there any people who should not get the COVID-19 vaccine? (aidschicago.org)
  • According to CDC, individuals should not get the vaccine if they have a condition that might exclude them, such as a known allergic reaction to the COVID-19 vaccine or its ingredients. (aidschicago.org)
  • Experts are going to weigh the benefits and the risks of clearing Pfizer's COVID-19 vaccine for emergency use in the U.S. Now, depending on how this meeting goes, we could know soon when our vaccination program is going to start. (wwno.org)
  • Here we present a series of strong evidence that the Covid-19 vaccines are causing recipients to develop acquired immune deficiency syndrome (AIDS) or a novel condition with similar attributes that can only be described as Covid-19 Vaccine Induced Acquired Immune Deficiency Syndrome (VAIDS). (shtfplan.com)
  • The lowest Covid-19 vaccine effectiveness was seen in the 40-49 age group in England throughout January 2022, recorded at minus-209.4%, with the 50-59 age group not far behind. (shtfplan.com)
  • The technology may have wide-ranging applications aside from its use as a COVID-19 vaccine. (house.gov)
  • A letter , written by Lynda Dee of AIDS Action Baltimore , outlines the multiple reasons why there is no reason for the HIV exclusion to exist in any COVID-19 vaccine trial. (aidsunited.org)
  • With the Covid-19 vaccine being distributed to hospitals and communities throughout the state, scammers are jumping at the opportunity to defraud hopeful consumers. (sazlegalaid.org)
  • If you have any questions regarding the Covid-19 vaccine, be sure to contact your health-care provider. (sazlegalaid.org)
  • The latest news about the Wuhan coronavirus (Covid-19) "vaccine" genocide can be found at ChemicalViolence.com . (greatreject.org)
  • The nine-year-old twins didn't flinch as each received test doses of Pfizer's COVID-19 vaccine - and then a sparkly Band-Aid to cover the spot. (smh.com.au)
  • Hence, this study aims to assess COVID-19 vaccine hesitancy among people living with HIV / AIDS (PLHIV) attending clinicaloutpatient follow-up at State Specialist Hospital Maiduguri (SSHM), Borno State , Nigeria . (bvsalud.org)
  • a hospital -based cross-sectional study design was conducted to assess COVID-19 vaccine hesitancy among 344 PLHIV receiving antiretroviral therapy ( ART ) at the United States President´s Emergency Plan for AIDS (PEPFAR) clinic in SSHM from 4 th January to 25th February 2022. (bvsalud.org)
  • The factors that are associated with COVID-19 vaccine hesitancy were identified using the Chi-square statistical test. (bvsalud.org)
  • among the 344 respondents of the study, only 88 (26.6%) received the COVID-19 vaccine . (bvsalud.org)
  • hesitancy towards COVID-19 vaccine is high among PLHIV and there is no any statistically significant association between COVID-19 vaccine hesitancy and the independent variables of the study where p-value is greater than 0.05. (bvsalud.org)
  • received the COVID-19 vaccine. (who.int)
  • And even after all that, I was still questioning getting the vaccine until checking out the Pfizer and Moderna publications. (sfaf.org)
  • The three vaccines that are available include one from Moderna, one from Pfizer, and one from Johnson & Johnson. (aidschicago.org)
  • The mRNA technology used in the Pfizer and Moderna vaccines represents unique technology developed through billions of dollars of investments from the companies themselves as well as U.S. taxpayers. (house.gov)
  • its leading authors are Barney Graham and Kizzmekia Corbett at the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center, part of the National Institutes of Health, and Andrea Carfi of biotech company Moderna. (utexas.edu)
  • NIAID and the biotechnology company Moderna, based in Cambridge, Massachusetts, worked to develop a messenger RNA (mRNA) vaccine, which, according to the NIH , directs the body's cells to express the spike in its prefusion conformation to elicit an immune response. (utexas.edu)
  • So far in the US, teen testing is furthest along: Pfizer and Moderna expect to release results soon showing how two doses of their vaccines performed in the 12 and older crowd. (smh.com.au)
  • As coronavirus vaccine distribution gathers pace across the U.S., there is limited consensus and some confusion as to which populations should be prioritized for the vaccine. (amfar.org)
  • At the federal level, the U.S. Centers for Disease Control and Prevention (CDC) develops guidance on coronavirus vaccine distribution based on the recommendations of its Advisory Committee on Immunization Practices. (amfar.org)
  • The widespread interest among Mississippians for the coronavirus vaccine is encouraging. (supertalk.fm)
  • Most recently Yisheng completed Phase II and Phase I clinical studies of PIKA based rabies and hepatitis B vaccines, respectively, which exhibited promising efficacy and safety in human subjects. (biospace.com)
  • I am told by the medical scientists that a medical vaccine with 80 percent efficacy is considered a very good vaccine. (man2manalliance.org)
  • Deviation from the recommended route may reduce vaccine efficacy or increase local adverse reactions. (cdc.gov)
  • The research, being led by Dr James Dixon in the university's School of Pharmacy and Biodiscovery Institute (BDI) with Professor Janet Daly, Professor of Viral Zoonoses and Deputy Director of the Wolfson Centre for Global Virus Research, will focus on a new DNA vaccine platform to induce safe protective immunity from Zika. (ntu.ac.uk)
  • Such a vaccine preparation should induce both humoral and cellular immune responses. (aphios.com)
  • The designed vaccine could induce humoral and cellular immunity . (bvsalud.org)
  • The study concluded: "Our findings reveal a potential molecular mechanism by which the spike protein might impede adaptive immunity and underscore the potential side effects of full-length spike-based vaccines. (newstarget.com)
  • The country needs at least 140 million doses of the new coronavirus vaccines in order to inoculate 70 million Filipinos this year and achieve herd immunity. (inquirer.net)
  • Researchers at Washington University School of Medicine in St. Louis are studying why immunity elicited by the flu vaccine wanes so rapidly. (wustl.edu)
  • In contrast to the flu vaccine, the yellow-fever vaccine provides robust life-long immunity. (wustl.edu)
  • The results of these studies could help researchers figure out how to design a flu vaccine that elicits immunity that doesn't fade over time. (wustl.edu)
  • Getting this data, for all the vaccines being rolled out, is critical because countries must vaccinate children to achieve herd immunity, noted Duke pediatric and vaccine specialist Dr. Emmanuel Walter, who is helping to lead the Pfizer study. (smh.com.au)
  • To robust the immunity of the multi- epitope vaccine, cholera toxin b (CTB) and three HTL epitopes of tetanus toxin fragment C (TTFrC) were linked at the N-terminal and C-terminal of the construct, respectively. (bvsalud.org)
  • Ellebedy and colleagues will compare how people's immune systems respond to the yellow-fever vaccine and the inactivated flu vaccine to better understand how vaccines elicit long-lasting immune responses. (wustl.edu)
  • Once we understand that, we can start thinking about how to redesign the flu vaccine to elicit an optimal, long-lasting response. (wustl.edu)
  • The NIAID requires a Primate Core Immunology Laboratory to assay specimens from macaques, chimpanzees, or other primates for humoral and cellular immune responses induced by immunization with prototype Simian Immunodeficiency Virus (SIV) and Human Immunodeficiency Virus (HIV) vaccines. (nih.gov)
  • What we have now is a vaccine that we take every year, and we're not sure if it even covers the whole flu season," said principal investigator Ali Ellebedy, PhD , an assistant professor of pathology and immunology and a researcher with the Andrew M. and Jane M. Bursky Center for Human Immunology & Immunotherapy Programs . (wustl.edu)
  • A study published last year showed that the coronavirus vaccines have spike proteins that inhibit natural DNA damage repair , which is needed for the body's adaptive immune response. (newstarget.com)
  • Although we still have a long way to go, we're making really good progress toward a human vaccine," said William Schief, professor at TSRI and director of vaccine design for IAVI's Neutralizing Antibody Center (NAC) at TSRI, whose lab developed many of the vaccine proteins tested in these studies. (infectioncontroltoday.com)
  • An inactivated attenuated HIV vaccine preparation, which retains the conformation of envelope proteins, may become a valuable component of such a vaccination regimen. (aphios.com)
  • For the first time, using a powerful, non-invasive microscopic imaging technique, the scientists were able to watch in vivo and in real time as the vaccine induced the formation of the inflammasome, a complex assembly of proteins with a highly specific structure which appears in macrophages, the first immune cells targeted by the vaccine. (inserm.fr)
  • Vaccines work by exposing the body's immune system to harmless but recognizable bits of proteins or sugars from microbes such as viruses and bacteria. (wustl.edu)
  • When a person receives a vaccine against, say, the flu virus, his or her immune cells seize the viral proteins and take them to the lymph nodes. (wustl.edu)
  • The UK Vaccine Network sits within the DHSC's Global Health Security programme and was established to address market failure in the development of vaccines and vaccine technologies. (ntu.ac.uk)
  • National AIDS and STD Control Programme (2010) National HIV indicators for Kenya: 2009. (scirp.org)
  • The Yale team is currently testing nasal vaccine strains against COVID strains in animal models. (eurasiareview.com)
  • Intranasal vaccine is administered into each nostril using a manufacturer-filled nasal sprayer. (cdc.gov)
  • An annual seasonal flu vaccine (either through a shot or nasal mist) is the best way to reduce a person's chances of getting seasonal flu and spreading it to others. (cdc.gov)
  • Live, attenuated influenza vaccine (LAIV) is a nasal spray that can be given to non-pregnant people 2 through 49 years of age. (cdc.gov)
  • In the United States, there are currently two ways someone can get a flu vaccine-by injection (a shot) or nasal spray. (cdc.gov)
  • Also known as live, attenuated influenza vaccine (LAIV), this nasal spray contains live viruses. (cdc.gov)
  • FDA approved this live attenuated influenza virus (LAIV) nasal spray vaccine for persons 2 through 49 years of age. (cdc.gov)
  • The UK Health Security Agency (UKHSA) publishes a weekly Vaccine Surveillance Report, with each report containing four weeks worth of data on Covid-19 cases, hospitalizations, and deaths by vaccination status. (shtfplan.com)
  • As President Joe Biden's administration looks to increase the relatively low vaccination rate in the U.S., such oral options could provide a solution for those concerned about the vaccines themselves. (investorplace.com)
  • The necessary vaccine strategy for HIV may, therefore, resemble the situation that currently exists with influenza vaccination, where annual shots that target the predominant viral strain, which differs from year to year, are needed. (aphios.com)
  • A large chunk of federal funding will aid Mississippi's vaccination distribution efforts. (supertalk.fm)
  • Even if a vaccine were available, these different forms of HIV would almost certainly allow some of the virus to "escape" from any protective immune response that the human body mounted against it after vaccination. (man2manalliance.org)
  • The figures above indicate that their figures may well have been correct immediately after vaccination (the younger age groups have had the vaccine for the shortest time)," The Exposé explains. (greatreject.org)
  • discuss the history of polio globally and the United States, outline the current investigation and response to the case of paralytic polio New York, describe how to recognize, diagnose, and report suspected paralytic polio cases in the United States, and distinguish the differences between inactivated polio vaccine and oral polio vaccine and the importance of maintaining high polio vaccination coverage. (cdc.gov)
  • understand the history of polio in the U.S. and globally, describe polioviruses, understand the incubation period and transmission of poliovirus, and understand the impact of polio vaccination and the different types of vaccine. (cdc.gov)
  • CDC recommends annual influenza vaccination for everyone 6 months and older with any flu vaccine licensed by the Food and Drug Administration (FDA) that is appropriate for the recipient's age and health status. (cdc.gov)
  • But rather than spend precious months trying to clarify their underlying causes, amfAR believes that the available data persuasively demonstrate the need to prioritize access to the vaccine for all people living with HIV without further delay. (amfar.org)
  • The number of HIV vaccine researchers is now increasing, given the support of several organizations (e.g. (cdc.gov)
  • These organizations, collaborations, and researchers are attempting to better organize the human and technical resources needed to challenge this formidable foe on the scale of the Manhattan Project or the March of Dimes search for a polio vaccine. (cdc.gov)
  • Working with researchers at Icahn School of Medicine at Mount Sinai in New York, they tested a protein-based vaccine designed to jump start an IgA immune response, administering it to mice through injections, as is commonly done with systemic immunizations, and also intranasally. (eurasiareview.com)
  • We look forward to working with researchers at Yisheng to develop a more powerful AIDS vaccine. (biospace.com)
  • With the aid of a $3.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH), researchers at Washington University School of Medicine in St. Louis will investigate why the flu vaccine elicits such a short-lived immune response, and how to extend its effectiveness. (wustl.edu)
  • In the latter, Williamson is the head of the HIV Vaccine Development Group, a multi-disciplinary team of senior academics, researchers and students developing candidate HIV vaccines, which has been funded by the South African AIDS Vaccine Initiative (SAAVI) since 2000. (uct.ac.za)
  • Researchers are beginning to test younger and younger kids to make sure COVID-19 vaccines are safe and work for each age. (smh.com.au)
  • Instead researchers are measuring whether the vaccines rev up youngsters' immune systems much like they do adults' - suggesting they'll offer similar protection. (smh.com.au)
  • International AIDS Vaccine Initiative, New York. (scirp.org)
  • Training slides provide an overview of available vaccines for COVID-19 and RSV, and offer vaccine administration recommendations for 2023-2024. (aidsetc.org)
  • The influenza vaccine is only good for one flu season, partly because different strains of the virus circulate every year. (wustl.edu)
  • Yisheng Biopharma Co., Ltd. is a biopharmaceutical company headquartered in Beijing, China , focusing on the research, development, manufacturing and sales and marketing of immunological and vaccine products, with approximately 1 , 000 employees in China , the USA and Singapore. (biospace.com)
  • The immunological and physicochemical properties of the designed vaccine were evaluated. (bvsalud.org)
  • UNAIDS/WHO (2008) Kenya Epidemiological Fact Sheet on HIV and AIDS, 2008. (scirp.org)
  • UNAIDS Executive Director Michel Sidibe, Deputy President of South Africa Cyril Ramaphosa and United Nations Secretary-General Ban Ki-moon at AIDS 2016. (fredhutch.org)
  • The vaccine currently licensed in the United States is produced from pooled plasma of hepatitis B surface antigen-positive individuals, some of whom are also in high-risk groups for acquired immunodeficiency syndrome (AIDS). (cdc.gov)
  • The purpose of this contract is to support the NIAID in its mission to stimulate research towards discovery and testing of prototype vaccines for the acquired immunodeficiency syndrome (AIDS). (nih.gov)
  • AIDS stands for acquired immunodeficiency syndrome. (medlineplus.gov)
  • There is no denying, based on the data, that fully vaccinated people now suffer from what appears to be acquired immunodeficiency syndrome, more popularly known as AIDS. (greatreject.org)
  • This trial (known as RV 144) showed that the combined vaccine was safe and 31 percent effective in preventing new HIV infections. (sciencedaily.com)
  • 2010) Modeling HIV vaccines in Brazil: Assessing the impact of a future HIV vaccine on reducing new infections, mortality and number of people receiving ARV. (scirp.org)
  • MSD Animal Health (known as Merck Animal Health in the United States and Canada) has obtained approval from Indonesian authorities to begin marketing AQUAVAC Strep Sa, an inactivated vaccine that aids in the protection against Streptococcus agalactiae infections in tilapia and other susceptible fish. (thefishsite.com)
  • In fact, AIDS (acquired immune deficiency syndrome) is just the name used to describe a number of potentially life-threatening infections and illnesses that happen when your immune system has been severely damaged. (shtfplan.com)
  • HIV has turned out to have several unique properties that make the development of a vaccine harder than developing one against other viral infections. (aidsmap.com)
  • HIV vaccines could work because humans can regulate their infections, as some individuals control viraemia, for extended periods. (uct.ac.za)
  • Scientists in Nottingham have been awarded £462,462 for the development of a vaccine for the Zika virus from £10m of UK Aid funding for research into vaccines to protect the world from deadly diseases. (ntu.ac.uk)
  • Scientists in Nottingham Trent University's John van Geest Cancer Research Centre will help to screen the new vaccine for its capacity to trigger immune responses against the Zika virus. (ntu.ac.uk)
  • Under the terms of the agreement, the scientists at TSRI will evaluate the potential of PIKA adjuvant for AIDS vaccine candidates. (biospace.com)
  • While lauding himself and the scientists working on a vaccine for the coronavirus, he claimed that "before the end of the year I predict we will have a very successful vaccine. (huffpost.com)
  • The closing session of AIDS 2016, the biennial meeting of the International AIDS Society, in Durban, South Africa, drew about 18,000 scientists, world leaders, celebrities, advocates and people living with HIV from 180 countries. (fredhutch.org)
  • I saw the kind of pain people went through and heard about people who were found in their homes five days after they died, with their children still beside them," she told a packed hall of scientists, policymakers, advocates and other people with HIV attending the AIDS 2016 conference last week in Durban, South Africa. (fredhutch.org)
  • Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. (inserm.fr)
  • The scientists administered the vaccine to healthy mice, then observed in real time how cells from the immune system were mobilized to the lymph node, the organ where the vaccine response is developed, in just a few hours. (inserm.fr)
  • These in vivo films have given the scientists a detailed picture of the main stages in the mechanistic action of this vaccine and highlighted an important pathway that orchestrates the effective mobilization of the immune response. (inserm.fr)
  • At present, scientists do not know if each subtype and every variant will need its own specific vaccine. (man2manalliance.org)
  • This, and a number of promising animal study results, have revitalised interest in HIV vaccine research, and most scientists now believe that an effective HIV vaccine is possible, even if few are prepared to predict when one might be available. (aidsmap.com)
  • In the first phase of the Pfizer study, a small number of children receive different doses of vaccine as scientists winnow out the best dosage to test in several thousand kids in the next phase. (smh.com.au)
  • Armstrong noted that calling the adverse effect "AIDS" freaks people out, so public health authorities chose to call it Vaccine-Acquired Immune Deficiency Syndrome (VAIDS) instead. (newstarget.com)
  • VAIDS is basically AIDS given by a vaccine. (newstarget.com)
  • Pfizer originally claimed a 95% efficiency for their vaccine (calculated as in the last column above). (greatreject.org)
  • Despite all the success with SARS-CoV-2, vaccines are not yet available for Zika as immune responses to closely-related viruses such as dengue make designing effective and safe strategies problematic. (ntu.ac.uk)
  • In her recent inaugural lecture, Cancer, Viruses and Vaccines , Williamson explained that vaccines may not stop people from getting infected, but will hopefully slow disease onset for individuals. (uct.ac.za)
  • The model was used to analyze the effects of scaling up current prevention programs and adding potential HIV vaccines with varying levels of effectiveness and coverage. (scirp.org)
  • Vaccine effectiveness isn't really a measure of a vaccine, it is a measure of a vaccine recipient's immune system performance compared to the immune system performance of an unvaccinated person. (shtfplan.com)
  • So, when the authorities state that the effectiveness of the vaccines weakens over time, what they really mean is that the performance of your immune system weakens over time. (shtfplan.com)
  • A vaccine effectiveness of + 50% would mean that the fully vaccinated are 50% more protected against Covid-19 than the unvaccinated. (shtfplan.com)
  • Now that we know the case rates, we can use Pfizer's vaccine effectiveness formula to work out real-world vaccine effectiveness. (shtfplan.com)
  • But don't forget, as we proved with the evidence presented in Exhibit A, Vaccine effectiveness isn't really a measure of a vaccine, it is a measure of a vaccine recipient's immune system performance compared to the immune system performance of an unvaccinated person. (shtfplan.com)
  • The best guess is that the genetic complexity of HIV will influence the effectiveness of any tested vaccine. (man2manalliance.org)
  • Although the current vaccines have a pivotal role in the control of this pathogen, the emergence of new variants has a negative impact on their effectiveness . (bvsalud.org)
  • The vaccine contained no detectable AIDS virus-related sequences at a sensitivity of less than one picogram of DNA per 20-ug dose of vaccine. (cdc.gov)
  • This tool lets you send a friendly reminder for your third dose of vaccine. (cliniquelactuel.com)
  • They found that mice which had received vaccine intranasally were much better protected against the respiratory influenza than those that received injections. (eurasiareview.com)
  • According to Galvez, such a measure will help the Philippines in its quest for enough doses of Covid-19 vaccines because it will give confidence to drug manufacturers supplying the government with the jabs. (inquirer.net)
  • HARRIS: And if there is a quick decision, the first doses of this vaccine could get into people's arms within days. (wwno.org)
  • But designing a flu vaccine that protects people for years instead of months requires a deeper understanding of how strong and persistent immune responses develop, and why the current flu vaccine fails to deliver such a response. (wustl.edu)
  • The immune responses to the designed vaccine were simulated. (bvsalud.org)
  • Williamson said vaccines are one of humankind's most important inventions, saving up to three million children every year, eradicating smallpox and almost eradicating polio. (uct.ac.za)
  • This effort will support the research of AIDS investigators, including three SIV Vaccine Evaluation Units (SIV VEU), a Chimpanzee Unit, the National Cooperative Vaccine Evaluation Group (NCVDG), the AIDS Vaccine Evaluation Group (AVEG), and other programs initiated by NIAID. (nih.gov)
  • Last year, NIAID issued a strategic plan for developing a universal flu vaccine that would eliminate this onerous and expensive annual operation. (wustl.edu)
  • Scholars@Duke publication: An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. (duke.edu)
  • Live, attenuated influenza (LAIV [FluMist]) vaccine is the only vaccine administered by the intranasal route. (cdc.gov)
  • Previous workers have reported that sera of HB vaccine recipients did not show helper-T/supressor-T ratio inversion, a finding common in AIDS patients (5). (cdc.gov)
  • MANILA, Philippines - Vaccine czar Carlito Galvez Jr. on Friday stressed the significance of passing a bill that would provide a vaccine indemnification fund to compensate recipients who may suffer from side effects of Covid-19 shots. (inquirer.net)
  • There will be a one week delay on the arrival of vaccines coming from the World Health Organization-led COVAX facility, but Galvez said they are ironing out the indemnity agreement for the supply in order to assure that the Philippine government will assume responsibility should vaccine recipients experience adverse side effects. (inquirer.net)
  • WHO Initiative for Vaccine Research. (who.int)
  • Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2? (news-medical.net)
  • Live oral rotavirus vaccines have been used to reduce its incidence in many countries. (news-medical.net)
  • Rotavirus vaccine (RV1 [Rotarix], RV5 [RotaTeq]) is the only routinely recommended vaccine administered orally. (cdc.gov)
  • Rotavirus vaccine should never be injected. (cdc.gov)
  • Unlike the last major AIDS conference held in sub-Saharan Africa, this one held out hope for a preventive vaccine and even of what was once unimaginable: an HIV cure or at least long-term remission. (fredhutch.org)
  • Ethical considerations in HIV preventive vaccine research. (who.int)
  • This earlier vaccine, called AIDSVAX, was used in combination with another experimental vaccine in a large-scale clinical trial in Thailand involving 16,000 people. (sciencedaily.com)
  • PIKA adjuvant is formulated as a component of vaccine candidates. (biospace.com)
  • The purpose of this Funding Opportunity Announcement (FOA) is to support translation of advanced HIV-1 vaccine candidates from pre-clinical studies through different phases of process and product development, Current Good Manufacturing Practice (CGMP) manufacturing and regulatory filing to the point of clinical testing. (cdc.gov)
  • We [South Africans] should participate in the development of vaccines, not just test other people's products. (uct.ac.za)
  • HIV diversity and capability for antigenic drift are only two of the reasons for the inefficiency of first-generation anti-HIV vaccines, which induced a humoral (antibody) response against a limited number of epitopes. (aphios.com)
  • Multi- epitope peptide vaccine (MEV), comprised of immune-dominant epitopes , is designed by immunoinformatic tools and it is a promising strategy against infectious diseases . (bvsalud.org)
  • Selected epitopes with MHC molecules and the designed vaccines with Toll-like receptors (TLR-2 and TLR-4) were docked and analyzed. (bvsalud.org)
  • Phil Berman has been working to develop an AIDS vaccine for nearly 30 years, first at the pioneering biotech company Genentech, then as cofounder of VaxGen, and now at UC Santa Cruz, where he is the Baskin Professor of Biomolecular Engineering. (sciencedaily.com)
  • Berman has redesigned a vaccine that he invented while at Genentech and led through clinical testing at VaxGen. (sciencedaily.com)
  • See chart below to identify the route for each injectable vaccine. (cdc.gov)
  • Prepare each injectable vaccine using a separate syringe. (cdc.gov)
  • The editors were careful to include chapters on important nonscientific aspects of HIV vaccine development, such as clinical site development, regulatory issues, scale-up, and manufacturing. (cdc.gov)
  • Professor Daly said 'We are pleased to also be collaborating with Professor Luís CS Ferreira and colleagues at the University of Sao Paulo's Vaccine Development Laboratory in Brazil on this project. (ntu.ac.uk)
  • The partnership with TSRI is critical to our long-term vision in advancing vaccine development. (biospace.com)
  • There have been so many people lost to HIV and now to COVID-19 who won't have the opportunity to get the vaccine or benefit from its development. (sfaf.org)
  • The game changing impact that an AIDS vaccine could have on the AIDS epidemic in Kenya under-scores the importance of sustaining political support and financial investment to accelerate HIV/AIDS vaccine research and development. (scirp.org)
  • American developers will now be forced to hand over the groundbreaking technology that allowed the development of these life-saving vaccines to foreign competitors like China. (house.gov)
  • Waiving the patents on these vaccines will disincentivize future investment and development of vaccines and treatments. (house.gov)
  • The record-breaking development of COVID-19 vaccines is a marvel of modern medicine, American ingenuity, and free enterprise. (house.gov)
  • The development of a vaccine against the infectious agent that attacks the immune system has proven to be extremely challenging. (aphios.com)
  • The enormous genetic diversity of HIV presents a major problem for vaccine development. (aphios.com)
  • Several things were key for rapid vaccine development, including understanding the precise atomic-level structure of the spike protein and how to stabilize it," said UT Austin associate professor of molecular biosciences Jason McLellan, an author on the paper. (utexas.edu)
  • Central Africa sees a highly mixed picture -- HIV-1 subtypes A, D, F, G, H, J, and K. The implications of these differences for vaccine development remain uncertain. (man2manalliance.org)
  • But the development of vaccines takes a long time. (uct.ac.za)
  • Sixth annual meeting of the national cooperative vaccine development groups for AIDS (pp. 945-952). (bvsalud.org)
  • TAMPA, Florida - Pre-exposure prophylaxis (PrEP) has shown to be effective in many clinical and real-world studies, but concerns remain, according to research presented at the Association of Nurses in AIDS Care (ANAC) 2022 Annual Meeting. (medscape.com)
  • Alliance for Vaccines and Immunisation. (cdc.gov)
  • In contrast, data are providing valuable details on the involvement of spike protein subunits in DNA damage repair, including spike-based vaccines that may inhibit the recombination of V (D) J in B cells. (newstarget.com)
  • Animals were challenged with a pathogenic AIDS virus (SHIV89.6P). Control monkeys showed a severe loss of CD4+ T cells and high viral loads, and 7/8 progressed to AIDS with an average time of 148 days. (duke.edu)
  • The ride raises awareness and vital funds for HIV/AIDS vaccine research having donated to date over $2.4 million to the Emory Vaccine Center, one of the world's leading vaccine research centers working to find an HIV vaccine. (wikipedia.org)
  • Action Cycling Atlanta was incorporated as a 501c3 charitable organization and chose to continue fundraising for AIDS vaccine research at the Emory Vaccine Center, located in Atlanta, GA and a former beneficiary of the Pallotta events. (wikipedia.org)
  • The majority of these funds ($557,000) has gone towards AIDS vaccine research at Emory Vaccine Center. (wikipedia.org)
  • To date (August 2017), Action Cycling Atlanta, through its Action Cycling 200 and AIDS Vaccine 200 rides has donated a total of $2,781,090 for AIDS vaccine research and AIDS-related services. (wikipedia.org)
  • Since his arrival at UC Santa Cruz in 2006, Berman has established a major vaccine research effort funded by a series of grants from the National Institutes of Health, including two new grants in 2014 totaling $2.6 million. (sciencedaily.com)
  • Graham Pockley, Professor of Immunobiology in Nottingham Trent University's John van Geest Cancer Research Centre, said: "We will provide our specialist facilities and expertise to support the University of Nottingham in this crucial work to develop a vaccine for Zika virus, for which there are currently no treatments. (ntu.ac.uk)
  • It does this through funding vaccine research to help combat infectious diseases that have epidemic potential in low and middle-income countries (LMICs). (ntu.ac.uk)
  • UKVN is a UK Aid investment, which means all projects funded must support research primarily and directly for the benefit of people in LMICs. (ntu.ac.uk)
  • TSRI has gained a great deal of expertise in AIDS research which lays the groundwork in revolutionizing vaccine design strategy," commented Assistant Professor Jiang Zhu at TSRI. (biospace.com)
  • A great deal of time, money and ressources are continually dedicated to the research into an effective vaccine. (cliniquelactuel.com)
  • We need innovation and research that will deliver a vaccine and cure. (fredhutch.org)
  • This research was supported by the French Vaccine Research Institute, the French Foundation for Medical Research and the European Research Council (ERC). (inserm.fr)
  • 5) Vaccine Research Institute, Créteil, France. (inserm.fr)
  • Earlier research into coronaviruses was critical for the fastest-ever progression from virus genome sequencing to vaccine testing in humans, which took only 66 days. (utexas.edu)
  • We need more research to develop innovative vaccines and a robust pipeline of candidate vaccines - not less. (uct.ac.za)
  • While some prevention successes have been attained (e.g., screening of the blood supply in industrialized countries), a safe and effective vaccine-the "holy grail" of public health prevention-remains elusive. (cdc.gov)
  • Dr Dixon said: "Our vision is to produce an effective, safe, single-dose prophylactic vaccine platform for Zika using our peptide-based delivery system which is applicable to any emergent virus. (ntu.ac.uk)
  • A direct legacy of this historical activism is the EUA which has allowed each of the COVID-19 vaccines to be made available to the population in record time while making sure they are extremely safe. (aidschicago.org)
  • Are the COVID-19 vaccines safe for people with HIV? (aidschicago.org)
  • That is, is the vaccine safe, and is it effective? (wwno.org)
  • The holy grail of AIDS prevention is a single-dose, safe, affordable, oral vaccine that gives lifelong protection against all subtypes of HIV. (man2manalliance.org)
  • And in China, Sinovac recently announced it has submitted preliminary data to Chinese regulators showing its vaccine is safe in children as young as 3. (smh.com.au)
  • Therefore, it is urgent to consider the protective and safe vaccine against all subcoronavirus species and variants based on the conserved region of the virus . (bvsalud.org)
  • There are safe vaccines that can help reduce the risk from flu and its potentially serious complications. (cdc.gov)
  • I got the vaccine not just because I've been getting vaccinated by this health system my whole life, but because I've been working in infectious disease science and public health for the past six years. (sfaf.org)
  • We are very pleased to join forces with TSRI in exploring a more effective vaccine against AIDS, which remains a significant unmet medical need. (biospace.com)
  • The introduction of a partially effective AIDS vaccine could significantly alter the trajectory of the epidemic. (scirp.org)
  • COVID-19 vaccines effective? (aidschicago.org)
  • The vaccines for COVID-19 are extremely effective at preventing serious illness. (aidschicago.org)
  • Results of search for 'su:{AIDS vaccines. (who.int)
  • This data alone should deeply concern even the most avid vaccine advocates. (shtfplan.com)
  • Ben Armstrong discussed how doctors are saying Wuhan coronavirus (COVID-19) vaccines are causing cancer and vaccine-induced AIDS at an alarming rate during the February 2 episode of "The Ben Armstrong Show. (newstarget.com)
  • The latest data from the United Kingdom's PHE Vaccine Surveillance Report suggests that people who have been "fully vaccinated" for the Wuhan coronavirus (Covid-19) are losing about five percent of their immune systems per week. (greatreject.org)
  • IAVI (2005) Modeling the impact of AIDS vaccines. (scirp.org)
  • What impact would an HIV/AIDS vaccine have on the HIV/AIDS epidemic in Kenya? (scirp.org)
  • The Kenyan HIV/AIDS epidemic was modeled using the most current data from national sources including epidemiology and behavioral surveillance. (scirp.org)
  • The first hurdle facing vaccine designers, therefore, is dealing with the extraordinary genetic complexity of the HIV epidemic. (man2manalliance.org)